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Abstract 
Cardiovascular disease (CVD) remains the leading cause of death in the United Kingdom and is 
associated  with  a  huge  burden  of  morbidity.  Within  the  group  of  cardiovascular  diseases 
coronary artery disease (CAD) is the single largest cause of death. Death rates from CAD have 
been falling since the 1970s predominantly due to a reduction in the prevalence in major risk 
factors such as cigarette smoking. Type 2 diabetes mellitus (DM) is an important risk factor for 
CVD. Type 2 DM is increasing in prevalence and there is concern that this will contribute to an 
increase in the burden of CVD. Reducing cardiovascular risk in patients with type 2 DM has to 
date focussed on tight blood pressure and glycaemic control together with statin therapy to 
achieve  tight  low  density  lipoprotein  cholesterol  (LDL)  targets.  Recent  studies  such  as 
ADVANCE  and  ACCORD  have  highlighted  some  of  the  limitations  with  this  approach. 
Important  vascular  abnormalities  underlying  the  development  of  CAD  include  endothelial 
dysfunction  and  increased  arterial  stiffness.  Some  of  the  mechanisms  underlying  these 
abnormalities are thought to include increased oxidative stress, inflammation, insulin resistance 
and  dyslipidaemia.  These  processes  in  patients  with  type  2  DM  are  currently  not  fully 
understood. It is hoped that through increased understanding of these processes new strategies 
for reducing cardiovascular risk in patients with type 2 DM can be identified. 
This study aimed to investigate some of the processes thought to underlie CVD in patients with 
type 2 DM namely endothelial dysfunction, arterial stiffness, oxidative stress and dyslipidaemia. 
Finally this study aimed to assess the impact of two cardiovascular prevention strategies (statin 
therapy and increased physical activity) on these processes believed to underlie the development 
of CVD. 
One hundred and twenty six patients with CAD (36 patients with type 2 DM, 90 patients without 
diabetes) and 80 controls (64 healthy controls and 16 varicose vein controls) were recruited as  
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part of the VASCAB study. In these patients in vivo and ex vivo endothelial function studies 
were performed. Indicators of arterial stiffness were measured using pulse wave velocity and 
pulse  wave  analysis  techniques.  Superoxide  levels  were  assessed  in  vascular  tissue, 
mononuclear  cells  and  whole  blood.  LDL  and  high  density  lipoprotein  cholesterol  (HDL) 
subfractions  were  analysed  in  patients  with  CAD.  To  assess  the  impact  of  intensive  statin 
therapy  and  tight  LDL  targets,  endothelial  function  and  vascular  superoxide  levels  were 
compared in patients recruited as part of the VASCAB study (2007 cohort) to a group of patients 
recruited in  2003.  Finally  patients  attending  the  cardiac rehabilitation  programme  following 
surgical revascularisation were recruited to assess the impact of increased physical activity on 
endothelial function and oxidative stress. 
Endothelial function was impaired in patients with CAD compared to controls. In patients with 
CAD, type 2 DM was associated with greater impairment of endothelial function compared to 
patients with CAD alone. Superoxide levels in the vasculature, mononuclear cells and whole 
blood were similar in patients with and without type 2 DM. Type 2 DM was associated with 
significantly lower HDL levels and a preponderance to small dense LDL compared to patients 
without diabetes. Arterial stiffness was increased in patients with CAD compared to controls. 
There was however no significant difference in arterial stiffness in patients with type 2 DM and 
CAD compared to patients with CAD alone. Intensive statin therapy was associated with lower 
LDL levels and improved endothelial function but no change in vascular superoxide levels. 
Following the cardiac rehabilitation programme endothelial function was improved and HDL 
levels increased. There were no changes in levels of oxidative stress. 
Endothelial  dysfunction  in  patients  with  type  2  DM  may  partly  account  for  the  increased 
cardiovascular risk and worse cardiovascular outcomes seen in this group of patients. Increased 
oxidative stress did not explain the endothelial dysfunction associated with type 2 DM. The 
dyslipidaemia that was associated with type 2 DM (low HLD and small dense LDL levels) may  
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partly explain the increased endothelial dysfunction observed. Targeting endothelial dysfunction 
may  therefore  be  a  strategy  for  reducing  cardiovascular  risk  in  patients  with  type  2  DM. 
Intensive statin therapy and increased physical activity were both associated with improvements 
in endothelial function. The lack of evidence for increased arterial stiffness in patients with type 
2 DM may reflect deficiencies in the methods used for assessing arterial stiffness. However this 
study  highlights  the  difficulties  of  assessing  arterial  stiffness  clinically  and  raises  questions 
regarding the impact of type 2 DM on commonly used measures of arterial stiffness. 
Future prospective studies assessing the impact of improving endothelial function in patients 
with type 2 DM on cardiovascular outcomes are required.  
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1  Introduction 
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1.1  The clinical context 
1.1.1  Cardiovascular disease  
Cardiovascular disease (CVD) remains the leading cause of death in the United Kingdom and is 
associated with a huge burden of morbidity. The term CVD covers stroke, peripheral vascular 
disease  and  coronary  artery  disease  (CAD)  all  of  which  have  the  same  underlying 
pathophysiology; atherosclerosis. Within the group of CVD, CAD is the single largest cause of 
death. CAD causes over 90,000 deaths a year in the UK; approximately 20% of deaths in men 
and 14% death in women 
1. CAD is also the most common cause of premature death (death in 
the under 75s) in both men and women 
1. 
The most important modifiable risk factors for CVD are cigarette smoking and cholesterol levels 
followed by hypertension, diabetes mellitus, abdominal obesity and psychosocial factors. The 
INTERHEART  study  showed  that these  risk  factors  together  with  dietary  factors,  levels  of 
physical activity and alcohol consumption accounted for 90% of the risk for acute myocardial 
infarction
2. 
Death rates from CVD have been falling since the 1970s. Over half of this reduction (58%) is 
the consequence of a reduction in cardiovascular risk factors, most notably cigarette smoking
1. 
The remainder of the reduction can be attributed to improvements in medical management of 
CVD 
1. The role of diabetes mellitus (DM) in the development of CVD and CAD is of particular 
interest as rates of this condition are dramatically increasing throughout the world. There is 
concern that the increase in type 2 DM may contribute to an increase in prevalence of CVD. 
1.1.2  Type 2 DM  
DM is diagnosed on the basis of elevated blood glucose levels. The current WHO guidelines are 
a fasting glucose level of greater than 7mmol/L or random glucose greater than 11.1 mmol/L
3.  
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These  levels  were  set  based  on  the  levels  of  hyperglycaemia  above  which  microvascular 
complications specific to diabetes occur (e.g. retinopathy). 
Type 2 DM is the commonest type of diabetes accounting for between 80 and 95% of cases of 
diabetes.  Classifying  an  individual  as  having  type  2  DM  remains  a  predominantly  clinical 
diagnosis. Type 2 DM is diagnosed in a patient with hyperglycaemia, no evidence of significant 
insulin  deficiency  and  no  evidence  of  secondary  causes  of  diabetes  (e.g.  pancreatic 
insufficiency).  
The pathogenesis of type 2 DM is complex but involves both insulin resistance and inadequate 
insulin secretion. Obesity, in particular abdominal obesity is central to the development of type 2 
DM; over 80% of patients with type 2 DM are obese. Blood glucose levels are normally kept 
within tight control. Oral intake is balanced against insulin dependent glucose uptake by muscle, 
adipose tissue and the liver, and glucose production by the liver. Obesity and inactivity reduce 
insulin  sensitivity.  Increased  insulin  production  by  the  β-cells  of  the  pancreas  are  able  to 
compensate for this initially, however eventually this is insufficient and blood glucose levels 
start to rise 
4.  
Type 2 DM therefore develops over many years. It is preceded by a pre-diabetic state that starts 
with abdominal obesity and insulin resistance, followed by marginally elevated blood glucose 
levels, termed impaired glucose tolerance and impaired fasting glucose. Over time if nothing is 
done to halt the process a significant proportion of these patients will go on to develop type 2 
DM 
4.  
The prevalence of type 2 DM is increasing dramatically, fuelled both by the obesity epidemic 
and the aging population. In 2000 the prevalence of diabetes was estimated to be 171 million 
worldwide (2.8%). Based purely on demographic data and in particular the aging population it is 
projected that by 2030, 366 million people worldwide will have diabetes (4.4%) 
5;6. This is  
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likely to be an underestimate as the calculations are based on the assumption that current levels 
of obesity remains constant which is unlikely 
6. The 2009 Scottish diabetes survey reported the 
prevalence of diabetes at 4.3% with 87.4% of people having type 2 DM. Once again this has 
been increasing over the recent years 
7.  
Type 2 DM is associated with a number of long term complications in the vasculature which are 
divided  into  microvascular  (retinopathy,  neuropathy  and  nephropathy)  and  macrovascular 
(CAD, stroke and peripheral vascular disease) complications.  
1.1.3  Type 2 DM and CVD  
CVD is the leading cause of death in patients with Type 2 DM accounting for 50-70% of all 
deaths 
8. Indeed patients with Type 2 DM have the same risk of myocardial infarction as patients 
who have already suffered a heart attack, leading many clinicians to consider type 2 DM to be a 
cardiovascular equivalent 
9. Similar to the situation in the general population there is evidence 
death rates from CAD in patients with type 2 DM are also falling 
10. However the prevalence of 
Type 2 DM is increasing rapidly and the concern is that the prevalence of CAD may also start 
increasing  in  unison  with  this.  Tackling  CAD  aggressively  in  patients  with  Type  2  DM  is 
therefore essential. CAD is not only more prevalent in patients with Type 2 DM but when it 
does occur the atherosclerotic lesions are more severe and diffuse 
11;12.  
Hyperglycaemia partly explains the increased cardiovascular risk associated with type 2 DM. 
however  the  risk  associated  with  hyperglycaemia  is  modest  compared  to  the  overall 
cardiovascular risk associated with type 2 DM. A 1% increase in HbA1c is associated with 18% 
increase in cardiovascular events 
13.Other cardiovascular risk factors associated with type 2 DM 
such as hypertension and dyslipidaemia are as, if not more important in the development of 
CVD in type 2 DM. For example blood pressure shows a stronger association with CVD in 
patients with type 2 DM compared to blood glucose levels 
14.  
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Insulin resistance is also an important cardiovascular risk factor independent of diabetes status 
15-17. Insulin resistance is associated with a characteristic dyslipidaemia (high triglycerides, low 
HDL and preponderance of small dense LDL particles), hypertension and obesity 
18. A number 
of  interventions  can  improve  insulin  sensitivity  including  pharmacological  agents  such  as 
metformin, increased physical activity and weight loss 
4. Measures of insulin sensitivity are not 
currently assessed in routine clinical practice, and targeting insulin resistance in the prevention 
of CVD is not currently a clinical priority.  
Current strategies for reducing cardiovascular risk in patients with type 2 DM predominantly 
focus on blood pressure and lipid management together with glycaemic control. The evidence 
behind these strategies will be discussed below. 
1.1.3.1  Hyperglycaemia  
Hyperglycaemia can be assessed by blood glucose levels or glycated haemoglobin  (HbA1c). 
HbA1c  gives  an  indication  of  blood  glucose  levels  over  the  preceding  6-8  weeks. 
Epidemiological studies have shown that hyperglycaemia, assessed by either HbA1c or blood 
glucose levels, are an important risk factor for CVD 
19;20. Previous studies had found a linear 
relationship between levels of glycaemia and cardiovascular risk 
20. A recent large meta-analysis 
however  found  a  non-linear  relationship  between  fasting  blood  glucose  levels  and 
cardiovascular risk 
21. For fasting blood glucose levels between 3.9 and 5.59 there was no longer 
a  significant  association  with  cardiovascular  risk 
21.  Optimal  blood  glucose  targets  for  the 
prevention of CVD are not clear. Based on the earlier epidemiological studies it was assumed 
that achieving tight glycaemic control with the aim of near normal blood glucose levels would 
lead  to  a  reduction  in  CVD  in  patients  with  type  2  DM.  Many  cardiovascular  prevention 
guidelines therefore recommend target HbA1c levels of 7% or less 
22-24. Evidence from a number 
of randomised controlled trials has however questioned this strategy.  
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Managing hyperglycaemia 
Managing  hyperglycaemia  usually  begins  with  lifestyle  interventions  such  as  dietary 
modification and the recommendation to increase physical activity. This is then followed by oral 
agents; three main drug classes of which are currently in widespread clinical use (biguanides, 
thiazolidinediones and sulphonylureas). These can be divided into insulin sensitizers, biguanides 
(metformin) and thiazolidinediones, and insulin secretogogues such as sulphonylureas. Insulin is 
usually added once oral agents fail. 
Based on the epidemiological evidence it was hypothesised that improving glycaemic control in 
patients  with  type  2  DM  would  reduce  cardiovascular  events.  A  number  of  randomised 
controlled trials have aimed to test this hypothesis; 4 of the key studies will be discussed below. 
The  UKPDS  (UK  Prospective  diabetes  study)  study  began  in  1977  and  reported  in  1998 
compared intensive glucose control compared to conventional treatment in 3867 patients with 
newly diagnosed type 2 DM 
25. Intensive blood glucose control was achieved with increased use 
of sulphonylureas and insulin compared to conventional treatment. The difference in HbA1c was 
7.0% in the intensive group compared to 7.9% in conventional group. There was no reduction in 
macrovascular disease in the intensive group compared to conventional group. Weight gain was 
higher in the intensive group and episodes of hypoglycaemia more common.  
The  ADVANCE  study  (Action  in  Diabetes  and  Vascular  Disease:  Preterax  and  Diamicron 
Modified Release Controlled Evaluation study) looked at intensive blood glucose control and 
vascular outcomes in approximately 11,000 patients with type 2 DM. Patients were randomised 
to standard glucose control or intensive glucose control 
26. All patients in the intensive group 
were prescribed the sulphonylurea, gliclazide together with other drugs as necessary to achieve 
an  HbA1c  of  6.5%  or  less.  The  primary  endpoint  was  the  combined  outcome  of  major 
macrovascular and microvascular events. After 5 years of follow-up the average HbA1c level in  
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the  intensive  group  was  6.5%  compared  to  7.3%  in  the  standard  group.  There  was  a  10% 
reduction  in  the  combined  primary  endpoint  but  this  was  achieved  through  a  21%  relative 
reduction  in  nephropathy.  There  was  no  reduction in  macrovascular  events in  the  intensive 
group. All cause mortality was similar between the two groups. Severe hypoglycaemia occurred 
more frequently in the intensive group. At the end of follow-up mean weight was 0.7kg greater 
in the intensive group compared to standard.  
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes study) also aimed to 
test whether intensive glucose control would reduce macrovascular disease in patients with type 
2 DM 
27. The study also randomised patients to aggressive blood pressure and lipid control in a 
double  two-by-two  factorial  design.  All  ten  thousand  patients  were  randomised  to  either 
intensive  or  standard  blood  glucose  control  with  the  primary  outcome  non-fatal  myocardial 
infarction or stroke or death from any cardiovascular cause. Blood glucose control was achieved 
in both groups through the combination of oral agents together with insulin. Within the intensive 
group there was higher prescription of all blood glucose lowering therapies but in particular the 
use of 3 or more agents, insulin and thiazolidinediones. The study was terminated by the safety 
monitoring committee 17 months early due to the finding of increased mortality in the intensive 
group. At the time the study ended HbA1c levels were 6.4% in the intensive group compared to 
7.5% in the standard group. All cause mortality was significantly increased in the intensive 
group with no reduction in major cardiovascular events. Hypogylcaemia and weight gain was 
more common in the intensive group. 
Finally VADT (Veterans Affairs Diabetes Trial) assessed intensive versus standard control in 
1791 military veterans and once again found no significant effect on cardiovascular death or all 
cause mortality in the intensive group 
28. The HbA1c was 8.4% in the standard group compared 
to 6.9% in the intensive group.  
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In  these  studies  improved  glycaemic  control  did not  result  in  a  reduction  in cardiovascular 
mortality and morbidity. Given the epidemiological evidence linking hyperglycaemia and CVD 
these findings are somewhat unexpected and the reasons for this discrepancy are not clear. The 
studies may have been underpowered since in all studies cardiovascular event rates were lower 
than expected. A recent meta-analysis published looking at 33 000 patients in 5 randomised 
controlled trials suggested that improved glycaemic control, as assessed by HbA1c, is associated 
with a reduction in cardiovascular events without an increase in all cause mortality 
29.  
The increased weight gain and episodes of hypoglycaemia found in the intensive groups may 
also be important. The ACCORD study which found increased mortality in the intensive group 
achieved tight glycaemic control rapidly in patients with long standing diabetes. The risk of 
severe hypoglycaemia was therefore greatest in this study with rates of 24.1% in the intensive 
group compared to 17.6% in the standard group 
27. Hypoglycaemia is postulated as a cause of 
sudden death in patients with type 1 DM and may be a precipitant for cardiac arrhythmias 
through QT prolongation 
30. 
The  method  by  which  glycaemic  control  is  achieved  may  be  important.  Clearly  in  the 
epidemiological studies low blood glucose levels occur via very different processes to those 
induced during the management of patients with type 2 DM. All the discussed studies used a 
combination of various oral agents with the addition of insulin as necessary. Within the UKPDS 
study a subgroup of overweight patients with intensive blood glucose control using metformin 
showed a reduction in all cause mortality compared to obese patients receiving conventional 
treatment
31. The metformin group had significantly fewer myocardial infarctions compared to 
obese group receiving conventional management however rates of myocardial infarct did not 
differ from the other intensive therapy groups.
31. In the more recent studies thiazolidinediones 
were  commonly  prescribed,  particularly  in  the  ACCORD  trial 
26.  Recently  there  has  been 
increasing concern with possible increased risk of CVD associated with thiazolidinediones 
32.   
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At present there is insufficient evidence from randomised control trials to advocate attempting to 
achieve  near  normal  blood  glucose  levels  specifically  for  the  prevention  of  CV  disease  in 
patients  with  type  2  DM.  Furthermore  in  some  circumstances  tight  glycaemic  control  may 
actually be harmful. 
1.1.3.2  Hypertension  
Hypertension is an important risk factor for CVD and is more prevalent in patients with type 2 
DM. In the general population reducing blood pressure by an average of 12/6mmHg reduces the 
incidence of CAD by 20% with comparable reductions in patients with and without type 2 DM 
33. The relationship between blood pressure and incidence of macrovascular disease in patients 
with type 2 DM is stronger than the  relationship with hyperglycaemia 
34 Controlling blood 
pressure is therefore one of the cornerstones in preventing CVD in patients with type 2 DM.  
The majority of studies have shown blood pressure to be a continuous risk factor for CVD. With 
the  lower  the  blood  pressure  the  lower  the  cardiovascular  risk  and  with  no  level  of  blood 
pressure  which  is  not  associated  with  further  risk  reduction
33;34.  When  to  introduce 
antihypertensive therapy is therefore a balance between benefit and adverse effects of treatment 
and dependant on overall cardiovascular risk. In high risk patients such as those with type 2 DM 
and established CVD lower blood pressure targets are therefore recommended 
22-24. There was 
until very recently little evidence from randomised controlled trials to support this strategy of 
intensive blood pressure lowering in patients with type 2 DM. The blood pressure arm of the 
ACCORD study aimed to address whether very tight blood pressure targets would reduce CVD 
in patients with type 2 DM
35. The results of the ACCORD trial showed no benefit with targeting 
systolic blood pressure to less than 120mmHg compared to 140mmHg
35. In addition, patients in 
the intensive group experienced more adverse events attributed to antihypertensive therapy 
35. 
The optimal blood pressure target for the reduction of cardiovascular events in patients with type  
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2 DM is therefore not clear however based on the evidence there appears to be little addition 
benefit from tighter blood pressure control.  
Achieving  blood  pressure  control  appears  to  be  the  more  important  factor  than  choice  of 
antihypertensive therapy. Meta analysis has failed to show any class of anti-hypertensive to be 
superior in preventing CVD 
33. There is however a disparity between the expected reduction in 
CVD with blood pressure lowering based on epidemiology evidence and the actual reduction 
achieved in randomised controlled trials 
36. Much of this evidence comes from early trials that 
used beta-blockers and diuretics raising the question whether newer agents would be superior. 
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) suggested increased benefit from 
the  combination  of  calcium  channel  blocker  (CCB)  with  angiotensin  converting  enzyme 
inhibitor  (ACEi)  compared  to  β-blocker  and  diuretic  in  a  population  of  patients  with 
hypertension  and  at  least  3  other  cardiovascular  risk  factors  including  type  2  DM 
37.  This 
difference may simply reflect slightly (although not significant) lower blood pressure in the 
CCB/ACEi group. Other possible explanations are improved metabolic profile or differences in 
central pressures with ACEi and CCB combination 
37;38. What is known is that ACEi and ARBs 
significantly  reduce  progression  of  kidney  disease  in  patients  with  DM 
39.  For  this  reason 
ACEi/ARBs are commonly used as first line antihypertensives in patients with type 2 DM. 
1.1.3.3  Dyslipidaemia  
Type  2  DM  and  other  insulin  resistant  states  are  associated  with  a  typical  pattern  of  lipid 
abnormalities that is characterised by low HDL levels and elevated triglyceride levels LDL 
levels are comparable to those in the general population 
40. 
LDL cholesterol 
Epidemiological studies have shown increasing prevalence of CVD with increasing levels of 
LDL 
41.  Lowering  cholesterol  by  any  means,  diet,  drugs  or  even  ileal  bypass,  significantly  
37 
reduces rates of cardiovascular disease 
42;43. The majority of the evidence for lowering LDL 
however comes from the numerous “statin” trials. HMG-COA reductase inhibitors or “statins” 
are a safe and well tolerated class of medication that lower cholesterol levels by inhibiting 
HMG-CoA reductase which is the rate limiting step in the production of cholesterol. The meta-
analysis by the Cholesterol Trialists Collaboration, looked at 90 056 participants in 14 statin 
trials
44. This analysis showed that the 5 year incidence of coronary events, revascularization and 
stroke was reduced by approximately 20% for every 1 mmol reduction in LDL. Importantly this 
reduction in cardiovascular disease was seen irrespective of starting levels of LDL with benefit 
continued to be seen in patients with normal and even low LDL levels. These results were seen 
both in patients with and without diabetes. Increasingly guidelines are therefore recommending 
ever lower targets for LDL levels in patients at high risk of CVD. This includes patients with 
established CVD and patients with type 2 DM (table 1.1). 
Table 1.1. LDL targets for patients at high risk of CVD 
Organisation  Most recent LDL 
target 
Previous LDL target 
JBS*  <2mmol/L (2005)  <3mmol/L (2000) 
Joint Task Force**   <2mmol/L (2007)  <3mmol/L (2003) 
AHA/ACC***  <1.8 (2006)  <2.6 (2001) 
*JBS;  Joint  British  Societies’  guidelines  on  prevention  of  cardiovascular  disease  in  clinical 
practice 2005 
22 2000 
45 **Joint task force; Joint Task Force of European and other Societies 
European task force on cardiovascular disease prevention in clinical practice 2007 
24 2003 
46. 
***AHA/ACC, American Heart Association, American College of Cardiology Guidelines for 
Secondary Prevention for Patients with coronary and Other Atherosclerotic Vascular Disease 
2006 
23 2001
47.  
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Levels of LDL are not higher in patients with type 2 DM compared to the general population. In 
the Framingham Heart Study the prevalence of high LDL levels in men and women with DM 
was 9% and 15% respectively compared to 11% and 16% in men and women without DM 
40. 
However as LDL is such a strong risk factor for CVD and statins are so efficient and well 
tolerated lowering LDL in patients with diabetes has been a major target for reducing CVD. 
HDL cholesterol  
Low HDL levels are a feature of the dyslipidemia associated with type 2 DM and other insulin 
resistant states. Low HDL levels are an important risk factor for CVD. This relationship was 
first identified in the 1970s through the Framingham heart study and a number of subsequent 
studies  since 
48-50.  HDL  can  be  raised  by  lifestyle  factors  including  weight  loss,  dietary 
manipulation and increased physical activity 
51-53. There is currently no pharmacological agent 
available  that  raises  HDL  alone.  The  cholesterol  ester  transfer  protein  (CETP)  inhibitor 
torcetrapib which specifically raised HDL has been withdrawn due to increased cardiovascular 
events 
54. Statins have very minor effect on HDL levels
44. Fibrates, thiazolidinediones and niacin 
can  increase  HDL  to  varying  degrees  but  all  also  have  a  number  of  other  effects 
55-57.  In 
summary although low HDL is an important risk factor for CVD it is probably one that is not at 
present being adequately addressed in clinical practice.  
1.1.3.4  Other strategies: lifestyle factors: obesity and physical activity 
Lifestyle modification is an important part of the management of type 2 DM. Modifying oral 
intake and levels of physical activity are usually the initial steps recommended for improving 
glycaemic control. Obesity and levels of physical activity are also risk factors for CVD so 
important targets in the quest to reduce CVD 
2;58. 
  
39 
Obesity 
Obesity is defined by a body mass index (BMI) of 30kg/m
2 or greater
59. Waist circumference is 
clinically the best method for detecting increased visceral fat
59. The prevalence of obesity is 
increasing rapidly throughout the world 
60. Obesity, particularly central obesity is pivotal in the 
development of type 2 DM and is also an important risk factor for CVD 
2;61. Hypertension, 
dyslipidaemia and type 2 DM are all more prevalent in people who are obese 
60. 
The driving force behind the obesity epidemic is a combination of reduced physical activity and 
the greater availability of energy rich foods. This can be illustrated by the dramatic increases in 
prevalence of type 2 DM seen when rural communities migrate to cities and adopt western style 
diets 
62;63.  It  therefore  follows  that  the  management  of  obesity  should  focus  on  increasing 
physical activity and reducing energy consumption. Studies show that weight loss of only 5%-
10% result in improvements in blood glucose levels, lipids and blood pressure
64. Even modest 
weight  reduction  can  be  extremely  difficult  to  achieve
65.  There  is  therefore  interest  in  the 
development of pharmacological agents to augment the weight loss that can be achieved with 
lifestyle modification. To date pharmacological agents had little success with rimonabant and 
sibutramine both being withdrawn due to safety concerns
66;67. The only pharmacological agent 
currently  available  specifically  aimed  at  tackling  obesity  is  orlistat.  Orlistat  impairs  the 
absorption of fat and only has modest effects on weight loss
68. Obesity is a cardiovascular risk 
factor that is probably not adequately addressed in the management of patients with type 2 DM. 
Sedentary lifestyles  
For over 50 years it has been recognised that sedentary lifestyles are an important risk factor for 
CVD.  In  1953  the  now  classic  epidemiological  study  by  Morris  et  al.
58  showed  that  the 
conductors compared to bus drivers had lower rates of CAD. Furthermore when conductors 
were diagnosed with CAD it tended to be later in life with a lower mortality. This difference was  
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partly attributed to the conductors being more physically active at work compared to bus drivers. 
Since then numerous studies have confirmed a reduction in levels of CVD with increased levels 
of physical activity 
69-71. Physical activity reduces blood pressure increases HDL and reduces 
risk of type 2 DM, however there also appears to be an independent effect of physical activity 
69. 
For  the  prevention  of  CVD  it  is  recommended  that  individuals  take  30  minutes  of  regular 
physical activity most days of the week 
22. The 2008 Scottish health survey estimates only 39% 
of adults met these recommendations
72.  
1.1.4  Summary 
Type 2 DM is associated with increased risk of CVD. Tackling the traditional risk factors such 
as LDL and hypertension can partly reduce this risk. Hyperglycaemia is an important risk factor 
for CVD but current evidence does not support strict blood glucose lowering for the prevention 
of CVD. Lifestyle factors such as obesity and sedentary lifestyles are important risk factors for 
both type  2  DM  and  CVD  and  are  therefore attractive  targets although  ones  that  are  often 
difficult to modify. In view of these difficulties novel strategies for reducing CVD in patients 
with DM are required. 
1.2  Mechanisms underlying CVD: the cardiovascular continuum 
A greater understanding of the mechanisms underlying the development of CVD in patients with 
type 2 DM may help identify novel cardiovascular management strategies. CVD can be viewed 
as  a  continuum  that  spans  from  patients  with  cardiovascular  risk  factors,  through  vascular 
abnormalities  such  as  endothelial  dysfunction  and  arterial  stiffness,  to  the  development  of 
atherosclerotic lesions and eventually established end stage disease (figure 1.1) 
73..  
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Figure 1.1 The cardiovascular continuum. (Adapted from Dzau et al. 
73) 
 
1.2.1  The atherosclerotic lesion 
The underlying pathological abnormality in CVD is the atherosclerotic lesion. Atherosclerotic 
lesions occur in the arterial system predominantly at the sites of bifurcations. Atherosclerotic 
lesions develop slowly over many years, with the initial abnormality; fatty streaks developing in 
adolescence 
74 . Extracellular deposition of lipids is followed by an inflammatory infiltrate of 
monocytes and T lymphocytes to form fatty streaks 
74. Monocytes develop in to macrophages 
and scavenge modified lipids to form foam cells 
75. The inflammatory infiltrate and foam cells 
secrete inflammatory mediators and produce reactive oxidative species resulting in the migration 
and proliferation of vascular smooth muscle cells
76. This process continues with further lipid 
deposition,  inflammatory  infiltration  and  vascular  smooth  muscle  cell  proliferation.  As  the 
lesion develops focal necrosis occurs at the centre; attracting further inflammatory cells and 
formation of fibrous tissue
74. The lesion is now termed a complex lesion consisting of a fibrous 
cap overlying a core of lipid and necrotic tissue. The lesion may continue to expand producing 
clinical symptoms secondary to gradual reduction in arterial flow. The plaque may also rupture 
with thrombus forming lending to acute occlusion of the vessel
74-77.  
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Multiple processes are involved in the initial development and progression of atherosclerotic 
plaques. Important processes in the development of atherosclerosis are endothelial dysfunction, 
oxidative  stress,  inflammation  and  increased  arterial  stiffness
74;76;78-80.  Cardiovascular  risk 
factors such as dyslipidemia, hyperglycaemia and hypertension are understood to act through 
these processes to contribute to the development of atherosclerosis and CVD
78;79;81. 
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Figure 1.2 The atherosclerotic process (Adapted from Ross
74). 
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1.2.2  Endothelial dysfunction 
Disruption of the normal endothelial function or endothelial dysfunction is one of the earliest 
steps in the development of atherosclerosis
82;83. The basic structure of the human vasculature 
consists of adventitial tissue, vascular smooth muscle cells and finally the endothelium. The  
45 
endothelium is composed of a single layer of endothelial cells and is pivotal in maintaining 
normal vascular function. In health the endothelium maintains the balance between vasodilation 
and vasoconstriction, pro-thrombotic and anti-thrombotic, inflammatory and anti-inflammatory 
processes
82;83. Production of nitric oxide (NO) is one of the key mediators of these processes. 
NO  is  produced  by  endothelial  nitric  oxide  synthase  (eNOS)  through  the  conversion  of  L-
arginine to L-citrulline
78. NO is a potent vasodilator and the balance between production of NO 
and vasoconstrictors such as endothelin maintains vascular tone. In the vascular smooth muscle 
cells (VSMC) NO activates guanylate cyclase resulting in cGMP mediated vasodilation
78. In 
addition NO reduces platelet adhesion, leukocyte migration and proliferation of VSMC
78;84. In 
health  these  processes  are  balanced  and  produce  a  vascular  phenotype  that  prevents  the 
development of atherosclerosis. 
Endothelial dysfunction describes a pathological state in which many of the normal functions of 
the endothelium are disrupted. Impairment of normal endothelial function therefore results in a 
complex  array  of  abnormalities  including  disruption  of  normal  vaso-regulation,  increased 
adhesion and migration of leukocytes, platelet aggregation and vascular smooth muscle cell 
proliferation
83. All of which as discussed are key steps in the development of atherosclerotic 
plaques.  Reduced  NO  bioavailability  is  fundamental  to  the  development  of  endothelial 
dysfunction
84. The hallmark of endothelial dysfunction is therefore attenuated NO dependent 
vasodilation
85.  
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Figure 1.3 Endothelial dysfunction (Adapted from Hamilton et al.
79) 
 
1.2.3  Oxidative stress 
Reactive oxygen species (ROS) are a group of highly oxidative molecules and are produced in 
all  cells.  They  include  superoxide  (O2
-),  hydroxyl  radical  (HO
∙)  hydrogen  peroxide  (H2O2), 
peroxynitrite (ONOO
-) and lipid radicals among others
84;86. Of these O2
- is one of the most 
important  ROS.  O2
-  is  the  principle  ROS  produced  by  the  vasculature  and  inflammatory 
cells
86;87. In addition O2
- produces further ROS through chain reactions. For example, O2
- rapidly 
scavenges NO to produce peroxynitrite
84 Not only does this reduce the bioavailability of NO but 
peroxynitrite itself is highly oxidative
84. ROS are produced during normal cellular function and 
play a physiological role in intracellular signalling
88. However due to the highly reactive nature 
of ROS complex antioxidant scavenging systems are in place to keep levels in balance. For 
example O2
- is converted by superoxide dismutase to H2O2
88. H2O2 is converted to water by  
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catalase  and  glutathione  peroxidase
88.  Increased  oxidative  stress  occurs  when  there  is  an 
imbalance  between  the  production of  ROS and the  antioxidant  systems  that scavenge  these 
molecules. Increased oxidative stress can therefore result from either increased production of 
ROS or impaired scavenging systems or a combination of both.  
Increased oxidative stress and ROS exacerbate many of the proatherogenic processes underlying 
the  development  of  CVD.  Oxidative  stress  contributes  to  the  development  of  endothelial 
dysfunction. ROS such as O2
- react rapidly with NO
84;89. Reduced bioavailability of NO results 
in impaired endothelial function manifested by loss of vasodilation, platelet aggregation and 
inflammation
90. Increased levels of ROS also potentiate the formation of oxidized LDL a key 
substance in the formation and maintenance of atherosclerotic lesions
91. Furthermore oxidized 
LDL can itself increase levels of oxidative stress 
91. ROS exacerbate inflammation in the vessel 
wall through the increased adhesion and migration of monocytes 
92. Increased oxidative stress 
can contribute to proliferation and migration of vascular smooth muscle cells
90. 
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Figure 1.4 Oxidative stress (Adapted from Hamilton et al.
79). 
 
1.2.4  Arterial stiffness 
As  part  of  the  aging  process  vessels  become  increasingly  stiff  and  this  process  can  be 
accelerated by the presence of cardiovascular risk factors such as hypertension, hyperlipidaemia 
and diabetes
80;93. The mechanical properties of arteries are complex however in simple terms 
normal  arterial  physiology  protects  the  microcirculation  from  pressure-induced  damage  and 
ensures adequate perfusion of the coronary vessels during diastole
94. Increased arterial stiffness 
can alter these normal processes and contribute to the development of cardiovascular disease. 
Under normal conditions the aorta transforms the pulsatile on-off blood flow of the left ventricle 
in to less pulsatile flow in distal vessels and smooth non pulsatile flow in capillaries
94. This 
system  protects  the  microcirculation  from  damage  due  to  high  pressures  and  ensures  the 
coronary arteries have sufficient blood flow in diastole to meet metabolic requirements of the 
heart. The ability of the aorta and proximal arteries to buffer the pulsatile flow during systole  
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depends in part on the compliance of these vessels
94. The phenomenon of wave reflection also 
plays a role in normal arterial function. Changes in vessel diameter and stiffness occur as the 
arterial tree branches and tapers. This results in reflection of a proportion of the propagating 
pressure wave
95. In ideal circumstances the reflected wave returns to the central aorta in diastole 
enhancing coronary perfusion. Furthermore wave reflection reduces the transmission of pulsatile 
energy to the microcirculation
96. Increased arterial stiffness reduces compliance of aorta and 
proximal vessels. This results in a reduction in the buffering properties of these vessels and early 
return of  the reflected wave
97. Reflected waves arriving in late systole increase or augment 
central  systolic  pressure  increasing  left  ventricular  afterload  and  altering  coronary  artery 
perfusion
95. These changes contribute to left ventricular hypertrophy, worsening of coronary 
ischaemia, and increased vessel wall stress with risk of atherosclerotic plaque rupture
96.  
1.3  CAD and the role of surgical revascularisation 
As discussed CVD encompasses stroke, peripheral vascular disease and CAD all of which have 
the same underlying pathogenesis. The focus of this study will be patients with CAD undergoing 
elective  surgical  revascularisation  or  coronary  artery  bypass  grafting  (CABG).  Patients 
undergoing CABG are an attractive study group for a number of reasons. Firstly they represent a 
group of patients with severe atherosclerotic disease. Secondly they are well phenotyped with all 
patients having undergone thorough investigation including diagnostic angiography to confirm 
the diagnosis of severe CAD prior to surgery. Thirdly there is the opportunity to obtain samples 
of the by-pass grafts for ex vivo studies that are surplus to clinical requirements.  
Revascularisation techniques, either percutaneous or surgical, for patients with established CAD 
have become an important and effective management option. For most patients with left main 
stem coronary artery lesions or triple vessel CAD surgical revascularisation is the treatment of 
choice
98. Approximately 1600 patients undergo CABG in Scotland annually. In 2009, 45.7% of  
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patients undergoing CABG had triple vessel disease and 42.1% had left main stem lesions. 
Approximately 24% of these patients had diabetes
99. Overall short and long term outcomes 
following CABG are good. In patients undergoing CABG in Scotland in patient mortality is 
2.3%,  with  10  year  survival  of  26.3%
99.  These  rates  are  similar  to  those  reported  in  other 
studies
100;101. Both short and long term outcomes are worse in patients with diabetes compared to 
patients  without  diabetes
101-103.  CABG  in  patients  with  diabetes  is  however  associated  with 
improved long term survival compared to percutaneous intervention
101;103. CABG is therefore 
the management of choice for patients with diabetes and multivessel CAD
104. 
1.4  Study aims and objectives 
Type 2 DM is associated with increased cardiovascular risk. Recent studies such as ACCORD 
and ADVANCE have highlighted some of the limitations with current cardiovascular prevention 
strategies for patients with type 2 DM. This study has three broad aims. By studying patients 
with  severe  CAD  undergoing  CABG  this  study  firstly  aims  to  investigate  some  of  the 
mechanisms underlying cardiovascular disease and secondly to assess the impact of type 2 DM. 
Finally the effect of two CV prevention strategies on these mechanisms will be evaluated. 
Chapter 3 focuses on the assessment of arterial stiffness. Arterial stiffness is understood to play 
an important role in the development of CVD. Clinical assessment of arterial stiffness may assist 
in the management and prevention of CVD. The hypothesis was that patients with CAD would 
have increased arterial stiffness compared to healthy controls. Secondly patients with CAD and 
type 2 DM would have increased arterial stiffness compared patients with CAD alone. 
The aims of chapter 3 were therefore: 
1.  To use pulse wave velocity (PWV) and pulse wave analysis (PWA) techniques to assess 
indicators of arterial stiffness in patients with CAD compared to healthy controls.  
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2.  To use PWV and PWA techniques to assess indicators of arterial stiffness in patients 
with CAD and type 2 DM compared to patients with CAD alone. 
3.  To investigate the use of simpler indicators of arterial stiffness such as augmentation 
index compared to aortic PWV (current gold standard for assessing arterial stiffness). 
Since endothelial dysfunction is understood to be a pivotal process underlying the development 
of cardiovascular disease this is the focus of chapter 4. The hypothesis was to confirm that 
patients with CVD would have impaired endothelial function compared to healthy controls and 
secondly to confirm that patients with type 2 DM and CAD would have greater impairment of 
endothelial function compared to patients with CAD alone. 
The aims of chapter 4 were therefore to: 
1)  Investigate endothelial function using ex vivo and in vivo techniques in patients with 
CAD compared to healthy controls 
2)  In patients with CAD assess the impact of type 2 DM on endothelial function. 
3)  To evaluate the use of a non-invasive PWA based technique for assessing endothelial 
function in vivo. 
Chapter 5 focuses on oxidative stress as this is understood to be one of the major mechanisms 
underlying both endothelial function and CV disease. The hypothesis was that patients with 
CAD would have increased oxidative stress compared to healthy controls. Furthermore that 
patients with CAD and type 2 DM would have increased levels of oxidative stress compared to 
patients with CAD alone. 
The aims of chapter 5 were therefore to:  
1)  Measure superoxide levels in vascular tissue, mononuclear cells and whole blood as an 
indicator of levels of oxidative stress.  
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2)  Compare levels of oxidative stress in patients with CAD compared to healthy controls. 
3)  Measure levels of oxidative stress in patients with CAD and type 2 DM compared to 
patients with CAD alone 
4)  Evaluate the  use  of  whole  blood superoxide  as  a  simple  direct  measure  of  reactive 
oxygen species and an indicator of levels of oxidative stress. 
Chapter 6 aims to investigate whether dyslipidaemia in patients with type 2 DM and CAD might 
partially account for the impaired endothelial function found in patients with type 2 DM. The 
hypothesis  was  that  patients  with  type  2  DM  would  have  lower  HDL  levels and  increased 
triglyceride  levels  and  small  dense  LDL  particles  compared  to  patients  without  diabetes. 
Furthermore  that  these  abnormalities  may  partially  explain  the  endothelial  dysfunction 
associated with type 2 DM described in chapter 4.  
The aims of chapter 6 were therefore to assess triglyceride, HDL and LDL levels in patients 
with type 2 DM and CAD compared to patients with CAD alone. Furthermore to investigate 
LDL and HDL particle size in patients with CAD and type 2 DM compared to patients with 
CAD alone. 
LDL reduction by statin therapy is a major strategy for management of CVD in patients with 
and without DM; this is the focus of chapter 7. LDL levels are an important risk factor for CVD 
and  determinant  of  endothelial  function.  Over  the  years  guidelines  have  recommended 
increasingly tight LDL targets. The hypothesis was that patients managed under these newer 
guidelines would have lower LDL levels, reduced oxidative stress and improved endothelial 
function compared to patients managed during older guidelines. Furthermore that this effect 
would be greater in patients with type 2 DM and CAD who are understood to have greater 
impairment of endothelial function and increased oxidative stress compared to patients without 
DM.  
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The aims of chapter 7 were to assess LDL levels, oxidative stress and endothelial function in 
patients with CAD undergoing CABG in 2007 compared to a group of patients investigated in 
2003. 
Levels  of  physical  activity  are  low  in  the  general  population.  Sedentary  lifestyles  are  an 
important risk factor for CVD and type 2 DM. The focus of chapter 8 is therefore the effect of 
increased physical activity on processes underlying CVD. The hypothesis was that in patients 
who attended exercise classes as part of cardiac rehabilitation would have improved endothelial 
function and reduced oxidative stress compared to patients who elected not to attend exercise 
classes. 
The aims of chapter 8 were firstly to assess endothelial function and oxidative stress in patients 
before  and  after  12  weeks  of  exercise  classes  that  form  part  of  the  cardiac  rehabilitation 
programme. Secondly to assess the impact of number of classes attended on these variables.  
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2  Methods  
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2.1  Participants 
2.1.1  VASCAB study 
The CAD group consisted of patients with stable coronary artery disease attending for elective 
CABG. Volunteers were recruited at preoperative assessment clinic at the Western Infirmary, 
Glasgow between October 2006 and February 2008. This clinic took place on a Wednesday 
afternoon and included patients from across the West of Scotland. Patients were recruited the 
week preceding by-pass surgery. Recruits were examined in the clinical research facility at the 
BHF Glasgow Cardiovascular Research Centre (BHF GCRC) the afternoon prior to surgery (the 
day  of  hospital  admission).  Patients  were  asked  to  avoid  large  meals  for  3  hours  prior  to 
assessment  and  to  avoid  smoking.  Patients  were  asked  to  take  their  medication  as  usual. 
Exclusion criteria were atrial fibrillation, co-existing valvular heart disease, type 1 DM and 
previous CABG. Classification of diabetes was made following case note review and history 
using the WHO guidelines for classification of diabetes
3. This was done to ensure that patients 
treated with insulin only were not misclassified. 
Two  hundred  and  sixteen  patients undergoing  CABG  were eligible  for recruitment  into the 
study. Thirty (14%) patients declined to be part of the study upon initial approach in the pre-
operative clinic. Sixty (28%) further patients did not attend the initial appointment at the BHF 
GCRC. Cancellation of appointments was usually the consequence of either a change in the date 
or location for the patients operation. 
The control group consisted of both patients attending for elective VV removal and participants 
recruited from local health clubs. 
Control (or healthy) saphenous veins were obtained from patients attending for elective VV 
removal who were recruited from the vascular surgery unit at Gartnavel hospital during pre- 
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operative assessment by the surgical team. Exclusion criteria were previous history of CAD 
(including  angina,  myocardial  infarction  and  CABG),  type  1  or  type  2  DM,  hypertension 
requiring two or more antihypertensive agents and untreated hypercholesterolaemia. Patients 
were examined 8 weeks after surgery in clinical research facility at the BHF GCRC. 
Patients undergoing surgery for VV tend to be younger with a higher proportion of females 
compared to CABG patients. In view of this a further group of healthy controls were recruited. 
This group were age and sex matched to the CABG patients and recruited from local health 
clubs in response to advertisements. Exclusion criteria were previous history of CAD (including 
angina, myocardial infarction and CABG), type 1 or type 2 DM, hypertension requiring two or 
more antihypertensive agents and untreated hypercholesterolaemia.  
2.1.2  2003 cohort 
The 2003 group consists of patients with CAD and controls attending for VV surgery that were 
studied between February 2003 and February 2004. Detailed history and clinical examination 
was taken between 1 and 7 days prior to surgery. The control groups were used to confirm 
consistency of vascular function and O2
- studies between 2003 and 2007.  
2.1.3  Exercise study  
Patients  attending  cardiac  rehabilitation  following  coronary  artery  bypass  grafting  were 
recruited. The rehabilitation assessment clinic was held in the Western Infirmary, Glasgow on 
Friday mornings and run by the cardiac rehabilitation nurses and physiotherapists. Patients were 
assessed  in  the  clinic  approximately  6  weeks  after  discharge  following  CABG.  Detailed 
assessment of the patient’s recovery from surgery was evaluated by the cardiac rehabilitation 
team. Exercise tolerance was then assessed by the physiotherapists using a validated step test or 
shuttle walk test 
105;106. Cardiac rehabilitation consists of a 10 week programme which includes 
twice  weekly  exercise  classes.  The  exercise  classes  are  adapted  to  an  individual’s  exercise  
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capacity  and  consist  of  15  minutes  warning  up  and  down  and  30  minutes  cardiovascular 
training. Patients are asked to work at 65-80% of age predicted maximal heart rate based on self 
assessment of pulse rate and use of the Borg scale (Borg’s perceived exertion scale).  
Seventy seven patients were eligible for recruitment in to the exercise study. Thirty four patients 
agreed to participate in the study. 
Patients were assessed at BHF GCRC centre prior to commencing cardiac rehabilitation and 
then 12 weeks later. Patients attended the research centre in the morning following an overnight 
fast. 
Assessment of physical activity and functional capacity 
Levels of physical activity were assessed before and after cardiac rehabilitation programme 
using Scottish physical activity questionnaire (SPAQ see figure 10.2 in supplementary data). 
This is based on the more widely used Stanford 7 day recall questionnaire. In the SPAQ the 
language has been modified for use with a Scottish population and to enable the questionnaire to 
be self reported rather than interviewer based. SPAQ has been validated and shown to be a good 
estimate of levels of physical activity compared to objective measures using accelerometers 
107. 
Functional  capacity  before  and  after  cardiac  rehabilitation  was  assessed  by  physiotherapists 
using the shuttle walk test or chester step test
105;106.  
2.2  Ethics 
All  studies  were  performed  to  comply  with  the  declaration  of  Helsinki.  All  studies  were 
approved by the local ethics committee and approval letters are enclosed in section 10. All 
participants gave informed written consent.  
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2.3  Clinical examination  
All clinical studies were performed in the clinical research facility at the BHF GCRC except for 
the 2003 cohort. Details for the clinical examination in the 2003 cohort are provided separately 
below.  
All participants completed questionnaires (see section 10.1 in supplementary data) providing 
detailed information on lifestyle and medical history. Blood pressure was measured according to 
current  WHO  guidelines.  Participants  were  seated  for  5  minutes  prior  to  blood  pressure 
measurement. The arm was supported at the level of the heart. Any tight clothing was removed. 
Blood pressure was measured three times using a calibrated oscillometric device (Omron HEM-
750CP). The appropriate cuff size was used to ensure that the bladder encircled at least 80% of 
the arm. The first recording was discarded. The average of the second and third recordings was 
used in subsequent analysis. 
Height  was  measured  with  the  patient  barefoot  and  to  the  nearest  millimetre.  Tanita  Body 
Composition  Analyzer  BC-418MA  (Tanita  UK  limited)  was  used  to  measure  weight. 
Participants  were  weighed  fully  clothed  with  an  appropriate  clothing  allowance  subtracted 
(0.5kg for light summer clothes, 1kg for normal indoor wear). Waist and hip measurements were 
measured using an anthropometric tape measure. Waist circumference was taken as the smallest 
circumference  around  the  abdomen  with  the  participant  relaxed.  Hip  circumference  was 
measured as the largest measured circumference at the level of the buttocks. 
In the 2003 cohort detailed history and clinical examination was taken between 1 and 7 days 
prior to surgery. 
2.4  Routine biochemistry 
Venous blood samples were taken using Vacutainer® system. Plasma samples were centrifuged 
and  stored  at  -70
o  C.  Cholesterol,  triglyceride,  HDL  and  high-sensitivity  C-reactive  protein  
59 
(CRP) assays were performed by the staff (Professor Naved Sattar, Dr Lynne Cherry and Miss 
Christine Gourlay) of the routine lipids section of Glasgow Royal Infirmary. Cholesterol and 
triglycerides were measured using enzymatic colorimetric methods in Roche/Hitachi modular P 
analyser. Very low density lipoprotein (VLDL) and LDL cholesterol results were calculated 
using Friedewald equation (LDL= [total cholesterol]-[HDL]-[Triglyceride]/2.19). VLDL= [total 
cholesterol-LDL].  CRP  was  measured  using  particle-enhanced  immunoturbidimetric  assay 
(Roche diagnostics). 
Glycated haemoglobin (HbA1c) and urinary albumin:creatinine ratio (ACR) were assessed by a 
latex immunoagglutination inhibition method using the Bayer DCA 2000® (Bayer Diagnostics) 
Venous blood glucose was obtained using Accu-Chek® Advantage (Roche Diagnostics). 
2.5  Pulse wave analysis 
Pulse wave analysis (PWA) was performed using the SphygmoCor® device (AtCor medical). 
This system uses a tonometer connected to an electronics module to non-invasively record a 
peripheral pressure waveform. All PWA measurements were performed at the right radial artery. 
The wrist was slightly dorsiflexed and supported, the maximal pulsation of the radial artery was 
located. The tonometer was then placed over the site of maximal pulsation and gentle pressure 
applied. The position of the tonometer was adjusted until good quality pressure pulse tracings 
were obtained. Ten seconds of good quality pulse pressure tracings were then captured using the 
SphygmoCor® software.  
The shape of the tracing was inspected. The shape will change according to the age of the 
patient  and  cardiovascular  risk  factors;  however  the  basic  features  should  remain  constant 
(figure 2.1). The following were checked in all tracings; an initial sharp upstroke rising to an 
initial peak (T1) followed by a second shoulder (T2) and finally a notch marking closure of the  
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aortic  valve.  Waveforms  lacking  these  features  usually  reflect  incorrect  placement  of  the 
tonometer and were therefore repeated following repositioning. 
Figure 2.1 Typical Pulse wave tracing (from Williams et al.
38). 
 
1 
 
 
 
As well as the shape the recording was checked for quality. Quality control indices check pulse 
wave variables are within limits set using the configuration settings and include average pulse 
height, pulse height variation, diastolic variation. The quality index is an indicator of the overall 
quality of the captured data and was calculated by the software by assigning a weighting to each 
of the quality control indices. Recordings with a quality index of 80% or greater were accepted. 
Overlaid  recorded  data  was  also  checked.  This  area  displays  a  visual  guide  to  how  well 
individual pulses can be overlaid to form an average pulse. This is visually checked to ensure 
little variability. Baseline PWA recordings were made in duplicate. 
T0, time at the start of the waveform. T1, time from start of waveform to first peak. 
T2, time from start of waveform to second peak. ED ejection duration i.e. time form 
start  of  waveform  to  closure  of  aortic  valve  (incisura)  SP,  systolic  pressure.  DP, 
diastolic pressure, PP pulse pressure (SP-DP). P1, difference between the minimum 
pressure and the pressure at T1. ∆ P, Augmented pressure, difference between SP and 
P1. AIx ,Augmentation index, Augmented pressure divided by PP expressed as a 
percentage.   
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For each patient where the PWA tracings were of an acceptable quality the following variables 
from the aortic pressure waveforms were recorded; Time to the peak/shoulder of the first and 
second  pressure  wave  components  (T1,  T2).  The  pressure  at  T1  (P1  height).  The  pressure 
difference between P1 and the maximal pressure during systole (ΔP or augmentation). AIx; 
augmented pressure as a percentage of pulse pressure (ΔP/PP) x100. Time to reflected wave 
(TR) and ejection duration time from start of waveform to closure of aortic valve. 
2.6  Pulse wave velocity 
Pulse wave velocity (PWV) was measured non-invasively using SphygmoCor® device (AtCor 
medical, model SCOR_Vx, NSW, Australia). The system uses a high-fidelity tonometer (SPC-
301, Millar Instruments) and ECG leads connected to an electronics module to non-invasively 
record a peripheral artery pressure and ECG waveforms. PWV is determined from the distance 
between artery sites and the delay between the R wave in the ECG and the sharp systolic up-
stroke of the pulse wave. 
Measurements were recording in a quiet room at 20
oC. Participants were asked not to smoke or 
take caffeinated drinks for 3 hours prior to study. Participants were rested for 10minutes supine 
prior to recording commencing. Participants were asked to lie still and refrain from talking 
during the study. The ECG leads were connected and ECG tracing inspected to confirm sinus 
rhythm. Supine blood pressure was measured using a calibrated oscillometric device (Omron 
HEM-750CP).  
2.6.1   Brachial PWV  
The participant’s wrist was slightly dorsiflexed and the radial pulse located. The distance from 
the maximal pulsation of the radial artery to the suprasternal notch was measured. The patient 
was asked to slightly extend their neck and the carotid pulse was located. The distance from the  
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most  prominent  pulsation  of  the  carotid  artery  to  the  suprasternal  notch  was  recorded.  All 
measurements were in millimetres (mm) to the nearest mm.  
Pulse pressure wave forms were initially recorded at the radial artery in the right arm using the 
tonometer.  Once  again  the  participant’s  wrist  was  slightly  dorsiflexed  and  the  maximum 
pulsation of the radial artery located. The tonometer was placed over the maximal pulsation of 
the radial artery and the position adjusted until a good quality waveform was obtained. Pulse 
pressure recordings were then obtained for the carotid artery. With the patients neck slightly 
extended  maximal  pulsation  of  the  carotid  artery  was  located  and  pulse  pressure  tracings 
recorded. Capture time was set at 10 seconds. The Intersecting tangent method was used to 
identify the onset of the pressure pulse. This algorithm uses the point formed by the intersection 
of a line tangent to the initial systolic upstroke of the pressure waveform and a horizontal line 
through the minimum point. Brachial PWV were recorded in duplicate. 
2.6.2  Aortic PWV 
The above method was then employed to obtain aortic PWV readings. The distance from the 
maximal pulsation of the femoral artery to the umbilicus and then to the suprasternal notch was 
recorded. Maximum pulsation of the femoral artery was located and pressure tracings recorded. 
Pressure tracings were then captured from the carotid artery. Aortic PWV readings were also 
recorded in duplicate. 
2.7  Assessment of endothelial function 
2.7.1  Ex vivo assessment of endothelial function; organ bath studies 
Residual segments of saphenous veins were obtained during CABG surgery of patients with 
CAD. Control saphenous veins were obtained from patients undergoing elective VV surgery. In 
the operating theatre vessels were immediately stored in sterile saline solution before being 
transferred  to  the  research  laboratories  at  BHF  GCRC.  On  arrival  the  vessels  were  then  
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transferred  into  Krebs  HEPES  solution  (10mmol)  and  stored  under  refrigeration  until  the 
following  day.  Directly  prior  to  the  experiment,  vessels  were  cleaned  of  adherent  fat  and 
connective tissue, and then sliced into rings of 2-3mm length. The rings were transferred onto 
metal  hooks  and  suspended  in  organ  chambers  filled  with  10ml  oxygenated  Krebs  buffer 
solution (37°; 7.4 pH), containing indomethacin (0.02 mmol/L) to inhibit prostanoid-mediated 
vasoactive
  effects.  The  isometric  tension  studies  were  performed  using  a  Grass  FT03  force 
transducer and displayed using a MacLab dedicated computer. 
After stabilisation at a resting tension for approximately 1 hour, the vessels were activated with 
potassium chloride (KCl) 0.1M. Vessels were then washed out for 30 minutes and the KCl 
repeated. After activation, the vessels were washed out and allowed to rest for 30 minutes before 
any vasoactive agents were added. Resting tension was adjusted to 1g. 
To  assess  endothelium  dependent  vasodilation  the  vessels  were  pre-contracted  with 
phenylephrine 3x10
-6M before measurement of relaxation to calcium ionophore A23187. The 
dose-response curve to calcium ionophore was then carried out from concentrations 10
-8 to 10
-
5M.  Calcium  ionophore  stimulates  the  synthesis  and  release  of  nitric  oxide  by  increasing 
intracellular calcium, and is therefore an endothelium dependent vasodilator.  
To assess endothelium independent vasodilation a dose-response curve to sodium nitroprusside 
(10
-8 to 3x10
-6M; David Bull Laboratories, UK) was carried out. Vessels were preconstricted 
with phenylephrine 3x10
-6M before measurement of relaxation to sodium nitroprusside (SNP). 
SNP acts as a NO donor therefore causing endothelium independent vasodilation. 
Endothelial function studies in both the 2003 cohort and the VASCAB study (2007 cohort) were 
performed under the supervision of the same experienced researcher Dr Carlene Hamilton. 
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2.7.2  In vivo assessment of endothelial function 
In  vivo  assessment  of  endothelial  function  was  performed  using  the  methods  described  by 
Wilkinson  et  al.
108  and  Hayward  et al.
109. This  method  uses  PWA to  assess change  in  AIx 
following  administration  of  salbutamol  (endothelial  dependent  vasodilation)  and  GTN 
(endothelial independent vasodilation). Within observer variability of AIx  measurement was 
assessed in 10 healthy volunteers. AIx was measured twice on day 1 and then measurements 
repeated 24-48 hours later, to check for validity of repeated AIx measurements.  
Measurements were recording in a quiet room at 20
oC. Participants were rested for 10 minutes 
supine prior to the recording commencing. Participants were asked to remain still and to refrain 
from  talking  throughout  the  test.  Supine  blood  pressure  was  measured  using  a  calibrated 
oscillometric device (Omron HEM-750CP).  
Basal PWA recordings were made in triplicate according to the methods described in section 
2.1.4. Following the capture of basal PWA recordings 400µg of inhaled salbutamol (Salamol®; 
IVAX, UK) was administered via volumatic spacer device (Allen and Hanburys, Middlesex, 
UK). Salbutamol was administered via the use of a spacer device with assistance from the 
researcher to ensure reliable drug delivery as inhaler devices can be difficult to use without 
practice. 
Salbutamol  causes  reduced  pulse  wave  reflection
110.  These  effects  appear  to  be  due  to 
endothelial  dependent  NO  release  as  they  are  ameliorated  with  the  infusion  of  the  eNOS 
inhibitor L-NMMA
111. It is likely that salbutamol simulates NO release through the L-arginine 
NO pathway
111. 
PWA recordings were obtained in triplicate at 5, 10, 15 and 20 minutes following salbutamol. 
These timings are based on the findings by Wilkinson et al.
108 that the maximal change in AIx to  
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salbutamol  occurred  at  12±3  and  11±3  minutes  in  patients  with  hypercholesterolaemia  and 
healthy controls respectively. 
The average peripheral AIx was calculated at each time point. Peripheral AIx was used since it 
was felt to be preferable to use the raw readings rather than central recordings calculated using a 
generalised transfer function. Change in peripheral AIx from baseline was calculated for each 
time point. The maximum change in peripheral AIx from baseline was used as a measure of 
endothelium dependent vasodilation. 
Following salbutamol administration participants were then rested for 5 minutes. A further 3 
PWA  recordings  were  performed.  400µl  sublingual  GTN  (Nitrolingual®,  Lipha,  UK)  was 
administered. GTN is an NO donor resulting in endothelium independent vasodilation 
112. PWA 
was recorded in triplicate 5 minutes later. The change in peripheral AIx from baseline was then 
calculated. This was used as a measure of endothelial independent vasodilatation. 
2.8  Oxidative stress studies 
2.8.1   Vascular O2- measurement  
Vascular O2
- studies in both 2003 and VASCAB study (2007) group were performed under the 
supervision of the same experienced researcher Dr Carlene Hamilton. 
Residual segments of saphenous veins were obtained during CABG surgery of patients with 
CAD. Control saphenous veins were obtained from patients undergoing elective VV surgery. In 
the operating theatre vessels were immediately stored in sterile saline solution before being 
transferred  to  the  research  laboratories  at  BHF  GCRC.  On  arrival  the  vessels  were  then 
transferred  into  Krebs  HEPES  solution  (10mmol)  and  stored  under  refrigeration  until  the 
following day.   
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The following morning blood vessels were carefully dissected
 free of loose connective tissue, 
divided into 3-4 mm segments,
 and weighed. The vessels were then incubated in Krebs buffer
 at 
pH 7.4±0.02.
  
Vascular·O2
-  was  measured  by  lucigenin-enhanced  chemiluminescence.  Lucigenin-enhanced 
chemiluminescence is the most commonly used chemiluminescence technique for the detection 
of O2
-113. When O2
- reacts with lucigenin a series of reactions occur culminating in the release of 
a photon. The photon release can then be detected using a scintillation counter. Lucigenin based 
techniques are specific for O2
- and have been widely used. One of the major concerns is that 
lucigenin can itself react with oxygen to produce O2
- and therefore levels may be overestimated. 
This phenomenon can be partly overcome by using low doses of lucigenin 
114. Vascular O2
- was 
measured
 in a liquid scintillation counter (Hewlett Packard model Tricarb
 2100TR) in out of 
coincidence mode with a single active photomultiplier tube. Low dose lucigenin (5µmol/L) was 
used as described by Berry et al.
114. Counts were obtained at 2 minute intervals and quantified 
with a xanthine/xanthine
 oxidase calibration curve for·O2
- generation. Results were reported
 as 
pmol min
-1 mg tissue
-1. In all experiments, O2
- production was measured in paired samples. 
2.8.2  Electron paramagnetic resonance spectroscopy studies  
Electron paramagnetic resonance (EPR) spectroscopy measures the absorption of microwave 
radiation by molecules such as free radicals following stimulation by an electromagnetic field. 
The amplitude of the EPR signal is proportional to the numbers of free radicals in the sample. 
Interactions between the nuclei and unpaired electrons contribute to the magnetic field applied 
by the spectrometer. This results in several peaks being detected by the spectrometer. Since most 
ROS  are  short  lived,  compounds  that  form  stable  adducts  with  free  radicals  have  been 
developed. These compounds are specific to one ROS species and produce a characteristic EPR 
spectrum
113;115.  
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2.8.2.1  Mononuclear cell O2- measurement 
Venous blood was collected using the vacutainer
® system in to ethylenediaminetetraacetic acid 
(EDTA) tubes. Samples were kept at room temperature and processing begun within 30 minutes 
of venesection. Total white cell count and differential white cell count were obtained using 
coulter®A
c·T diff 2
TM Analyser (Beckman coulter).  
Mononuclear cells were isolated from venous blood using a Ficoll gradient as described by 
Fortuno et al.
116. Ten ml of venous blood was diluted with 10ml of 0.9% saline. This diluted 
blood was carefully layered on top of 10ml of lymphoprep
TM The sample was centrifuged for 
25minutes at 20
oC and 800g so as to produce a buffy coat of mononuclear cells between the 
plasma and erythrocytes. The buffy coat was carefully removed and 50ml of phosphate buffered 
saline  (PBS)  added.  The  isolated  mononuclear  cells  were  washed  twice  in  PBS,  through 
centrifugion for 10min at room temperature and 300g. Finally the pellet containing the isolated 
mononuclear cells was re-suspended in 1ml of PBS. For the duration of the study the isolated 
mononuclear cells were kept under soft agitation at 37
oC using a thermomixer to prevent cell 
aggregation. Total white cell count and differential white cell count were again obtained using 
coulter®A
c·T diff 2
TM Analyser (Beckman coulter). The isolated white cells were then diluted to 
give a final concentration of 5x10
6 cells/ml. 
Mononuclear O2
- levels were detected by electron paramagnetic resonance (Bruker BioSpin e-
scan  R,  Bruker  Corporation)  with  the  spin  probe  1-Hydroxy-3-carboxy-  2,2,5,5-
tetramethylpyrrolidine  (CPH,  Noxygen).  CPH  reacts  with  O2
-  to  produce  a  stable  nitroxide 
radical with half life of several hours
115.  
Basal  mononuclear  cell  O2
-  levels  were  recorded  initially.  3µl  of  CPH  (final  concentration 
500uM) and 2µl of PBS were added to 55µl of the isolated mononuclear cells. The sample was 
mixed  and  immediately  transferred  to  a  thin  glass  capillary  and  placed  in  EPR  machine.  
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Instrument settings used were: centre field of 3375G, modulation amplitude of 2.27G, sweep 
time of 5.24s, sweep width of 60G and 10 scans. Counts were recorded once a minute for 10 
minutes and the rate of O2
- anion production (counts/minute) was calculated by means of a 
standard curve. Basal O2
- levels were recorded in duplicate and the mean of recordings taken. 
Stimulated O2
- release was measured using the protein kinase C activator Phorbol 12-myristate 
13-acetate (PMA Sigma-Aldrich Company Ltd). PMA causes NAD(P)H oxidase-dependant O2
- 
release from mononuclear cells 
116. 3µl of CPH and 2µl of PMA (Final concentration 3.2uM) 
was  added  to  55µl  of  isolated  mononuclear  cells.  The  sample  was  mixed  and  immediately 
transferred to glass capillary for EPR O2
- measurement. Stimulated O2
- release was recorded in 
duplicate and the mean of recordings taken. To adjust for slight variations in capillary diameter, 
a note was made of capillary batch number used and result adjusted against standard. Intra assay 
variability,  assessed  in  3  independent  experiments,  performing  5  measurements  within  90 
minutes after blood collection, was 10%. Inter assay variability, as analyzed in 7 independent 
experiments performing 3 measurements, was 10%. 
2.8.2.2  Whole blood O2-measurement 
Venous blood was collected via the Vacutainer
® system in to lithium-heparin tubes and placed 
immediately on ice. Samples were analysed within 30 minutes of venesection. 475µl of whole 
blood was added to 25µl of CPH (final concentration 500uM). Sample was transferred to a glass 
capillary and placed in EPR machine for O2
- measurement. Machine settings were: centre field 
of 3375G, modulation amplitude of 2.27G; sweep time of 5.24s; sweep width of 60G and 10 
scans. Whole blood O2
- measurements were recorded in duplicate and the mean of readings 
taken. To adjust for slight variations in capillary diameter, a note was made of capillary batch 
number used and result adjusted against standard. 
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2.9  Detailed lipid profiles 
LDL and HDL size and relative proportions in plasma were determined using non-denaturing 
gradient gel electrophoresis using 2-16% polyacrilamide gels (Alamo Gels, San Antonio, TX) as 
previously  described 
117.  Using  in  house  standards  prepared  by  density  gradient 
ultracentrifugation  LDL  was  divided  in  to  three  fractions;  LDL  I  (28.92-31.38nm),  LDL  II 
(25.88-27.06nm) and LDL III (24.5-25.5nm). The gels were stained with comassie blue and 
scanned  using  an  imaging  densitometer  (Model  GS-700,  Biorad,  Hemel  Hempstead).  LDL 
subfraction is reported as a percentage of total LDL. LDL peak particle diameter (PPD) was 
reported as the size of the major LDL subfraction. HDL mean particle diameter (MPD) and 
LDL-MPD were calculated to give the mean diameter across the entire HDL or LDL profile. 
2.10 Statistical analysis  
Statistical  analyses  were  performed  using  SPSS  (version  15;  SPSS  Inc.,Chicago,IL,USA) 
software.  In  text  and  tables,  data  are  expressed  as  mean  ±  standard  deviation  or  median 
[interquartile  range]  as  appropriate.  Normal  distribution  of  data  was  examined  by  the 
Kolmogorov-Smirnov test and by visual inspection of Q-Q plots. Unpaired Student’s  t-tests 
were  performed  for  comparison  of  normally  distributed  data.  Wilcoxon  test  was  used  for 
comparison  of  data  that  were  not  normally  distributed.  Fisher’s  exact  test  was  used  for 
comparison of categorical data. 95% confidence intervals were calculated for the difference 
between means where appropriate. Paired t-tests were used for repeated measurements in the 
exercise study. Pearson’s correlation coefficients were been calculated where indicated. Multiple 
linear  regression  analysis  was  used  to  investigate  determinants  of  endothelial  function  in 
chapters 4 and 6. In the full model all variables were forced into the model. In the stepwise 
model variables with a significance of ≥0.1 were removed. A P-value of less than 0.05 (two-
sided) was considered significant.  
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3  Arterial Stiffness 
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3.1  Introduction  
Arterial  stiffness  refers  to  important  changes  in  the  mechanical  properties  of  arteries  that 
contribute  to  the  development  of  cardiovascular  disease  (CVD).  The  ability  to  assess  these 
changes is of interest to help stratify cardiovascular risk and as a therapeutic target. 
3.1.1  Mechanisms underlying increased arterial stiffness 
As  the  structure  of  the  vasculature  changes  the  mechanisms  underlying  increased  arterial 
stiffness alter. In the walls of the aorta and large arteries varying amounts of elastin and collagen 
are the main determinants of compliance
94. Alterations in the proportion and composition of 
elastin and collagen that occur with aging and disease contribute to increased arterial stiffness in 
these vessels 
93;118. In medium size conduit arteries and the microcirculation vascular smooth 
muscle quantity and function is important in determining the compliance and calibre of vessels 
94. Endothelial function in these vessels therefore may contribute to arterial stiffness 
119.  
3.1.2  Assessing arterial stiffness 
Arterial stiffness is a concept, a descriptive term, which cannot be absolutely quantified by one 
single measure. There are a number of different variables that can be measured as indicators of 
degree of arterial stiffening. As discussed the causes and underlying mechanisms of arterial 
stiffness vary according to the vessel being studied and this needs to be taken into account when 
interpreting studies. Incorporating simple non-invasive methods of assessing arterial stiffness 
into clinical practice is of interest for quantifying cardiac risk and making arterial stiffness a 
therapeutic target. Indeed the 2007 European Society of Hypertension guidelines recommend the 
use  of  arterial  stiffness  measures,  aortic  pulse  wave  velocity  (PWV),  in  the  assessment  of 
patients  with  hypertension 
120.  The  guidelines  do  however  acknowledge  that  methods  for 
assessing arterial stiffness are currently not widely available outside the research setting. For 
assessment of arterial stiffness to become a routine part of clinical practice tests need to be non- 
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invasive  and  easy  to  perform.  Furthermore  the  tests  need  to  provide  valuable  prognostic 
information independent  of  currently  available risk  factors. The  use  of  PWV,  augmentation 
index (AIx) and central pulse pressure (PP) will be discussed below as methods for assessing 
aspects of arterial stiffness in clinical practice. 
3.1.3  PWV 
3.1.3.1  Basic principles and measurement of PWV 
The speed at which a pulse wave travels in a vessel is related to distensibility of the vessel, the 
stiffer the vessel the faster the pulse wave will travel. The velocity or speed off a pulse wave is 
therefore an indicator of arterial stiffness. PWV is obtained by measuring the time for a pulse 
wave to travel a specified distance. In the SphygmoCor® system the pulse wave is captured 
noninvasively using applantation tonometry at a proximal site and a distal site. Time to the foot 
of the wave is measured and gated against the R wave in an ECG recorded simultaneously. The 
distance is then measured and the PWV in m/s can be calculated. Aortic PWV is measured from 
carotid to femoral artery. Peripheral PWV can be measured from carotid to radial or brachial 
arteries or femoral to dorsalis pedis or posterior tibial arteries. Aortic PWV has recently been 
recognised as the gold standard measurement of arterial stiffness 
121. The utility of peripheral 
measurement of PWV is currently uncertain 
121. 
3.1.3.2  Aortic PWV and CVD 
Age and hypertension are the most important determinants of aortic PWV 
122. Aortic PWV is 
increased in patients with cardiovascular risk factors and established CVD 
123. Other factors 
associated with increased aortic PWV include hypercholesterolaemia, diabetes mellitus (DM), 
endothelial  dysfunction  and  sedentary  lifestyles 
124-128.  However  the  relative  contribution  of 
these other factors in determining aortic PWV is unclear. Indeed a recent meta-analysis has  
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suggested that other cardiovascular risk factors in addition to age and hypertension only make a 
small contribution to aortic PWV 
122. 
As discussed the compliance of large vessels such as aorta is principally determined by elastin 
and collagen. Aging is associated with a reduction in both function and quantities of elastin in 
the walls of the aorta 
93. It is thought that cardiovascular risk factors such as hypertension and 
DM  accelerate  this  process;  however  the  underlying  mechanisms  are  not  fully  understood. 
Mechanisms  thought  to  be  involved  include  Angiotensin  II  stimulated  collagen  formation, 
advanced glycation end products (AGE) and inflammation 
80. Acute changes in blood pressure 
can also affect aortic stiffness. As blood pressure increases the aorta becomes stiffer due to 
recruitment of collagen fibres 
118. Short term changes in blood pressure therefore need to be 
taken into consideration when interpreting studies assessing PWV.  
Aortic  PWV is  a predictor  of future cardiovascular  events  in  a  number  of  different  patient 
groups including patients with end stage renal failure, essential hypertension and type 2 DM 
129-
132.  Strategies  to  reduce  aortic  PWV  are  therefore  a  possible  therapeutic  target  in  the 
management and prevention of CVD.  
3.1.3.3  Strategies to reduce PWV 
There are limited studies assessing the effect of interventions on aortic PWV and no long term 
outcome studies. Endurance trained male athletes have lower aortic PWV compared to less 
active aged matched men 
126 The effects of exercise training programmes on aortic PWV are 
however  not  known.  The  effect  of  antihypertensive  agents  on  aortic  PWV  is  also  unclear. 
McKenzie et al.
133 showed no effect on aortic PWV with either angiotenisn-converting enzyme 
inhibitors (ACEi), diuretics, beta blockers or calcium channel blockers (CCB), however this was 
a short term study. In patients with type 2 DM Angiotensin-receptor blockers (ARBs) decreased 
aortic PWV more than CCB and this effect was independent of blood pressure lowering 
134.  
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Novel agents such as inhibitors of AGE formation and agents that break down AGE cross links 
are of interest although development of these agents has been slow 
135. 
3.1.3.4  Limitations of aortic PWV 
Aortic  PWV  is  considered  the  gold  standard  for  assessment  of  arterial  stiffness  and  is 
recommended in 2007 ESH guidelines for the assessment of patients with hypertension 
121. 
Aortic PWV is in theory easy to perform but there can be a number of difficulties in certain 
patient groups 
121. The accuracy of the PWV result is dependent on the accuracy of the distances 
measured 
136. In the calculation of aortic PWV this can be difficult for a number of reasons. 
Measuring  the  distances  between  the  femoral  pulsation  and  the  sternum  may  be  inaccurate 
particularly in obese patients. In addition the surface measurement that aim to estimate the 
length of the aorta may be inaccurate in more elderly individuals with tortuous aortas. Obtaining 
pulse wave recordings at the femoral artery may also be difficult particularly in overweight 
patients.  They  are  also  more  intrusive  due  to  the  intimate  nature  of  recording  femoral 
waveforms. Simpler methods for assessing arterial stiffness are therefore attractive. It is possible 
to calculate brachial PWV by recording the pulse wave at the radial and carotid artery. Certainly 
this would resolve a number of problems seen with aortic PWV, as the distance measurements 
are simpler and recording pulse wave at the radial less technically challenging compared to 
recording  femoral  waveforms.  However  in  patients  with  end  stage  renal  failure  PWV  in 
peripheral arteries had no prognostic value 
137. In addition it is not clear whether brachial PWV 
correlates well with aortic PWV. Cameron found that only Aortic PWV and not brachial PWV 
correlated with age in patients with type 2 DM 
138. It is possible that since the brachial artery is 
not affected by CVD to the same degree as the aorta, PWV measurements in this artery do not 
reflect the degree of CVD. Finally PWV gives information only on the speed of pulse wave 
travel and no information on the consequences of this, i.e. no indication of changes in wave 
reflection/central pressures 
118.   
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3.1.4  Pulse wave analysis 
In addition to measuring the speed of flow in vessels the shape of the pulse wave can give 
information on vascular function and degree of arterial stiffness 
97. Pulse wave analysis (PWA) 
can be performed through applantation tonometry at the radial artery. A transfer factor can then 
be  applied  to  generate  the  aortic  or  central  pulse  wave 
139.  Alternately  waveforms  can  be 
captured directly at the carotid artery without the need for a transfer function. A number of 
parameters can then be calculated including central blood pressure measurements and AIx 
97.A 
typical pulse wave tracing using the SphygmoCor® system is shown in figure 3.1. 
Figure 3.1 Typical pulse wave tracing produced by the SphymoCor® system 
 
Sp, systolic pressure, Dp diastolic pressure, Mp, mean arterial pressure, PP, pulse pressure.ms, 
milliseconds. T1 time from start of waveform to first peak. T2 time from start of waveform to 
second peak. TR time to start of reflected wave. P1, difference between the minimum pressure 
and  the  pressure  at  T1  AP,  Augmentation  difference  between  central  Sp  and  P1.  AIx 
augmentation  index  (AP  pressure  divided  by  PP  expressed  as  a  percentage).SEVR, 
subendocardial viability ratio. 
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3.1.4.1  AIx 
A number of variables can be obtained from analysis of the waveform however the AIx has been 
proposed as a single reading that provides an assessment of wave reflection and a surrogate 
marker of arterial stiffness 
97. 
3.1.4.2  Basic principles and assessment of AIx 
AIx is defined as the difference between the second and the first systolic peaks expressed as a 
percentage of the pulse pressure 
97. In other words AIx is the percentage of the systolic pressure 
wave attributable to wave reflection. AIx depends on the shape of the forward wave and the 
timing of the reflected wave 
118. The shape of the forward wave is determined by left ventricular 
outflow and elasticity of aorta 
118. The timing of the reflected wave is influenced by a number of 
factors including gender, height, reflected wave amplitude and vessel stiffness 
96. So although 
AIx is determined in part by arterial stiffness other factors are also important. AIx has been 
advocated by some to be suitable as a surrogate marker for arterial stiffness 
140. Whereas others 
advise that AIx has a role in complementing PWV recordings to provide information on the 
consequences of increased PWV on wave reflections and central blood pressures
121. The use of 
AIx has been much debated and its usefulness in the clinical assessment of cardiovascular risk is 
far from certain 
141.  
Central blood pressure readings and AIx can be obtained directly from the carotid artery or from 
reading taken at the radial artery with central recordings calculated using a transfer function 
139;142. Recording good quality waveforms at the carotid artery is difficult and it has been shown 
that the correlation between central AIx obtained from carotid and radial arteries is relatively 
poor 
143. Most studies therefore use radial measurements and a generalised transfer function to 
produce central readings. The use of a generalised transfer factor to generate central pressure 
readings  from  peripheral  pulse  waves  was  investigated  by  Chen  et  al.
139  in  24  patients 
undergoing cardiac catherization using non-invasive measures at the radial artery and invasive  
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measures in the aorta. These recordings were used to generate a generalised transfer function 
that was able to calculate central aortic pressures from the radial waveform. This generalised 
transfer function was subsequently validated in 400 subjects by Gallagher etc al.
142. There are 
concerns that this generalised transfer function may not be applicable to all patient groups. Hope 
et al.
144 showed there was significant error when the transfer function was used to generate 
central pressures compared to invasive measures and this was particularly marked in patients 
with type 2 DM. It was advocated that a specific diabetes transfer function should be used. This 
may also be important in other groups of patients. 
3.1.4.3  Determinants of AIx 
Age, gender, height and heart rate are all important determinants of AIx and need to be taken 
into consideration when comparing AIx between groups 
143;145-147. Age is a key determinant of 
AIx however this relationship is not linear. AIx increases more in younger individuals 
145. Some 
studies have shown a plateau in older patients whereas others have reported a decline 
145;148. This 
is different to the relationship seen with PWV and age in which the increase is more prominent 
in older individuals 
145. Gender is also an important determinant of AIx with women having 
higher AIx at all ages. 
147. Part of this difference can be explained by height. Body height is 
important  factor  determining  AIx  as  with  taller  statue,  wave  reflections  occur  later  due  to 
increased aortic length 
149. However height does not fully explain the differences in AIx between 
men and women and the underlying mechanisms are not fully understood 
146.Heart rate is also an 
important  determinant  of  AIx.  There  is  a  significant  inverse  relationship  with  AIx  with  an 
increase of 10 beats per minute being associated with approximately a 4% decrease in AIx 
140.  
3.1.4.4  AIx and CVD 
The data surrounding the significance of AIx in the assessment of CVD is mixed. AIx has been 
found to be correlated with cardiovascular risk factors 
150. It is also increased in patients with  
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hypercholesterolaemia 
151 and inversely related to endothelial function 
128. Weber et al.
152 found 
that in patients undergoing diagnostic angiography AIx is correlated with coronary artery plaque 
load. This relationship however was only seen in younger individuals; in patients over 60 years 
this relationship was no longer observed 
152.The prognostic significance of AIx for the prediction 
of future cardiovascular events is unclear. Increased AIx has been shown to be an independent 
predictor of all cause mortality and cardiovascular mortality in patients with end stage renal 
failure 
153.  In  a  further  study  by  Weber  et  al.
154  AIx  adjusted  for  heart  rate  was  also  an 
independent predictor of cardiovascular events in patients undergoing percutaneous coronary 
interventions. However in a substudy of the Australian Blood Pressure trial (ANBP2) Dart et 
al.
155 found carotid arterial waveforms were not predictive of cardiovascular events in elderly 
women with hypertension whereas brachial pressures were. Chirinos et al.
156 showed that in 
patients with established coronary artery disease (CAD) augmented pressure was predicted of all 
cause mortality but not AIx. Most recently the Conduit Artery Function Evaluation (CAFE) 
study  also  found  augmented  pressure  but  not  AIx  was  significantly  associated  with  the 
composite clinical endpoint of all cardiovascular events and renal failure 
38. 
3.1.4.5  AIx and type 2 DM 
There is also  a  great  deal  of  debate  surrounding  the  use of  AIx  in  patients with  DM. The 
presence of increased arterial stiffness as assessed by a number of methods in patients with type 
2 DM is supported by a wealth of data 
157-160 . In view of the difficulties discussed early with 
measuring aortic PWV particularly in obese individuals it is clear why a simpler method such as 
AIx would be attractive in patients with type 2 DM. The utility of AIx in patients with type 2 
DM is far from clear however. Some groups have found increased AIx in patients with type 2 
DM while others have not. Brooks et al.
161 found elevated AIx in patients with type 2 DM. 
Whereas Lacy et al.
127 found no increase in AIx in a group of patients with type 2 DM despite an 
increase in aortic PWV. These findings have been reported by other groups although the reasons  
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underlying this discrepancy are uncertain. Maple-Brown et al.
162 found no increase in AIx in 
patients with type 2 DM compared to obese individuals without type 2 DM. In this study AIx 
was found to be inversely related to obesity. One mechanism may be dampening of the reflected 
wave through fat, similar to the observation that wave reflection can be reduced by applying 
external pressure to the arm 
163. Whether this explanation is correct is unclear and whether it is 
part of the explanation for the findings in patients with type 2 DM (the majority of who are 
obese) is uncertain.  
3.1.4.6  AIx and PWV  
Although AIx is partly determined by PWV the relationship between AIx and PWV is not 
straightforward. As already discussed AIx is determined by a number of factors in addition to 
PWV. Yasmin et al.
164 showed that brachial PWV was weakly correlated with AIx (R=0.29) 
although  this relationship was  stronger  when  men  and  women  were  analysed  separately.  A 
number of studies have however shown no correlation between AIx and aortic PWV. Kelly et 
al.
165 showed that aortic PWV was correlated with AIx but this relationship was no longer seen 
after adjusting for age. Lemogoun et al.
166 also found no correlation between aortic PWV and 
AIx in healthy men. These findings call in to question the use of AIx as a surrogate for arterial 
stiffness.  
3.1.4.7  Strategies to reduce AIx 
Vasodilator drugs such as ACEi, ARBs and CCB can reduce AIx index to a greater degree than 
other antihypertensive agents
38;167;168. ACEi and β blocker have similar effects on brachial blood 
pressure but ACEi decrease AIx to a greater extent 
167. β blockers have little effect on wave 
reflection but can increase augmented outgoing pressure wave during systole as a result of heart 
rate and timing of systolic ejection 
168. A sub study of the ASCOT trial, the CAFE study showed 
combination of amlodipine and perindopril was associated with a significantly greater reduction  
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in AIx compared to atenolol and thiazide regime despite similar effects on brachial cuff blood 
pressure 
38. The combination of ACEi and CCB in the ascot study was associated with improved 
cardiovascular outcomes compared to a β blocker/thiazide based regime 
37. In the CAFE study 
although  central  pulse  pressure  was  significantly  associated  with  cardiovascular  events  and 
procedures augmentation index was not 
38.  
3.1.4.8  Limitations of AIx 
Radial artery tonometry is less technically demanding than pulse wave capture at femoral or 
carotid arteries. This is the major advantage of AIx over aortic PWV. In addition AIx provides 
information  on  wave  reflection,  an  important  consequence  of  increased  arterial  stiffness. 
However  as  discussed  there  are  a  number  of  concerns  regarding  the  use  of  AIx  for  the 
assessment of arterial stiffness, including the effect of age, heart rate, height and gender, the 
applicability of a generalised transfer function, and the use of AIx in certain groups of patients. 
AIx  needs  further  assessment  to  determine  whether  it  provides  useful  information  in  the 
assessment of CVD.  
3.1.5  Central blood pressure readings; Pulse Pressure 
3.1.5.1  The theory and assessment 
PP is the difference between systolic blood pressure and diastolic blood pressure. PP measures 
the  impairment  of  the  buffering  function  of  larger  arteries.  In  addition  early  return  of  the 
reflected wave will contribute to increased PP 
169. PP calculated from cuff measurements taken 
at the brachial artery is the simplest available marker for assessing arterial stiffness 
169. There is 
however increasing interest in the use of central pressure measurements calculated from non-
invasive  pulse  wave  recordings  taken  at  the  radial  artery  using  applantation  tonometry  as 
discussed above. 
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3.1.5.2  PP and CVD 
Brachial PP is predictive of CVD in healthy individuals , untreated and treated hypertension and 
in patients with type 2 DM 
170-172. Central PP may be a better assessment of cardiovascular risk 
as brachial PP tends to overestimate central PP in the young and underestimate in the elderly 
169. 
This is supported by the finding that central PP was a better predictor of carotid intima media 
thickness than brachial PP 
173. Carotid PP has also been shown to predicted CAD severity more 
accurately than brachial pressure 
174. Central PP was also a predictor of cardiovascular mortality 
in patients with end stage renal failure 
175. However Dart et al.
155 found that central pressures 
were not predictive of cardiovascular events in hypertensive women whereas brachial readings 
were.  There  is  little  evidence  to  support  that  reducing  PP  reduces  cardiovascular  events 
independently of systolic blood pressure
169.  
3.1.6  Summary 
Arterial stiffness is an important step in the cardiovascular continuum. PWV is the gold standard 
measurement of arterial stiffness and is an important prognostic indicator in patients with CVD 
and is increased in patients with type 2 DM. There a number of technical difficulties with 
measuring aortic-PWV and simpler methods are therefore attractive clinical tools. Two such 
methods are brachial PWV and AIx. The value of these two simpler techniques is as yet not 
clear and further evaluation of these techniques is required. 
3.2  Aims and objectives 
The hypotheses were that patients with CAD would have increased arterial stiffness (as assessed 
by aortic PWV and AIx) compared to controls. Furthermore in a subgroup of patients with type 
2 DM and CAD these markers of arterial stiffness would be increased compared to patients with 
CAD alone. 
The aims of this study were:  
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1.  To investigate aortic PWV in healthy controls and patients with CAD with and without 
type 2 DM. 
2.  To investigate the correlation between brachial and aortic PWV. 
3.  To investigate the use of AIx in patients with CAD with and without type 2 DM.  
3.3  Methods 
PWA  and  PWV  measurement  were  performed  in  patients  with  CAD  and  healthy  controls 
recruited as part of the VASCB study. Detailed descriptions of the methods used are provided in 
chapter 2. 
3.4  Results 
3.4.1  PWA  
Seventy four patients with CAD and 70 healthy controls attended for pulse wave recordings. In 
13  patients  with  CAD  and  7  healthy  controls  the  quality  of  recordings  was  inadequate  for 
analysis. Demographics and clinical characteristics are shown in table 3.1. Patients with CAD 
were  older  and  the  group  contained  a  higher  proportion  of  males  compared  to  controls. 
Prevalence of hypertension was significantly higher in the CAD group although brachial systolic 
and diastolic blood pressure recordings were not significantly different. Patients with CAD were 
more overweight compared to controls as illustrated by higher body mass index. There was 
significant  usage  of  statins,  ACEi/ARB,  CCB  and  nitrates  in  the  CAD  group  compared  to 
controls. Biochemistry results are shown in table 3.2. Participants that attended for PWA studies 
were  not  significantly  different  from  those  who  did  not  attend.  Demographics,  clinical 
characteristics  and  basic  biochemistry  for  all  patients  recruited  are  available  in  the 
supplementary tables (chapter 10).  
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PWA results are shown in table 3.3. Both brachial and central pulse pressure was higher in 
patients with CAD compared to controls. Heart was slower in patients with CAD compared to 
controls. Time to reflected wave was shorter in CAD patients compared to controls. Augmented 
pressure was higher in CAD group compared to controls. There was no significant difference in 
peripheral AIx, central AIx or central AIx corrected for heart rate between controls and CAD 
(figure 3.2). 
Since the control group contained more women than CAD and sex is an important determinant 
of AIx males were analysed separately (table 3.4). When males were analysed alone there was a 
trend to higher peripheral, central and central AIx corrected for heart rate but this was not 
significant. The male CAD patients had a significantly lower heart rate compared to healthy 
controls and shorter time to first reflected wave. 
PWA results for patients with and without type 2 DM are shown in table 3.5. Once again there 
was no significant difference in peripheral AIx, central AIx or central AIx corrected for heart 
rate. There was no difference in time to start of reflected wave between the two groups. 
3.4.2  PWV  
Of  the  74  CAD  patients  attending  for  pulse  wave  recordings  brachial  PWV  results  were 
available for 60 patients and aortic PWV for 16 patients. Fourteen brachial PWV recordings and 
18 aortic PWV recordings were rejected due to poor quality. In a further 26 CAD patients there 
was insufficient time for aortic PWV measurements. Fourteen patients with CAD declined to 
have recordings performed at groin. Of 70 controls attending for pulse wave studies, 57 brachial 
PWV  were  available  for  analysis  (13  rejected  due  to  poor  quality)  Forty  two  aortic  PWV 
recordings  from  controls  were  available  for  analysis  (18  rejected  due  to  poor  quality,  10 
participants  declined  to  have  recordings  performed  at  groin).  Demographics  and  clinical 
characteristics are shown in table 3.6. Biochemistry results are shown in table 3.7.  
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Aortic PWV was significantly faster in CAD compared to controls (10.16±2.17 vs. 8.42±1.75, 
P=0.003) (figure 3.5). Brachial PWV was significantly slower in patients with CAD compared 
to controls (8.22±1.43 m/s vs. 9.05±1.41m/s P=0.002, figure 3.6). 
In patient with CAD with and without type 2 DM there was no difference in brachial PWV 
8.14±1.67 (n=16), vs.8.25±1.67 (n=44), P=NS. Due to the small number of aortic PWV results 
in patients with CAD it was not possible to compare these groups. 
There was a significant correlation between brachial PWV and aortic PWV (R=0.399, P=0.005) 
When the two groups were analysed separately this relationship only remained in the control 
group (r=0.527, P=0.001). In patients with CAD there was no correlation between aortic and 
brachial PWV (figure 3.7). 
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Table 3.1 Demographics and clinical characteristics for patients with CAD and controls 
undergoing PWA studies 
  CAD (n=61)  Control (n=63)  P-value 
Age (years)  66.8±9.3  60.0±10.2  <0.0001 
Male (%)  48(78.7)  38 (60.3)  <0.0001 
Systolic BP, mm Hg  142.1±20.2  137.8±19.4  NS 
Diastolic BP, mm Hg  78.3±10.4  81.7±10.5  NS 
Heart rate (beats/min)  63.1±9.3  68.3±12.4  0.01 
BMI, kg/m
2  29.0±4.1  26.1±3.5  <0.0001 
Current smokers (%)  4 (6.6)  3(4.8)  NS 
Type 2 DM (%)  17(27.9)  0  n/a 
Hypertension (%)  35(57.4)  16(25.4)  0.002 
Myocardial Infarction (%)  33 (54.1)  0  n/a 
TIA/CVA (%)  3(4.9)  1 (1.6)  NS 
Chronic renal failure (%)  3 (4.9)  0  NS 
Heart failure (%)  7 (11.5)  0  n/a 
Aspirin (%)  56 (91.8)  6(9.5)  <0.0001 
Other antiplatelet agent (%)  18 (29.5)  1 (1.6)  <0.0001 
Statin (%)  56 (91.8)  9 (14.3)  <0.0001 
ACEi/ARB (%)  35 (57.4)  6(9.5)  <0.0001 
Beta-blocker (%)  47 (77)  4 (6.3)  <0.0001 
Calcium channel blocker (%)  25 (41)  3 (4.8)  <0.0001 
Nitrate (%)  41 (67.2)  0  <0.0001 
Diuretic (%)  11(18)  5 (7.9)  NS 
Oral hypoglycaemic agent (%)  10 (16.4)  0  n/a 
Insulin (%)  4 (6.6)  0  n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 3.2 Biochemistry results for patients with CAD and controls undergoing PWA 
studies 
  CAD (n=61)  Control (n=63)  P-value 
Cholesterol (mmol/L)  4.01±0.91  5.71±1.17  <0.0001 
Triglycerides (mmol/L)  1.88±0.91  1.54±0.79  0.026 
LDL(mmol/L)  1.97±0.70  3.50±1.07  <0.0001 
HDL(mmol/L)  1.17±0.27  1.50±0.35  <0.0001 
CRP (mg/L)  4.76±10.74  2.12±2.46  0.036 
HbA1c (%)  6.13±1.12  5.50±0.29  <0.0001 
Urinary ACR (mg/mmol)  3.05±6.79  1.33±0.97  0.045 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Table 3.3 Pulse wave analysis results in patients with CAD and Controls 
  CAD (n=61)  Control (n=63)  P-value 
Brachial Systolic BP, mm Hg  135.5±17.6  131.7±18.0  NS 
Brachial Diastolic BP, mmHg  74.5±9.5  77.5±10.4  NS 
Brachial Pulse Pressure, mm Hg  61.1+14.2  54.2+12.6   0.011 
Brachial Mean Arterial Pressure, mmHg  94.8±11.7  96.8+12.5  NS 
Peripheral AIx  88.5±12.5  84.6±16.5  NS 
Heart rate, bpm  57.3±7.3   60.6±9.6  0.031 
Central Systolic BP, mm Hg  126.4±17.4  122.8±18.1  NS 
Central Diastolic BP, mm Hg  75.1±9.6  78.5±10.4  NS 
Central Pulse pressure  51.3±13.5  44.3±12.5  0.003 
Central AIx (%)  31.5±7.7  29.0±11.0  NS 
Central AIx corrected for HR (%)  23.1±7.0  22.1±10.8  NS 
Augmentation, mm Hg  16.7±7.6   13.7±7.6  0.036 
P1 height, mm Hg  34.6±7.8  30.6±7.0  0.003 
T1, ms  108.2 ±9.8  112.2±9.9  0.025 
T2, ms  236.6±18.1  240.7±18.9  NS 
TR, ms  140.1±10.7  147.7±15.6  0.004 
ED, ms  338.8±23.8  337.6±21.4  NS 
HR heart rate. T1 time from start of waveform to first peak. T2 time from start of waveform to 
second peak. TR time to start of reflected wave. ED ejection duration ie time from start of 
waveform to closure of aortic valve. Augmentation difference between central SBP and P1. AIx 
augmentation index (Augmented pressure divided by pulse pressure expressed as a percentage). 
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Table 3.4 PWA results for males only 
  CAD males only 
(n=47) 
Healthy controls 
males only (n=27) 
Brachial SBP, mm Hg  135.1 ±16.9  136.4±19.0 
Brachial DBP, mm Hg  74.7 ±9.1  78.9± 9.1 
Brachial PP, mm Hg  60.4 ±13.1  57.6± 14.7 
Brachial MAP, mmHg  94.9 ±11.4  99± 11.9 
Peripheral AIx  89.1±13.5  83.7± 15.3 
Heart rate, bpm  56.2 ±6.5*  60.2±6.5 
Central SBP, mm Hg  126.2 ±17.4  126.9 ±19.1 
Central DBP  75.4 ±9.1  79.7 ±9.3 
Central PP  50.8 ±13.3  47.2 ±10.7 
Central AIx (%)  31.6 ±8.3  27.9± 10.7 
Central  AIx  corrected  for 
HR (%) 
22.8 ±7.5  20.9 ±10.0 
Augmentation, mm Hg  16.7 ±8.2  14.0 ±8.2 
P1height, mm Hg  109.5±12.3  113.0 ±14.0 
T1, ms  108.5 ±10.2  112.7 ±10.5 
T2, ms  237.5± 17.9  237.6± 17.4 
TR, ms  140.5 ±11.0**  146.7 ±12.7 
ED, ms  340.1± 24.3  333.2 ±18.7 
*P=0.027 **P=0.031. SBP, systolic blood pressure, DBP diastolic blood pressure, PP, pulse 
pressure, MAP, mean arterial pressure, HR heart rate. T1 time from start of waveform to first 
peak. T2 time from start of waveform to second peak. TR time to start of reflected wave. ED 
ejection  duration  ie  time  from  start  of  waveform  to  closure  of  aortic  valve.  Augmentation 
difference between central SBP and P1. AIx augmentation index (Augmented pressure divided 
by pulse pressure expressed as a percentage). 
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Table 3.5 PWA results for patients with CAD with and without type 2 DM 
  CAD and 
T2DM (n=17) 
CAD alone 
(n=44) 
Brachial SBP, mm Hg  135.7±10.8  135.4±19.7 
Brachial DBP, mm Hg  71.5±9.6  75.5±9.3 
Brachial PP, mm Hg  64.1±13.8  59.9±14.4 
Brachial MAP, mmHg  91.8±8.5  95.9±12.6 
Peripheral AIx (%)  85.8±11.8  89.5±12.8 
Heart rate, bpm  59.9±6.5  56.3±7.4 
Central SBP, mm Hg  124.6±9.1  127.1±19.8 
Central DBP, mm Hg  72.1±9.6  76.3±9.5 
Central PP, mm Hg  52.4±11.1  50.9±14.4 
Central AIx (%)  29.7±7.2  32.2±7.8 
Central AIx corrected for HR (%)  22.6±6.8  23.3±7.2 
Augmentation, mm Hg  15.6±5.1  17.1±8.4 
P1 height, mm Hg  36.8±8.7  33.8±7.3 
T1, ms  108.7±9.6  108.0±10.0 
T2, ms  228.5±14.7  239.8±18.5* 
TR, ms  139.9±10.0  140.2±11.1 
ED, ms  332.4±22.4  341.3±24.2 
*P=0.028. T1 time from start of waveform to first peak. T2, duration from start of waveform to 
second peak. TR time to start of reflected wave. ED ejection duration. P1, difference between 
the  minimum  pressure  and  the  pressure  at  T1.  Augmentation    difference  between  Systolic 
pressure  and  P1.  AIx  Augmentation  index  augmented  pressure  divided  by  pulse  pressure 
expressed as a percentage. 
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Figure 3.2 Peripheral AIx in patients with CAD and healthy controls  
 
Figure 3.3 Central AIx in patients with CAD and healthy controls 
 
   
P=NS 
P=NS 
n=63  n=61 
n=63  n=61  
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Figure 3.4. Central AIx corrected for heart rate in patients with CAD and healthy controls 
 
 
   
P=NS 
n=63  n=61  
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Table 3.6 Demographics and clinical characteristics for participants PWV studies 
  CAD (n=60)  Control (n=57)  P-value 
Age (years)  65.2±9.9  60.1±10.3  0.007 
Male (%)  49(81.7)  30(52.6)  0.001 
Systolic BP, mm Hg  139.4±21.3  138.3±19.4  NS 
Diastolic BP, mm Hg  77.4±11.0  81.7±10.5  0.031 
Pulse Pressure (mmHg)  62.0±15.8  56.5±13.4  0.046 
Heart rate (beats/min)  63.8±11.1  69.2±12.9  0.016 
BMI, kg/m
2  29.3±4.5  25.8±3.6  <0.0001 
Current smokers (%)  6(10)  4(7)  NS 
Type 2 DM (%)  16(26.7)  0  n/a 
Hypertension (%)  32(53.3)  18(31.6)  NS 
Myocardial Infarction (%)  34(56.7)  0  n/a 
TIA/CVA (%)  4 (6.7)  1(1.8)  NS 
Chronic renal failure (%)  3(5)  0  n/a 
Heart failure (%)  8 (13.3)  0  n/a 
Aspirin (%)  53(88.3)  6(10.5)  <0.0001 
Other antiplatelet agent (%)  19 (31.7)  1(1.8)  <0.0001 
Statin (%)  56(93.3)  6(10.5)  <0.0001 
ACEi/ARB (%)  36(60)  6(10.5)  <0.0001 
Beta-blocker (%)  49 (81.7)  5(8.8)  <0.0001 
Calcium channel blocker (%)  21(35)  3(5.3)  <0.0001 
Nitrate (%)  40 (66.7)  0  <0.0001 
Diuretic (%)  11(18.3)  4(7)  NS 
Oral hypoglycaemic agent (%)  12 (20)  0  n/a 
Insulin (%)  4 (6.7)  0  n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and percentage (%) BP, blood pressure, TIA; transient ischaemic attack, CVA, cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 3.7 Biochemistry results for healthy controls and patients with CAD in PWV study 
  CAD (n=60)  Control (n=57)  P-value 
Cholesterol (mmol/L)  4.09±0.93  5.76±1.14  <0.0001 
Triglycerides (mmol/L)  2.03±0.95  1.51±0.84  0.002 
LDL(mmol/L)  2.00±0.73  3.53±1.02  <0.0001 
HDL(mmol/L)  1.15±0.26  1.54±0.40  <0.0001 
CRP (mg/L)  4.33±9.88  1.96±2.23  0.024 
HbA1c (%)  6.19±1.22  5.50±0.30  <0.0001 
Urinary ACR (mg/mmol)  3.15±6.87  1.38±0.99  NS 
All  variables  mean  ±  standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 3.5. Aortic PWV in patients with CAD compared to controls 
 
Figure 3.6 Brachial PWV in patients with CAD compared to controls 
   
P=0.003 
P=0.002 
n=42  n=16 
n=57  n=60  
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Figure 3.7 Brachial and aortic PWV 
 
3.5  Discussion 
Arterial  stiffness  was  increased  in  patients  with  CAD  compared  to  controls  as  shown  by 
increased aortic PWV, increased brachial and central PP, and shorter time to reflected wave. 
Despite  this  evidence  for  increased  arterial  stiffness  in  patients  with  CAD  there  was  no 
significant difference in brachial PWV or AIx between patients with CAD and healthy controls. 
The hypothesis of increased arterial stiffness in patients with type 2 DM and CAD compared to 
patients with CAD alone could not be supported by the available data. There were no significant 
differences in PP (brachial or central) or time to reflected wave in patients with type 2 DM and 
r=0.399 
P=0.005  
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CAD compared to those with CAD alone. AIx was similar in patients with and without type 2 
DM. 
Our finding of increased aortic PWV in patients with established CAD is in keeping with other 
studies. Increased aortic PWV has been found in patients with cardiovascular risk factors and 
established cardiovascular disease 
123. The difficulties of obtaining aortic PWV recordings have 
been  previously  discussed  and  were  highlighted  in  our  study  by  the  significant  number  of 
patients in whom it was not possible to obtain aortic PWV recordings. Brachial PWV with radial 
recordings is simpler to perform and therefore an attractive alternative. The results of previous 
studies  question  the  use  of  brachial  PWV.  Cameron  et  al.
138  found  no  correlation  between 
brachial  PWV  and  age.  Pannier  et  al.
137  found  that  brachial  PWV  was  not  predictive  of 
cardiovascular events in patients with end stage renal failure whereas aortic PWV was. Although 
there  was  a  correlation  between  aortic  PWV  and  brachial  PWV  in  all  patients  studied  this 
relationship was not found in patients with CAD when the groups were analysed separately. The 
lack of correlation between PWV measured in peripheral sites is perhaps not surprising as it is 
likely there are different mechanisms contributing to stiffness in different arterial segments. This 
study  adds  further  evidence  against  the  use  of  peripheral  measurement  of  PWV  for  the 
assessment of arterial stiffness.  
In addition to aortic PWV a number of other markers of arterial stiffness were significantly 
different in patients with CAD compared to controls. Brachial and central PP was elevated in 
patients with CAD compared to those without. Time to reflected wave was decreased in patients 
with CAD. PP is well established as a marker of arterial stiffness that has previously been shown 
to be elevated in patients with cardiovascular risk factors and predictive of future cardiovascular 
events 
170-172. Time to reflected wave has been less extensively studied. Time to reflected wave is 
inversely correlated to aortic pulse wave velocity and may be a substitute for PWV
176. The 
prognostic significance of time to reflected wave compared to aortic PWV is not known.   
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AIx was not significantly different between patients with CAD and controls. There are a number 
of possible explanations for this finding. AIx is affected by a number of physiological variables 
that may account for this finding. There is strong relationship between heart rate and AIx
140. 
Heart rate was significantly higher in controls compared to patients with CAD. However heart 
rate and AIx are inversely related so a fall in heart rate is associated with an increase in AIx 
140. 
The faster heart rate in controls therefore should have increased the difference in AIx between 
the two groups. Furthermore when central AIx corrected for heart rate (Central AIx corrected for 
a heart rate of 75 beats per minute by SphygmoCor® software) was analysed there remained no 
significant difference between the two groups. Gender is also an important determinant of AIx, 
with women having higher augmentation index compared to men at all ages 
147. This is partly a 
reflection of difference in height however there is also an independent effect of sex 
146;149. Our 
control group contained more females compared to the CAD group which may have resulted in 
increased AIx in this group. When men were analysed alone there was a tendency to increased 
AIx in the CAD group although this was not significant. Age is an important determinant of AIx 
145. Our control group was significantly younger than patients with CAD, which should again be 
associated with lower AIx. However the mean age in our control group was 60 and CAD group 
65  years.  This  may  account  for  the  high  AIx  recordings  seen  in  both  groups.  Weber  et 
al.
152found  in  patients  undergoing  diagnostic  coronary  angiography  over  60  years  old  AIx 
readings were similar in patients with and without CAD and all AIx reading were high. In this 
study AIx recordings were higher in both CAD group and control compared to the study by 
Weber et al.  
Medication use in patients with CAD may have had an impact on AIx. Vasodilators such as 
ACEi/ARBs, CCB and nitrates can reduce AIx and central pressure components to a greater 
extent than brachial blood pressure recordings
38;167. Therefore despite the similar brachial blood  
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pressure indices between the patients and controls the use of medications such as ACEi and 
CCB in the CAD patients may have lowered AIx in this group.  
There was a trend to increased brachial and central PP and reduced time to reflected wave in 
patients with type 2 DM compared to those without, although these differences were small and 
not statistically significant. It was not possible to assess aortic PWV in patients with type 2 DM 
due to small numbers. It is well established that arterial stiffness is increased in patients with 
type 2 DM 
157-160. There is less information regarding arterial stiffness in patients with type 2 
DM and established CAD. Lacy et al.
127 found the time to reflected wave was reduced and aortic 
PWV increased in patients with type 2 DM compared to healthy controls. Time to reflected 
wave was shorter in their patients with type 2 DM 134±1.8 ms compared to our recordings 
139±10ms. Brachial pulse pressure and central pulse pressure were higher in our study in both 
patients with and without diabetes compared to the patients in the study by Lacy et al.
127. This is 
not  surprising  given  the  increased  age  of  patients  in  this  study.  There  are  a  number  of 
explanations for the findings in this study. The numbers of patients in this study are small and 
this may have been underpowered to detect a difference between the two groups. The recent 
meta-analysis by Cecelja et al.
122 showed that diabetes status only accounted for a small amount 
of the variability in aortic PWV. The finding of similar AIx in patients with and without type 2 
DM  is  in  keeping  with  other  studies 
127.  The  mechanisms  underlying  this  are  not  fully 
understood.  
Our results highlight the limitations of using simpler surrogates such as augmentation index for 
the assessment of arterial stiffness. Our finding that AIx was not increased in patients with CAD 
whereas other indicators of arterial stiffness were increased adds further evidence to previously 
published studies that question the use of AIx as a surrogate marker of arterial stiffness
127;166. 
The difficulty of using aortic PWV in certain groups has been highlighted by this study. The use 
of  aortic  PWV  may  be  more  applicable  to  selected  groups  with  early  disease  in  whom  
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measurement may be more straightforward. TR may be useful parameter that can be easily 
recorded from pulse wave and warrants further investigation.  
Further studies are required to investigate the effect of lowering aortic PWV on cardiovascular 
outcomes. The use of time to reflected wave may be a simpler measure of arterial stiffness 
compared  to  aortic  PWV  however  the  prognostic  value  of  this  recording  needs  further 
evaluation.  
There are clearly a number of limitations with this study. One of the major limitations with this 
study is the composition of the control group. The control group was significantly younger and 
contained  more  women  compared  to  the  CAD  group.  Age  is  one  of  the  most  important 
determinants of arterial stiffness. Gender has important differences in augmentation index.  
The  very  small  numbers  in  this  study  particularly  for  PWV  measurements  limits  the 
interpretation and analysis of these results. Although can detect differences not able to determine 
whether provide any useful prognostic information. The study design meant patients with CAD 
were seen on the day of admission for surgery. The time available for study tests was limited by 
clinical  commitments  and  this  impacted  on  the  number  of  patients  who  had  aortic  PWV 
recordings performed. 
The observational nature of this study clearly limits the conclusions that can be drawn. No 
conclusions can be drawn regarding causation. Vasodilator medications can impact on AIx and 
PWV.  Medications  were  not  withheld  prior  to  examinations.  Assessing  patients  on  usual 
medications  gives  probably  more  clinically  relevant  information.  However  it  is  difficult  to 
separate the impact of medications and mechanisms underlying pathological processes. There 
were no differences in markers of arterial stiffness in patients with type 2 DM compared to those 
without.  
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4  Endothelial function 
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4.1  Introduction 
Endothelial dysfunction plays a fundamental role in the development of cardiovascular disease 
(CVD)
82;83. It is therefore an attractive therapeutic target in the management and prevention of 
CVD.  
4.1.1  Assessment of endothelial dysfunction 
Clinical  assessment  of  endothelial  function  is  important  not  only  to  help  understand  the 
pathophysiology  of  CVD  but  also  in  the  evaluation  of  strategies  targeting  coronary  artery 
disease  (CAD).  An  ideal  tool  for  assessing  endothelial  function  clinically  would  be  non-
invasive, sensitive, reproducible and simple. At present such a test does not exist.  
Currently there are a number of different methods for assessing endothelial function in different 
vascular beds. Although the endothelium has numerous functions, assessment in the mainstay 
concentrates  on  measurement  of  endothelium  dependent  vasodilation.  A  stimulus  known  to 
cause nitric oxide (NO) release from endothelial cells such as shear stress or acetylcholine is 
applied.  Dilatation  of  vessel  or  vessels  is  then  measured  as  an  indicator  of  endothelium 
dependent vasodilation. In order to show that observed changes are an endothelium dependent 
effect and not due impaired vascular smooth muscle function a stimulus that acts directly on 
vascular smooth muscle cells is tested in parallel.  
4.1.1.1  Ex vivo assessment of endothelial function. 
Segments  of  vessels  can  be  assessed  in  organ  bath  experiments  which  enable  detailed 
pharmacological studies. Clearly the major limitation is the availability of vessels. Furthermore 
the tests are not repeatable over time and results need to be interpreted cautiously as the vessels 
are no longer in situ with ongoing exposure to circulating factors. Patients undergoing coronary 
artery bypass grafting (CABG) for CAD are a good source of vessels
87;177-181. Short segments of 
the grafts surplus to clinical requirements can be obtained at the time of surgery. Available  
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vessels  include  left  internal  mammary  arteries,  radial  arteries  and  saphenous  veins.  It  is 
saphenous  veins  that  are  used  most  commonly.  Although  veins  are  not  affected  by 
atherosclerotic  lesions  to  the  same  extent  of  arteries  endothelial  dysfunction  has  been 
demonstrated in both veins and arteries taken from patients with CAD
178. Given the limited 
availability of arterial samples the use of veins is therefore considered appropriate.  
Control vessels from patients without CVD are even more difficult to obtain. It is possible to 
access  saphenous  veins from  otherwise  healthy  patients  attending  for  elective  varicose  vein 
(VV) removal. Endothelial function in these vessels is significantly better than that of patients 
with CAD
179 
4.1.1.2  In vivo assessment of endothelial function 
There are currently a number of methods for assessing endothelial function in vivo in either 
conduit vessels or the microcirculation. Each method has different disadvantages and as yet no 
method is easily applicable for large scale clinical studies. 
Endothelial  function  in  the  coronary  arteries  can  be  assessed  during  cardiac  catheterization. 
Acetylcholine is infused and change in arterial diameter measured. With an intact endothelium 
there  is  vasodilation  whereas  endothelial  dysfunction  is  associated  with  vasoconstriction
182. 
Endothelium independent vasodilation is assessed following sub lingual administration of the 
NO donor glyceryl trinitrate (GTN). Cardiac catherization is attractive as the results provide 
direct  assessment  of  endothelial  function  in  coronary  arteries,  a  major  target  of  the 
atherosclerotic process. However this method of assessment is only applicable to patients with 
established CAD and is not easily repeatable due to the inherent risks associated with cardiac 
catherization. 
Venous plethysmography is a technique that can be used to assess microvascular endothelial 
function
183. The brachial artery is catheterized and pharmacological agents of interest infused.  
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Blood flow in the forearm is measured non-invasively using strain gauge plethysmography, with 
increases in blood flow being related to vascular reactivity. Although this technique is generally 
considered safe it does involve arterial catheterization and is therefore not completely without 
risk. It is not applicable for large studies or studies requiring repeated assessments of endothelial 
function. 
The current gold standard for non-invasive assessment of endothelial function is flow-mediated 
dilatation (FMD)
112. FMD measures change in diameter of a conduit vessel following a period of 
ischaemia. The brachial artery is the most commonly studied vessel. A sphygmomanometer cuff 
is placed on the forearm distal to the brachial artery and inflated to suprasystolic blood pressure 
for 4-5 minutes and the cuff is released. The resulting reactive hyperaemia increases shear stress 
leading  to  NO  release  and  therefore  endothelium  dependent  vasodilation
184.  Endothelium 
independent vasodilation is assessed by response of brachial artery to sublingual GTN. FMD is 
widely used and correlates well with coronary vascular endothelial function
112.However FMD is 
technically difficult and results are inconsistent when performed by inexperienced operators
185. 
This together with the expense of equipment currently limits the use of FMD. 
Alternative non-invasive techniques of endothelial function are therefore needed. One of these 
alternatives  is  the  pulse  wave  analysis  based  method  established  by  Hayward  et  al.
109  and 
validated by Wilkinson et al.
108. This method assesses changes in pulse wave reflection resulting 
from vascular dilation. Endothelial function can therefore be assessed using agents know to 
cause endothelium dependent vasodilation. Inhaled salbutamol results in endothelial dependent 
vasodilation  and  a  fall  in  pulse  wave  reflection
108-110.  Salbutamol  directly  infused  in  to  the 
brachial artery has no effect on pulse wave reflection. The result is therefore an assessment of 
endothelial  function  in  the  microcirculation
110.  Sublingual  GTN  can  be  used  to  assess 
endothelial independent vasodilation. Endothelial function assessed by changes in pulse wave 
reflection following salbutamol correlates well with endothelial function assessed by venous  
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occlusion plethysmography and FMD
108;186. However currently there are no long term studies 
looking at the prognostic value of this technique or interventional studies.  
4.1.2  Endothelial dysfunction in cardiovascular disease 
Endothelial dysfunction is found in patients with established CAD
87;109;179;182;187;188. Furthermore 
endothelial dysfunction occurs early in the development of CVD and is present prior to the 
development  of  overt  atherosclerotic  plaques
112.  Endothelial  dysfunction  is  therefore  an 
attractive therapeutic target early in the cardiovascular continuum. 
In patients with established cardiovascular disease the persisting endothelial dysfunction has 
important  implications.  Impaired  endothelial  function  as  assessed  by  FMD,  during  cardiac 
catheterisation  or  venous  plethysmography  is  an  important  prognostic  factor  for  future 
cardiovascular events in patients with established disease
187-189. The increased risk associated 
with endothelial dysfunction appeared to be independent of established CV risk factors
188. It is 
thought  in  patients  with  CAD  that  persisting  endothelial  dysfunction  continues  to  drive 
progression  of  the  atherosclerotic  process  and  may  contribute  to  episodes  of  myocardial 
ischemia,  angina  and  plaque  stability
187;190;191.  Currently  however  there  are  no  prospective 
studies linking improved endothelial function with improved cardiovascular outcomes. 
4.1.3  Endothelial dysfunction in type 2 diabetes mellitus 
Endothelial dysfunction is a key feature of type 2 diabetes mellitus (DM)
110;192-195. What is less 
clear is whether this is purely an endothelial abnormality. Some groups have reported normal 
endothelium  independent  vasodilation
110;195  whereas  others  have  described  both  impaired 
endothelium dependent and independent vasodilation
193;194.  
Endothelial  dysfunction  is  also  found  in  patients  with  insulin  resistant  states  prior  to  the 
development of overt hyperglycaemia and type 2 DM. For example endothelial dysfunction has 
been described in women with gestational diabetes, obesity and individuals with the metabolic  
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syndrome
196-198. Suggesting that insulin resistance is important and endothelial dysfunction is 
not simply a consequence of hyperglycaemia. Insulin has important actions on the vasculature 
causing vasodilation through endothelium derived NO
199. In individuals with insulin resistance 
this effect may be attenuated
197. Signalling pathways underling the vascular response to insulin 
are similar to those involved in insulin mediated glucose uptake
199. Therefore there may be a 
common mechanism underlying both the development of endothelial dysfunction and insulin 
resistance. 
The  mechanisms  underlying  endothelial  dysfunction  in  patients  with  type  2  DM  and  other 
insulin resistant states are not fully understood. There are a number of proposed mechanisms 
underlying  diabetes  related  endothelial  dysfunction  these  include  increased  oxidative  stress, 
inflammation, dyslipidemia and increased arginase activity
200-202. However most of the evidence 
points to increased oxidative stress as the predominant underlying cause
91. 
Endothelial dysfunction is predictive of future cardiovascular events in patients with type 2 
DM
203. Endothelial dysfunction seen in type 2 DM may in part explain the increased burden of 
cardiovascular  disease  associated  with type  2  DM  and  is therefore an  attractive  therapeutic 
target. 
4.1.4  Endothelial dysfunction and dyslipidaemia 
Hypercholesterolaemia has consistently been found to be associated with impaired endothelial 
function
108;204;205. Elevated cholesterol levels are important across the cardiovascular continuum. 
Endothelial function correlated with low density lipoprotein (LDL) cholesterol levels in both 
children  with  familial  hypercholesterolaemia  and  patients  with  severe  CAD  undergoing 
revascularisation
112;179. 
Cholesterol lowering by a number of methods either using statins, dietary methods or apheresis 
improves endothelial function
81. The improvement in endothelial function observed with statins  
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appears to be due to both lipid dependent and independent effects. This is demonstrated by the 
findings from three studies published by John et al.
206-208 investigating both the short and longer 
term effects of statin therapy on endothelial function. An initial study showed forearm blood 
flow improved after 24 weeks of treatment with fluvastatin compared to placebo
207. Infusion of 
the  NO  synthase  inhibitor  L-NMMA  reversed  the  improvement  in  endothelial  function 
suggesting that increases in NO availability were partly responsible for this finding
207. A further 
study John el al.
206 showed that endothelial function is also improved after short term statin 
therapy. Two weeks treatment with cerivastatin was associated with improvements in forearm 
blood flow and this once again was partly mediated by increased NO availability
206. Furthermore 
these effects of statins on endothelial function appear partly to be independent of lipid lowering 
effects.  A  subsequent  study  by  John  et  al.
208  showed  just  three  days  of  statin  therapy  was 
associated with improvements in endothelial function assessed by plethysmography. Assessment 
of endothelial function was repeated after 14 days of statin therapy and there were no further 
improvements  seen  in  endothelial  function  despite  further  reduction  in  LDL  levels
208.  The 
improvements in endothelial function appeared to be in part mediated by decreased oxidative 
stress as vitamin C infusion improved endothelial function before but not after statin therapy
208. 
The effect of high density lipoprotein (HDL) levels on endothelial function can be difficult to 
determine as low HDL levels are usually associated with other lipid abnormalities. However 
HDL levels also appear to be an important determinant of endothelial function. Lupatelli et al.
209 
measured FMD in 107 patients attending a lipid clinic with either elevated LDL or triglyceride 
levels. When FMD was divided into tertiles HDL was significantly lower in patients with the 
lowest FMD. Triglyceride levels were also elevated in this group whereas LDL levels were 
similar. Strategies to increase HDL levels independently of altering metabolic abnormalities are 
limited.  Therefore  evidence  from  interventional  studies  linking  increased  HDL  levels  with 
changes in endothelial function is also limited. In a small study by Spieker et al.
210 infusion of  
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reconstituted HDL reduced endothelial dysfunction seen in patients with hypercholesterolaemia. 
Kuvin et al.
211 also showed that treatment with niacin improved FMD in patients with CAD 
compared to controls. The change in FMD was strongly correlated with level of HDL achieved. 
The effect of hypertriglyceridaemia on endothelial function is less clear. Triglyceride levels 
have been shown to be an important determinant of endothelial function. Schnieder et al.
212 
investigated  endothelial  function  in  patients  with  hypercholesterolaemia.  In  these  patients 
triglyceride levels were an important determinant of endothelial function independent of other 
cardiovascular risk factors
212. FMD has also been shown to be impaired in men with elevated 
triglyceride levels compared to men with triglyceride levels in the normal range
213. However in 
the men with hypertriglyceridaemia HDL levels were significantly lower and fasting insulin 
levels higher compared to men with normal triglyceride levels
213. It may therefore be other 
metabolic  abnormalities  such  as  low  HDL  driving  endothelial  dysfunction  associated  with 
hypertriglyceridaemia. In a study by Gudmundsson et al.
214 no acute impairment in endothelial 
function was observed following triglyceride infusion. Strategies to lower triglyceride levels 
(such  as  fibrate  therapy)  alter  a  number  of  other  metabolic  abnormalities  therefore  direct 
evidence from interventional studies linking elevated triglycerides and endothelial dysfunction is 
lacking. The direct effect of hypertriglyceridaemia on endothelial function is not clear.  
4.1.5  Endothelial dysfunction and hypertension 
The effect of hypertension alone on endothelial function is not clear. Some studies have reported 
endothelial  dysfunction  in  patients  with  essential  hypertension
215;216.  However  a  number  of 
studies have found preserved endothelial function in essential hypertension
217;218.The conflicting 
results may be partly attributable to different assessment methods or a result of coexisting risk 
factors that tend to cluster in hypertension. Chan et al.
219 found that endothelial function as 
assessed by forearm blood flow was correlated with other cardiovascular risk factors but not 
blood pressure. However Preik et al.
220 showed that hypertension when present with other risk  
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factors  has  an  additive  detrimental  effect  on  endothelial  function.  Furthermore  endothelial 
function is predictive of future cardiovascular events in patients with hypertension
221. 
Conflicting results have also been reported regarding the effects of blood pressure treatment on 
endothelial function. In some but not all studies both calcium channel blockers, Angiotensin 
converting  enzyme  inhibitors  (ACEi)  and  Angiotensin  receptor  blockers  (ARBs)  have  been 
associated with improvements in endothelial function
81;222. 
4.1.6  Endothelial function and oxidative stress 
Impaired endothelium dependent vasodilation arises secondary to reduced NO bioavailability
78. 
This  could  result  from  decreased  production  of  NO  (reduced  eNOS,  reduced  cofactors  for 
eNOS, impaired eNOS signalling) or accelerated NO degradation. Increased NO degradation by 
reactive  oxygen  species  (ROS)  is  thought  to  be  one  of  the  key  mechanisms  underlying 
endothelial dysfunction
84. Hypercholesterolaemia, type 2 DM and hypertension have all been 
associated with increased levels of ROS such as superoxide
87;116;179. Furthermore administration 
of antioxidants has been shown to improve endothelial function
223;224.  
4.1.7  Summary 
Endothelial dysfunction is an important step in the development of cardiovascular disease. It is a 
feature found throughout the cardiovascular continuum from patients with single risk factors to 
those  with  established  CVD.  Endothelial  function  is  an  important  predictor  of  future 
cardiovascular events. Strategies aimed at tackling endothelial function are therefore attractive 
for the management of patients with both established CVD through to those with isolated risk 
factors. The current methods for assessing endothelial function that are available have various 
drawbacks  limiting  their  clinical  application.  A  better  understanding  of  methods  underlying 
endothelial dysfunction together with simpler assessment techniques are required.  
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4.2  Aims 
The hypotheses were firstly to confirm that patients with CAD would have impaired endothelial 
function compared to healthy controls. Secondly to confirm that patients with CAD and type 2 
DM would have greater impairment of endothelial function compared to patients with CAD 
alone. It was hypothesised that impairment in endothelial function would remain despite use of 
currently available secondary prevention therapies. 
The aims of the study were:  
  To assess endothelial function using in vivo and ex vivo methods in patients with severe 
CAD undergoing CABG (with and without type 2 DM) compared to healthy controls.  
  To assess the impact of type 2 DM on endothelial function in patients with CAD. 
  To evaluate whether a non invasive pulse wave analysis (PWA) based technique can be 
used to assess endothelial function in patients with established CAD.  
4.3  Methods 
In vivo and Ex vivo endothelial function studies were performed in participants recruited as part 
of the VASCAB study. A detailed description of participant recruitment, clinical examination, 
and methods for in-vivo and ex vivo assessment of endothelial function is given in chapter 2. 
4.4  Results 
4.4.1  Ex vivo vascular function studies in patients with CAD  
Ex vivo vascular function studies were performed in 49 out of a total of 126 CAD patients 
recruited. The reasons for organ bath results not being available for a patient recruited for the 
study were insufficient samples of vein, the vessel not being vital before studies completed, and 
date or location of operation being changed. Sixteen patients attending for elective VV surgery 
were recruited to provide control saphenous vein samples; of these 16 patients, 10 vessels were  
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suitable  for  organ  bath  experiments.  Reasons  for  unavailable  organ  bath  studies  include 
insufficient size of sample received and vessel not being vital before studies completed. In both 
patients with CAD and patients with VV clinical characteristics (age, sex, history of diabetes 
etc) did not differ from patients in whom vessels were not available. 
Participant characteristics for CAD and control (VV) participants are shown in table 4.1. Table 
10.1 in the supplementary data shows participant characteristics for all patients recruited within 
the study for comparison. Table 10.2 in the supplementary data shows participant characteristics 
for healthy controls compared to all patients with varicose veins. Patients with VV as expected 
are younger than the CAD patients with a lower proportion of males within the group. Although 
49% of CAD patients had a history of hypertension there was no significant difference in blood 
pressure between the two groups. This is probably reflects the universal use of one or more 
antihypertensive agent in the CAD patients. There was high usage of secondary prevention 
therapies (aspirin, statins, ARBs/ACEi and beta-blockers) within the CAD patients.  
The biochemistry results for participants in the ex vivo endothelial function study are shown in 
table 4.2. Total cholesterol and LDL levels were lower in the CAD group compared to VV 
controls, reflecting the high prevalence of statin prescription. HDL levels were lower in the 
CAD  group. Table  10.3 in the supplementary data shows biochemistry results for all study 
participants  for  comparison.  Table  10.4  in  the  supplementary  data  shows  the  biochemistry 
results  for  healthy  controls  compared to  patients  with VV.  Again  the  participants  in  whom 
vessels were available did not differ from all patients recruited for the study.  
Endothelium dependent vasodilation as assessed by maximum relaxation of saphenous veins to 
calcium  inophore  A23187  is  shown  in  figure  4.2.  Maximal  relaxation  following  calcium 
inophore  was  significantly  lower  in  saphenous  veins  from  patients  with  CAD  compared  to 
controls in keeping with impaired endothelial function (43.1±15.7% vs. 61.9±16.3. %, P=0.001).  
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95% Confidence intervals for the difference between mean relaxation to calcium inophore in 
patients  with  CAD  compared  to  controls  was  -7.8  to-29.7%.  Endothelium  independent 
vasodilation as assessed by maximum relaxation of saphenous veins to SNP is shown in figure 
4.3. There was no significant difference in endothelium independent vasodilatation between the 
2 groups, 111.2±15.7 vs 101.3±6.2 in CAD and controls respectively. The 95% confidence 
intervals for the difference in mean relaxation to SNP between patients with CAD compared to 
controls was -6.5 to 26.5%. 
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Table 4.1 Clinical characteristics for patients with CAD and patients with VV in ex vivo 
vascular function study.  
  CAD (n=49)  VV control (n=10)  P-value 
Age (years)  65.5±9.3  45.9±18.9  0.014 
Male (%)  39(79.6)  4(40)  0.018 
Systolic BP (mm Hg)  138.1±25.9  134.4±24.9  NS 
Diastolic BP (mm Hg)  77.9±12.7  86.2±13.4  NS 
Heart rate (beats/min)  64.2±13.9  68.6±13.3  0.04 
BMI (kg/m
2)  29.4±4.4  26.9±1.9  NS 
Current smokers (%)   2(4.1)  1(10)  NS 
Type 2 DM (%)  14(28.6)  0  n/a 
Hypertension (%)  24(49)  2(20)  NS 
Myocardial Infarction (%)  24(49)  0  n/a 
TIA/CVA (%)  3(6.1)  0  n/a 
Chronic renal failure (%)  3(6.1)  0  n/a 
Heart failure (%)  8(16.3)  0  n/a 
Aspirin (%)   43(87.8)  1(10)  <0.0001 
Other antiplatelet agent (%)  15(30.6)  0  0.049 
Statin (%)  43(87.8)  1(10)  <0.0001 
ACEi/ARB (%)  33(67.3)  1(10)  0.001 
Beta-blocker (%)  36(73.5)  1(10)  <0.0001 
Calcium channel blocker (%)  14(28.6)  1(10)  NS 
Nitrate (%)  26(53.1)  0  0.001 
Diuretic (%)  14(28.6)  1(10)  NS 
Oral hypoglycaemic agent (%)  7(14.3)  0  n/a 
Insulin (%)  3(6.1)  0  n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident,  BP,  Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 4.2. Biochemistry results in patients with CAD and patients with VV for ex vivo 
vascular function study  
  CAD (n=49)  VV Control 
(n=10) 
P-value 
Cholesterol (mmol/L)  3.99±1.01  5.20±0.82  0.007 
Triglycerides (mmol/L)  2.27±1.48  1.24±0.47  0.016 
LDL (mmol/L)  1.86±0.80  3.00±0.85  0.004 
HDL (mmol/L)  1.15±0.28  1.64±0.20  <0.0001 
CRP (mg/L)  4.36±10.59  3.70±4.54  NS 
HbA1c (%)  6.07±1.11  5.42±0.19  NS 
Urinary ACR (mg/mmol)  2.11±2.16  1.28±0.43  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP  C-reactive  protein;HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 4.1 Maximal relaxation of saphenous veins to calcium inophore A23187 in patients 
with CAD and control patients with VV.  
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Figure 4.2 Maximal relaxation to sodium nitroprusside in saphenous veins from control 
patients with VV and patients with CAD 
 
 
4.4.2  Ex vivo studies in patients with CAD and type 2 DM 
Twenty  eight  per  cent  of  the  CAD  patients  had  type  2  DM.  Participant  demographics  and 
clinical characteristics are shown in table 4.3. Body mass index and prevalence of hypertension 
was  higher  in  the  patients  with  diabetes  compared  to  those  without.  There  were  no  other 
significant differences between the two groups. Biochemistry results are shown in table  4.4. 
HbA1c was significantly higher in the patients with diabetes compared to those without. There 
P=0.22 
n=4  n=26
910  
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were no significant differences in cholesterol measures between the two groups. Endothelial 
function was worse in patients with CAD and diabetes compared to CAD alone (figure 4.4) 
Maximum  relaxation  to  calcium  ionophore  was  33.9±10.8%  in  patients  with  type  2  DM 
compared to.46.8±15.9% in patients without diabetes (P=0.008).The 95% confidence intervals 
for difference between the means were -22.3 to-3.6%. There was no significant difference in 
endothelium independent vasodilation, 107.6±11.5 vs 119.5±21.3, 95% confidence intervals for 
the  difference  between  the  means  were  -6.17  to  30.1%.  Results  are  shown  in  figure  4.5. 
Determinants of endothelial function  were investigated using  stepwise  regression.  Age,  sex, 
CAD  status,  diabetes  status,  LDL  and  HDL  levels  were  entered  into  a  stepwise  regression 
model.  Of  these  variables  diabetes  status  was  the  only  significant  predictor  of  endothelial 
function, R
2=0.157, P=0.003 (table 4.5). 
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Table 4.3 Demographics and clinical characteristics in patients with CAD with and 
without type 2 DM in ex vivo vascular function study. 
  CAD alone 
(n=35) 
CAD and type 2 
DM 
(n=14) 
P-value 
Age (years)  66±8.7  64±11.1  NS 
Male (%)  27 (77%)  12(87.5)  NS 
Systolic BP(mm Hg)  137.3±27.15  140.8±22.37  NS 
Diastolic BP (mm Hg)  79.0±11.76  73.9±15.5  NS 
Heart rate (beats/min)  64.3±12.79  63.8±17.79  NS 
BMI, kg/m
2  28.7±4.11  31.9±4.67  0.047 
Current Smokers (%)  1(2.9)  1(7.1)  NS 
Hypertension (%)  12(34.3)  12(85.7)  0.004 
Myocardial Infarction (%)  15(42.9)  9(64.3)  NS 
TIA/CVA (%)  2 (5.7)  1(7.1)  NS 
Chronic renal failure (%)  2(5.7)  1(7.1)  NS 
Heart failure (%)  3(8.6)  5(35.7)  NS 
Aspirin (%)  30(85.7)  13(92.9)  NS 
Other antiplatelet agent (%)  12(34.3)  3(21.4)  NS 
Statin (%)  30(85.7)  13(92.9)  NS 
ACEi/ARB (%)  21(60)  12(85.7)  NS 
Beta-blocker (%)  25(71.4)  11(78.6)  NS 
Calcium channel blocker (%)  9(25.7)  5(35.7)  NS 
Nitrate (%)  20(57.1)  6(42.9)  NS 
Diuretic (%)  8(22.9)  6(42.9)  NS 
Oral hypoglycaemic agent (%)  0  7(50)  n/a 
Insulin (%)  0  3(21.4)  n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident,  BP,  Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 4.4 Biochemical results for patients with CAD alone and patients with CAD and type 
2 DM in ex vivo vascular function study 
  CAD alone 
(n=35) 
CAD and type 2 
DM 
(n=14) 
P- value 
Cholesterol (mmol/L)  4.02±1.07  3.91±0.91  NS 
Triglycerides (mmol/L)  2.04±0.87  2.64±2.32  NS 
LDL (mmol/L)  1.91±0.81  1.78±0.72  NS 
HDL (mmol/L)  1.17±0.30  1.11±0.24  NS 
CRP (mg/L)  5.13±12.58  2.72±3.34  NS 
HbA1c (%)  5.59±0.36  7.41±1.35  <0.0001 
Urinary ACR (mg/mmol)  2.31±6.24  3.79±3.35  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 4.3. Maximal relaxation of saphenous veins to calcium inophore A23187 in patients 
with CAD alone and patients with CAD and type 2 DM 
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Figure 4.4 Maximal relaxation to sodium nitroprusside in saphenous veins from patients 
with CAD alone and patients with CAD and type 2 DM 
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Table 4.5 Determinants of ex vivo endothelial function 
  Full model (R
2=0.242)  Stepwise model (R
2=0.157) 
  β  P-value  β  P-value 
Age  0.72  0.642  _  _ 
Sex (0=female,1=male)  0.113  0.415  _  _ 
CAD (0=no,1=yes)  -0.323  0.073  _  _ 
Type 2 DM (0=no,1=yes)  -0.383  0.006  -0.397  0.003 
LDL-cholesterol  -0.018  0.907  _  _ 
HDL-cholesterol  -0.217  0.196  _  _ 
In the full model all variables were forced into the model. In the stepwise model variables with a 
significance of ≥0.1were removed. Β indicates the partial correlation coefficients. 
4.4.3  In vivo endothelial function studies 
Reproducibility  of  AIx  was  assessed  in  10  healthy  controls.  Intra-observer  results  for  AIx 
measurements taken on the same day were -0.034±1.92% and -0.67±3.86% for measurements 
taken 24-48 hours later. In vivo endothelial function studies were performed in 22 patients with 
CAD and 30 healthy controls. Reasons for not performing  in vivo vascular function studies 
included insufficient time for studies (74 CAD patients,18 controls) , participant unwilling to 
take either salbutamol or GTN (19 CAD patients and 18 controls) or PWA recording being of 
insufficient  quality  (33  CAD  patients  and  19  controls).  Table  4.6  shows  demographics  and 
clinical  characteristics  for  participants  in  in-vivo  vascular  function  study.  Table  4.7  shows 
biochemical analysis. Change in peripheral AIx following inhaled salbutamol was used to assess 
endothelial dependent vasodilation. Table 4.8 shows heart rate, systolic blood pressure, diastolic 
blood pressure and peripheral AIx at 5, 10, 15 and 20 minutes following salbutamol in patients 
with CAD and controls. In view of the variability to peak salbutamol effect between individuals 
the maximum change for each variable was also calculated. There was a significant increase in 
heart rate in both controls and patients with CAD following salbutamol compared to baseline.  
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However there was no difference between the maximum change in heart rate between the two 
groups. Overall there was no trend for change in systolic or diastolic blood pressure following 
salbutamol in either group with no difference in maximum change in either systolic or diastolic 
blood pressure. Peripheral AIx fell at all time points following salbutamol in controls, in CAD 
patients overall there was an increase in peripheral AIx 5 minutes post salbutamol but no other 
significant change. The maximum change in peripheral AIx post salbutamol was significantly 
greater  in  the  control  group  indicating  improved  endothelial  function  compared  to  CAD,-
7.32±8.1  vs  -0.6±9.4  in  controls  and  patients  with  CAD  respectively.  The  95%  confidence 
intervals  for  the  difference  between  the  mean  response  of  peripheral  AIx  to  salbutamol  in 
controls compared to patients with CAD were 1.80 to 11.65% (figure 4.6). 
Heart rate, systolic blood pressure, diastolic blood pressure and peripheral augmentation index 
following GTN administration are shown in table 4.9. There was a significant increase in heart 
rate following GTN in both groups but the maximum change in heart rate was not different 
between the 2 groups. There were no significant changes in blood pressure following GTN. 
Peripheral augmentation index fell significantly following GTN administration. Healthy controls 
showed a greater response to GTN compared to patients with CAD; this was of borderline 
significance  -16.8±8.65  vs  -11.9±7.1,  P=0.05.  95%  confidence  intervals  for  the  difference 
between the mean change in AIx following GTN between healthy controls and patients with 
CAD was 2.4 to 4.85% (Figure 4.7).  
In vivo endothelial function was assessed in 5 patients with type 2 DM and CAD compared to 17 
patients with CAD alone. Peripheral AIx fell to a lesser degree in the patients with type 2 DM 
compared to those without diabetes however in view of the small numbers detailed analysis is 
not appropriate.   
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Twelve patients (8 with CAD and 4 VV controls) had both in-vivo and ex vivo measures of 
endothelial function. In these 12 participants there was no relationship between the two different 
assessments of endothelial function, r=-0.27, P=0.4 (figure 4.8). 
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Table 4.6 Demographics and clinical characteristics for patients with CAD and healthy 
controls in in vivo vascular function study 
  CAD (n=22)  Control (n=30)  P-value 
Age (years)  66.6±10.8  60.8±12.8  NS 
Male (%)  18(81.8)  17(56.7)  NS 
Systolic BP (mm Hg)  139.8±19.8  142.0±20.5  NS 
Diastolic BP (mm Hg)  76.8±8.6  82.4±12.2  NS 
Pulse pressure (mm Hg)  63.0±17.3  59.6±13.8  NS 
Heart rate (beats/min)  64.4±8.7  72.0±13.2  0.015 
BMI, kg/m
2  30.0±3.2  26.0±3.3  <0.0001 
Current Smokers (%)  1(4.5)  2(6.7)  NS 
Type 2 DM (%)  5(22.7)  0  n/a 
Hypertension (%)  17(77.3)  8(26.7)  0.002 
Myocardial Infarction (%)  11(50)  0  n/a 
TIA/CVA (%)  1(4.5)  1 (3.3)  NS 
Chronic renal failure (%)  1(4.5)  0  n/a 
Heart failure (%)  1(4.5)  0  n/a 
Aspirin (%)  19(86.4)  3(10)  <0.0001 
Other antiplatelet agent (%)  7(31.8)  1(3.3)  0.007 
Statin (%)  22(100)  5(16.7)  <0.0001 
ACEi/ARB (%)  15(68.5)  2(6.7)  <0.0001 
Beta-blocker (%)  16(72.7)  2 (6.7)  <0.0001 
Calcium channel blocker (%)  9(40.9)  1 (3.3)  0.001 
Nitrate (%)  16(72.7)  0  <0.0001 
Diuretic (%)  5(22.7)  4(13.3)  NS 
Oral hypoglycaemic agent (%)  2(9.1)  0  n/a 
Insulin (%)  1(4.5)  0  n/a 
Continuous variables are mean±standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident,  BP,  Blood 
pressure, ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
    
125 
Table 4.7 Biochemical results for patients with CAD and healthy controls in in vivo 
vascular function study 
  CAD (n=22)  Control (n=30)  P-value 
Cholesterol (mmol/L)  4.01±0.84  5.69±1.09  <0.0001 
Triglycerides (mmol/L)  1.96±0.75  1.68±0.83  NS 
LDL (mmol/L)  1.93±0.71  3.36±1.04  <0.0001 
HDL (mmol/L)  1.18±0.29  1.53±0.37  0.001 
CRP (mg/L)  3.15±4.42  1.96±2.67  0.039 
HbA1c (%)  5.95±0.84  5.55±0.33  0.027 
Urinary ACR (mg/mmol)  4.14±10.7  1.40±0.84  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C  reactive  protein;HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Table 4.8 Response to salbutamol in patients with CAD and healthy controls 
  Healthy Control 
(n=30) 
P-value  CAD (n=22)  P-value  
Heart rate 
(beat/min) 
       
0  63.9±10.5    58.5±6.9   
5  66.3±10.8  0.001  59.6±7.2  0.006 
10  66.4±10.6  0.01  60.5±7.4  0.03 
15  64.7±10.1  0.013  60.2±7.4  0.018 
20  66.2±10.3  0.005  60.0±7.4  NS 
Max. change in 
Heart rate  
2.6±3.8    2.0±5.2   
SBP (mmHg)         
0  136.4±17.9    134.9±18.4   
5  139.3±20.9  NS  139.7±17.3  0.006 
10  137.0±18.1  NS  137.0±18.0  NS 
15  136.1±20.5  NS  138.6±19.6  NS 
20  135.6±18.5  NS  134.8±19.3  NS 
Max. change in 
SBP 
3.3±14.9    2.9±15.3   
DBP (mmHg)         
0  80.1±11.5    73.0±8.0   
5  82.7±11.4  NS  75.3±7.4  0.01 
10  76.2±17.5  NS  74.5±8.2  NS 
15  78.7±9.7  NS  76.8±8.2  0.01 
20  78.1±10.1  NS  74.4±7.9  NS 
Max change in 
DBP 
2.2±14.9    4.5±8.2   
Peripheral AIx (%)         
0  85.7±18.5    84.7±12.7   
5  82.7±17.7  0.005  86.3±12.7  0.032 
10  81.3±18.8  <0.0001  82.7±11.3  NS 
15  80.9±19.0  0.001  86.0±14.1  NS 
20  80.7±17.9  <0.0001  83.8±16.2  NS 
Max change 
peripheral AIx(%) 
-7.32±8.1    -0.6±9.4*   
BP,  blood  pressure;  AIx,  augmentation  index,  P-values  indicate  significant  change  from 
baseline. *Significant difference between CAD and controls (P=0.008).  
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Table 4.9. Response following GTN in healthy controls and patients with CAD 
  Healthy Control 
(n=30) 
P-value  CAD (n=22)  P-value 
Heart rate 
(beats/min)  
       
0  65.2±9.8    59.5±7.8   
5  68.3±9.7  <0.0001  63.3±7.1  <0.0001 
Change in heart rate  3.2±3.5    3.9±2.6   
SBP(mmHg)         
0  138.6±21.3    136.7±19.0   
5  138.1±18.4  NS  134.7±19.3  NS 
Change in SBP  -0.5±9.5    -3.2±8.0   
Diastolic BP(mmHg)         
0  80.3±9.7    75.1±8.4   
5  78.1±13.0  NS  74.6±7.9  NS 
Change in DBP  -2.1±10.2    -0.8±5.5   
Peripheral Aix (%)         
0  81.8±20.9    84.1±10.9   
5  64.6±20.2  <0.0001  70.2±19.6  <0.0001 
Change in peripheral 
AIx 
-16.8±8.7    -11.9±7.1*   
BP, blood pressure; AIx, augmentation index, P-values indicate significant change from baseline 
*Significant difference between CAD and controls (P=0.05). 
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Figure 4.5. Maximum change in peripheral AIx post salbutamol in patients with CAD and 
controls 
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Figure 4.6. Maximum change in peripheral AIx post GTN in patients with CAD and 
controls 
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Figure 4.7. Scatter plot of maximum change in peripheral AIx post salbutamol and 
maximum relaxation to calcium inophore 
 
4.5  Discussion 
Using an ex vivo method the presence of endothelial dysfunction was confirmed in patients with 
CAD  compared  to  healthy  controls.  There  was  no  impairment  in  endothelium  independent 
vasodilation.  These  results  are  consistent  with  a  plethora  of  published  data
87;109;179;182;187;188. 
Twenty eight per cent of the CAD patients had type 2 DM; this is representative of all patients 
undergoing CABG in Scotland
99. Endothelial function was significantly impaired in patients 
P=NS  
131 
with type 2 DM and CAD compared to patients with CAD alone. There was no difference in 
endothelium  independent  vasodilation.  These  findings  are  in  keeping  with  a  number  of 
previously  published  studies
110;195.  Endothelial  function  has  been  found  to  be  an  important 
prognostic  factor  in  patients  with  established  CAD
187;188.  The  greater  degree  of  endothelial 
impairment in patients with type 2 DM may explain the worse cardiovascular outcomes seen in 
these patients. 
Despite a number of interventions that have been associated with improved endothelial function, 
endothelial dysfunction persisted in patients with CAD, with and without type 2 DM. Previous 
studies have shown LDL levels to be one of the major determinants of endothelial function
179. 
LDL levels were significantly lower in the CAD group compared to controls. LDL levels were 
also well controlled in patients with type 2 DM, indeed there was a trend to lower LDL levels 
although this was not statistically significant. Statin therapy was widespread in all patients with 
CAD. Statins therapy has been shown to improve endothelial function through both a reduction 
in  LDL  levels  and  lipid  independent  effects
206-208.  In  some  studies  ACEi/ARBs  have  been 
associated with improvements in endothelial function
222. Use of ACEi/ARB was unsurprisingly 
high in patients with CAD compared to controls. In addition a higher proportion of patients with 
type 2 DM were on ACEi/ARBs although this was not statistically significant. 
Interestingly diabetes status was the only significant determinant of ex vivo endothelial function. 
Although this only accounted for approximately 16% of the variability observed, suggesting that 
factors other than those commonly known to alter endothelial function (Age, CAD status, LDL 
and  HDL)  are  important.  A  number  of  mechanisms  could  account  for  the  endothelial 
dysfunction  seen  in  patients  with  type  2  DM,  including  insulin  resistance,  hyperglycaemia, 
increased  oxidative  stress  and  dyslipidaemia.  These  same  mechanisms  may  also  partly 
contribute to the endothelial dysfunction observed in patients with CAD alone.   
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Hyperglycaemia as assessed by HbA1c was significantly higher in patients with type 2 DM 
compared  to  controls.  Hyperglycaemia  may  contribute  to  endothelial  dysfunction  through  a 
number of mechanisms including increased oxidative stress, advanced glycation end products 
and increased flux through the hexosamine biosynthetic pathway
91;225;226. Blood glucose levels 
may have also partly contributed to the impaired endothelial function observed in CAD patients 
without  type  2  DM.  Blood  glucose  is  continuous  variable  therefore  dividing  in  to  diabetes 
yes/no somewhat arbitrary. It is likely that a proportion of CAD patients without diabetes will 
have had impaired glucose tolerance. HbA1c with a cut off of 6.5% was accepted in January 
2011 by the WHO for the diagnosis of diabetes 
3. At present the use of HbA1c for the diagnosis 
of impaired glucose tolerance is not recommended
3. Although HbA1c was higher in patients with 
type 2 DM compared to controls, glycaemic control was reasonable in patients with type 2 DM 
(mean HbA1c 7.4±1.35%) and as highlighted by recent clinical trials tight glycaemic control may 
actually  be  harmful  in  some  groups  of  patients 
3;27.  Therefore  even  if  hyperglycaemia  is 
contributing to endothelial dysfunction further reductions in blood glucose levels may not be 
appropriate in this group of patients. 
Insulin resistance has also be shown to be associated with endothelial dysfunction and may 
partly explain the worse endothelial function in patients with type 2 DM
197. Insulin resistance 
like  blood  glucose  levels  is  a  continuous  variable  therefore  may  have  also  contributed  to 
endothelial dysfunction seen in CAD patients without type 2 DM. Insulin resistance was not 
assessed in this study however type 2 DM is by definition an insulin resistant state. It has been 
shown in patients with established CAD without diabetes insulin resistance is also common, 
illustrated by the high prevalence of the metabolic syndrome
227. A similar pattern is likely in this 
study. Previous studies have shown that insulin resistance is associated with endothelial function 
228;229. What degree this is a direct consequence of insulin resistance and how much can is the 
result of coexisting factors such as dyslipidaemia is not clear. Some but not all studies have  
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shown that insulin resistance is an independent predictor of endothelial function. In healthy 
individuals  without  diabetes  or  other  cardiovascular  risk  factors  fasting  insulin  levels  as  a 
surrogate for insulin resistance were related to brachial FMD
229. However Hamburg et al.
228 
showed  that  the  impaired  brachial  FMD  associated  with  insulin  resistance  was  due  to 
components  of  the  metabolic  syndrome  rather than  independent  effect  of  insulin resistance. 
Further evidence for the role of insulin resistance in the development of endothelial dysfunction 
comes from studies looking at the effects of improving insulin sensitivity. Insulin sensitizing 
agents have been shown to improve endothelial function. Rosiglitazone improves endothelial 
function assessed during venous plethysmography in patients with type 2 DM
230. Metformin also 
improves endothelial function in patients with type 2 DM and in individuals with the metabolic 
syndrome but normal glucose tolerance
231;232 Metformin was used in 47% of patients with type 2 
DM in this study, glitazones in 11%. Ongoing use of glitazones and in particular rosiglitazone in 
patients with CVD is not recommended due to studies suggesting increased CV events 
32. Indeed 
since October 2010 rosiglitazone has been withdrawn in Europe and has restrictions placed on 
its use within the USA. Metformin is however safe and well tolerated. Other strategies that are 
known to improve insulin sensitivity including weight loss and increased physical activity have 
also been shown to improve endothelial function
233-235. 
Lipid abnormalities in addition to LDL levels may also contribute to endothelial dysfunction. 
HDL  levels  have  been  shown  to  be  correlated  with  endothelial  function
209.  HDL  was 
significantly lower in patients with CAD compared to controls furthermore there was a trend 
towards lower HDL levels in the patients with type 2 DM although this was not significant. 
However in multivariate analysis HDL was not a significant determinant of endothelial function. 
Insulin resistant states are associated with changes in LDL subfractions with increased levels of 
small  dense  LDL  particles
236.  Small  dense  LDL  has  been  associated  with  endothelial 
dysfunction
237.  
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Increased oxidative stress has been reported in patients with type 2 DM
177. Increased oxidative 
stress  is  thought  to  be  one  of  the  major  mechanisms  underlying  endothelial  dysfunction  in 
patients with CAD
84. Antioxidants such as vitamin C improves endothelial function in patients 
with type 2 DM, however large clinical trials have not shown improved cardiovascular outcomes 
with  anti-oxidants
238-240.  The  role  of  oxidative  stress  in  the  development  of  endothelial 
dysfunction warrants further investigation.  
Using a non-invasive pulse wave analysis technique for assessing in vivo endothelial function 
the presence of endothelial dysfunction in patients with CAD compared to healthy controls was 
confirmed.  In  this  method  there  was  also  evidence  for  impaired  endothelial  independent 
vasodilation. Previous reports using this PWA technique in patients with CAD have reported 
normal responses to GTN
109. Our results may simply be due to small numbers in this study. 
There were insufficient numbers of patients in the PWA endothelial function group to assess the 
effect of type 2 DM although there was a trend to worse endothelial function in this group. 
Use of the PWA based technique for assessment of endothelial function has not been widely 
reported to date. Endothelial dysfunction using the PWA based technique was found in patients 
with established CVD and patients with hypercholesterolaemia 
108;109. Wilkinson et al 
108 have 
shown that response to salbutamol is consistent in healthy volunteers examined over a week 
with a mean difference of -2.3±3.0%. Repeatability of response to salbutamol was not further 
examined in this study however the within observer reproducibility of AIx index measurement 
in this study was similar to previously reported data 
241.  
The two methods for assessing endothelial function both detected endothelial dysfunction in 
patients with CAD compared to controls. There was however no correlation between the two 
methods. This is not surprising given the small numbers of patients in whom both methods were 
performed. Furthermore the two methods assess endothelial function in different vascular beds.  
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Rambaran  et  al.
186  compared  endothelial  function  assessed  by  change  in  wave  reflection 
following salbutamol and FMD. They found that although endothelial function as assessed by 
these two methods was correlated this relationship was not particularly strong. Only a subgroup 
of  the  all  the  participants  recruited  for  the  study  had  endothelial  function  data  available 
reflecting some of the difficulties with the two methods. Organ bath data was limited by the 
availability  of  vessels  which  cannot  be  easily  controlled  for.  More  disappointing  were  the 
number of patients in whom in vivo endothelial function data was available. The PWA technique 
was relatively easy to perform and well tolerated by participants. The major factor limiting 
completion of in vivo endothelial function studies was time. The protocol took approximately 1 
hour which was excessive for many of the CAD patients and was a major limitation of the 
technique. Patients were seen immediately prior to admission to hospital and time was limited 
due  to  admission  procedures  and  distance  many  of  the  patients  had  to  travel.  This  was  a 
deficiency of the study design. 
The presence of impaired endothelial function in patients with type 2 DM and CAD despite well 
controlled LDL levels, widespread use of statins and ACEi/ARBs and reasonable glycaemic 
control  highlights  the  need  for  further  cardiovascular  management  strategies  specifically 
targeted  at  improving  endothelial  function.  Insulin  resistance,  increased  oxidative  stress, 
inflammation and dyslipidaemia may all contribute to endothelial dysfunction seen in patients 
with  CAD  with  and  without  overt  diabetes.  Elucidating  the  relative  contribution  of  these 
mechanisms should help identify novel strategies for tackling endothelial dysfunction in these 
patients.  Since  endothelial  dysfunction  is  an  important  prognostic  factor  in  patients  with 
established  CAD  it  is  hoped  that  improved  endothelial  function  would  lead  to  improved 
cardiovascular outcomes. Large prospective studies are required to confirm this hypothesis. To 
date large trials assessing endothelial function have been limited by the availability of simple 
non-invasive techniques. The PWA technique used in this study would be suitable for larger  
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trials.  It  was  simple  to  perform  and  well  tolerated  by  the  majority  of  patients.  The  major 
drawback was the time required for completion of the protocol. Furthermore it is unclear as to 
the sensitivity of this test and the ability to detect the small changes in endothelial function that 
might be expected in an intervention study. 
There  are  a  number  of  limitations  to  this  study.  The  design  of  the  study  limited  the  time 
available to examine patients and therefore reduced the numbers of patients who had in vivo 
assessment  of  endothelial  function  performed.  The  small  number  of  patients  in  the  study, 
particularly with in vivo results limited the further analysis of the results. The cross-sectional 
design, limits the conclusions that can be drawn from this study. The VV control group was 
significantly younger than patients with CAD and contained more women. Age has previously 
been  shown  to  be  an  important  determinant  of  endothelial  function  and  results  need  to  be 
interpreted in the context of the age difference 
81. However the results of the ex vivo endothelial 
function studies were confirmed using an in vivo method in a healthy control group that was 
more closely matched for age to the patients with CAD.  
4.6  Chapter summary 
This  study  has  shown  patients  with  established  CAD  have  impaired  endothelial  function 
compared to healthy controls. Type 2 DM is associated with significantly impaired endothelial 
function compared to patients with CAD alone. The impairment in endothelial function persists 
despite good control of cardiovascular risk factors and widespread use of secondary prevention 
therapies.  Novel  strategies  targeting  endothelial  dysfunction  are  therefore  required.  A  non-
invasive PWA technique for assessing endothelial function is feasible for use in larger clinical 
trials however a major limitation is the time for required to complete studies.  
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5  Oxidative stress 
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5.1  Introduction  
Increased  production  of  reactive  oxygen  species  (ROS)  and  in  particular  superoxide  (O2
-)is 
understood to be pivotal the development of endothelial dysfunction and cardiovascular disease 
(CVD)
84.  Sources  of  O2
-  include  both  vascular  cells  and  circulating  cells  such  as 
phagocytes
92;178. Within the vasculature there are a number of enzymatic sources of O2
-. These 
include NAD(P)H oxidase, xanthine oxidase, endothelial nitric oxide synthase (eNOS) and the 
mitochondrial electron transport system
84. Of these NAD(P)H oxidase is understood to be one of 
the principle sources
87. The enzyme eNOS under normal conditions produces nitric oxide (NO). 
However under certain circumstances the enzyme becomes uncoupled and can switch to being a 
net producer of O2
-177. This may occur when the availability of the cofactor tetrahydrobiopterin 
is limited
177. Circulating cells such as phagocytes also contribute to the burden of oxidative 
stress  both  whilst  in  circulation  and  as  they  infiltrate  atherosclerotic  plaques
92.  Phagocytes 
produce O2
- via NAD(P)H oxidase system
242.  
5.1.1  Assessing oxidative stress 
The term oxidative stress refers to complex interactions between ROS and antioxidant systems. 
Levels of ROS can be measured directly or assessed using indirect markers. Direct measurement 
of ROS in the mainstay focuses on measurement of superoxide as this is considered to be the 
principle ROS. O2
- is highly reactive and unstable making assessment difficult. O2
- production 
can be measured directly in tissues affected by the CVD process for example vascular tissue, 
cardiac  tissue  and  also  in  cells  that  are  involved  in  the  pathogenesis  of  CVD  such  as 
mononuclear  cells  or  endothelial  progenitor  cells
116;178;243;244.  Primary  cells  such  as  vascular 
smooth  muscle  cells  can  also  be  cultured  and  ROS  species  measured
245.  Using  the  above 
methods for assessing oxidative stress in humans is clearly limited by the availability of suitable 
samples. Furthermore the results need to be interpreted cautiously as due the ex vivo nature of 
the methods processes involved may differ from those occurring in situ. Techniques suitable for  
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direct  measurement  of  O2
-  include  chemiluminescence-based  techniques  and  electron  spin 
resonance spectroscopy
113.  
Indirect  methods  involve  the  quantification  of  products  produced  as  a  result  of  oxidative 
damage. These include oxidised low density lipoprotein (LDL), isoprostanes and thiobarbituric 
acid-reacting substances. These indirect measures are attractive as samples of blood or urine are 
easily  obtained.  In  addition  the  techniques  required  for  these  assays  tend  to  be  more 
straightforward than those employed for the direct measurement of ROS. The sensitivity and 
specificity of these techniques has been questioned however
246. Oxidised LDL can be measured 
using  enzyme  linked  immunosorbant  assays.  There  are  a  number  of  different  assays  that 
measure slightly different changes in LDL particles that comprise the oxidised LDL entity. The 
results are therefore not necessarily comparable between different assays
247. Oxidised LDL has 
been shown to be a predictor of severity of coronary artery disease (CAD)
248;249. However some 
assays are not independent of LDL levels
247 There are as yet no prospective studies of oxidised 
LDL and cardiovascular outcomes. Isoprostanes are stable compounds formed following the 
reaction of ROS with the phospholipid domain of cell membranes and can be measured in urine 
or plasma 
250.Urinary isoprostanes have been shown to be an independent predictor of CAD
251. 
Prospective studies are once again needed. Thiobarbituric acid reacting substances are products 
of lipid peroxidation and had previously been used in a number of studies
246. However ongoing 
use of these in the assessment of oxidative stress has been questioned due to low accuracy of 
these methods
246;250. 
An  ideal  tool  for  assessing  oxidative  stress  would  be  simple,  specific,  non-invasive  and 
repeatable. At present such a test does not exist restricting the detailed assessment of oxidative 
stress in humans to ex vivo experiments.  
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5.1.2  Oxidative stress and CAD 
There is a wealth of data implicating increased oxidative stress, and in particular increased O2
- 
levels, as a major underlying mechanism underlying cardiovascular disease in animal models
79. 
This is supported by evidence from studies in humans although this is more limited due to the 
inherent difficulties with assessing oxidative stress in vivo. 
Vascular O2
- is increased in saphenous veins of patients with CAD compared to controls
179. In 
patients with CAD NAD(P)H oxidase is thought to be the predominant source of O2
-87. There is 
evidence that hypertension, hypercholesterolemia and diabetes mellitus (DM) all contribute to 
the increased levels of oxidative stress observed in patients  with CAD. Diabetes status and 
hypercholesterolaemia  are  both  independently  associated  with  levels  of  NAD(P)H  oxidase 
activity
87. Levels of O2
- are increased in circulating phagocytes in patients with hypertension and 
cardiovascular risk factors
116;252. Levels of mononuclear O2
- production has been shown to be 
associated with carotid–intima media thickness, a surrogate marker of atherosclerosis
253. Less is 
known  regarding  mononuclear  O2
-  production  in  vivo  in  patients  with  established  CAD. 
Mononuclear cell O2
- production was increased in patients with stable angina and these cells 
exhibited greater adhesiveness in ex vivo studies
254. 
5.1.3  Oxidative stress and DM 
The  role  of  oxidative  stress  in  patients  with  type  2  DM  is  of  particular  interest.  Increased 
oxidative stress has been implicated as a key mechanism underlying many of the complications 
of diabetes including CVD
255. In addition increased oxidative stress may contribute to insulin 
resistance and β-cell dysfunction driving the development of type 2 DM
225. Increased oxidative 
stress in patients with type 2 DM may partly explain the endothelial dysfunction and increased 
cardiovascular risk associated with DM.   
141 
Vascular O2
- is increased in vessels of patients with CAD and type 2 DM compared to patients 
with  CAD  alone
177.In  these  patients  important  sources  included  NAD(P)H  oxidase  and 
uncoupled eNOS
177. Mononuclear NAD(P)H oxidase O2
- production is increased in phagocytes 
of patients with metabolic syndrome and this appeared to be related to hyperinsulinaemia
252. 
Mononuclear cells from patients with type 2 DM secrete increased levels of O2
- compared to 
controls
256. Mononuclear cells incubated in hyperglycaemic conditions also produce increased 
O2
-257 Other markers of increased oxidative stress such as increased circulating markers and 
decreased antioxidant capacity abnormal in patients with type 2 DM 
91.  
The mechanisms underlying increased oxidative stress in type 2 DM are not fully understood. 
Hyperglycaemia appears to be one of the driving factors. Hyperglycaemia can cause increased 
oxidative stress through a number of mechanisms including glucose autoxidation, through the 
formation  of  advanced  glycation  end  products  (AGE)  and  activation  of  polyol  pathway
91. 
Important enzymes are thought to include NAD(P)H oxidases, mitochondrial electron transport 
chain and uncoupled eNOS 
177;258.  
5.1.4  Strategies to reduce oxidative stress 
Increased intake of fruit and vegetables protects against CVD 
259. The epidemiological data 
together  with  evidence  implicating  increased  oxidative  stress  in  the  pathogenesis  of  CVD 
disease led to the hope that oral antioxidants would be beneficial in reducing CVD. Both vitamin 
C  and  vitamin  E  improve  endothelial  dysfunction  in  patients  with  cardiovascular  risk 
factors
223;224.  Large  randomised  control  trials  have  however  shown  no  improvement  in 
cardiovascular outcomes. The HOPE trial randomised patients to either vitamin E or placebo 
and  showed  no  reduction  in  cardiovascular  events  after  5  years
260.  Furthermore  subgroup 
analysis showed no benefit of vitamin E in terms of CVD in patients with type 2 DM
239. This is 
despite evidence that patients with type 2 DM are thought to have higher levels of oxidative 
stress. Similar results were found in the heart protection study
240. The heart protection study  
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showed no improvement in cardiovascular outcomes with a combination of vitamin E, vitamin C 
and β carotene
240 It is not clear why the use of antioxidants failed to improve cardiovascular 
outcomes in these large trials. Due to the inherent difficulties of assessing oxidative stress these 
trials did not quantify the changes in levels of oxidative stress. Therefore it is unknown whether 
the administration of oral antioxidants had the desired effect on oxidative stress. The negative 
results  seen  in  large  clinical  trials  do  not  refute  the  importance  of  oxidative  stress  in  the 
development of cardiovascular disease. Various explanations have been proposed for the failure 
of antioxidants to improve cardiovascular outcomes. Possible reasons include selection of the 
wrong antioxidants, the wrong dose of antioxidants and targeting patients too far along the 
cardiovascular continuum
261. 
In  view of the disappointing results with oral vitamins and antioxidants other strategies for 
reducing  oxidative  stress  have  been  considered.  There  is  evidence  that  use  of  Angiotensin 
converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARBs) can reduce 
vascular  NAD(P)H  oxidase  O2
-  production
262.  Statins  have  been  shown  in  improve  both 
endothelial dependent vasodilation and reduce endothelial O2
- production
263. Exercise training 
has also been shown to reduce oxidative stress in patients with CAD
264. 
5.1.5  Summary  
Increased oxidative stress appears to be pivotal in the development of cardiovascular disease. 
Increased  oxidative  stress  can  contribute  to  endothelial  dysfunction  by  reducing  the 
bioavailability  of  NO.  Increased  oxidative  stress  may  be  particularly  important  in  the 
development of cardiovascular disease in patients with type 2 DM. However the failure of oral 
antioxidants  in  large  clinical  trials  highlights  the  need  for  further  understanding  of  the 
mechanisms underlying oxidative stress in CVD and diabetes and better tools for assessing 
oxidative stress clinically.  
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5.2  Aims 
The  hypotheses  were  firstly  that  patients  with  CAD  would  have  increased  oxidative  stress 
compared to healthy controls. Secondly patients with CAD and type 2 DM would have further 
elevations in oxidative stress compared to patients with CAD alone.  
The aims of this study were: 
1.  To assess O2
- levels in the vasculature, mononuclear cell and whole blood of patients 
with CAD compare to healthy controls 
2.  To assess the impact of type 2 DM on O2
- levels in patients with CAD 
3.  To assess the use of whole blood O2
- production as a simple marker of oxidative stress. 
5.3  Methods 
Vascular O2
- production was assessed in saphenous veins in patients with CAD and VV controls 
recruited as part of the VASCAB study. Mononuclear and whole blood O2
-  levels were 
 assessed 
using EPR spectroscopy in patients with CAD and controls recruited as part of the VASCAB 
study. Detailed methods are provided in chapter 2. 
5.4  Results 
5.4.1  Vascular O2- studies 
5.4.1.1  Vascular O2- studies in patients with CAD 
Vascular O2
- measurements were performed in saphenous veins from 71 patients with CAD 
undergoing CABG and in 13 control veins from patients undergoing VV surgery. Participant 
characteristics and demographics are shown in table 5.1. VV controls were significantly younger 
than CAD group with greater proportion of females. There was no significant difference in 
blood  pressure.  As  expected  there  was  high  usage  of  cardiovascular  secondary  prevention 
therapies in the CAD group. Biochemistry results are shown in table 5.2. Lipid profiles reflect 
the widespread use of statins in the patients with CAD with lower total cholesterol and LDL  
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cholesterol levels compared to controls. HDL was significantly lower in patients with CAD 
compared to controls. Triglyceride levels were significantly higher in patients with CAD. The 
patients in whom vascular O2
- levels were available did not differ from the whole study cohort in 
terms of clinical examination and biochemistry results (see supplementary data tables 10.1 to 
10.4). 
Levels of O2
- in saphenous veins from patients with CAD were significantly higher compared to 
varicose  vein  controls,  0.75±0.48  vs.0.43±0.33  nmol/mg/min  P=0.012  (figure  5.1).The  95% 
confidence intervals for the difference in mean vascular O2
- in patients with CAD compared to 
controls was 0.09 to 0.54 nmol/mg/min.  
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Table 5.1 Demographics and clinical characteristics for patients with CAD and control 
patients with VV in vascular O2
- studies 
  CAD 
 (n=71) 
VV Controls  
(n=13) 
P-value 
Age (years)  64.8±10.1  47.3±18.0  <0.0001 
Male (%)  58(81.7)  5(38.5)  0.003 
Systolic BP (mm Hg)  139.4±25.2  134.8±22.8  NS 
Diastolic BP(mm Hg)  78.2±11.8  85.3±12.4  NS 
Heart rate (beats/min)  63.6±12.7  73.5±17.7  NS  
Body Mass Index (kg/m
2)  29.6±5.0  26.5±2.0  NS 
Current Smoker (%)  3(4.2)  2(15.4)  NS 
Type 2 diabetes mellitus (%)  22(31)  0  n/a 
Hypertension (%)  41(57.7)  3(23.1)  0.015 
Myocardial Infarction (%)  38(53.5)  0  n/a 
TIA/CVA (%)  4(5.6)  1(7.7)  NS 
Chronic renal failure (%)  3(4.2)  0  NS 
Heart failure (%)  12(16.9)  0  n/a 
Aspirin (%)  61(85.9)  2(15.4)  <0.0001 
Other antiplatelet agent (%)  20(28.2)  1(7.7)  NS 
Statin (%)  63(88.7)  2(15.4)  <0.0001 
ACEi/ARB (%)  45(63.4)  1(7.7)  <0.0001 
Beta-blocker (%)  53(74.6)  1(7.7)  <0.0001 
Calcium channel blocker (%)  22(31.0)  1(7.7)  NS 
Nitrate (%)  36(50.7)  0  <0.0001 
Diuretic (%)  21(29.6)  2(15.4)  NS 
Oral hypoglycaemic agent (%)  11(15.5)  0  n/a 
Insulin (%)  4(5.6)  0  n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 5.2. Biochemistry results in patients with CAD and control patients with VV for 
vascular O2
- studies 
  CAD 
(n=71) 
VV controls 
(n=13) 
P-value 
Cholesterol (mmol/L)  4.07±1.04  4.96±0.99  0.034 
Triglycerides (mmol/L)  2.22±1.37  1.17±0.47  0.005 
LDL (mmol/L)  1.95±0.82  2.69±1.11  0.03 
HDL (mmol/L)  1.14±0.26  1.72±0.30  <0.0001 
CRP(mg/L)  4.45±9.27  3.55±4.17  NS 
HbA1c (%)  6.08±1.07  5.42±0.17  <0.0001 
Urinary ACR(mg/mmol)  3.06±7.50  1.19±0.46  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 5.1 Vascular O2
- production in saphenous veins from patients with CAD and 
control patients with VV. 
 
5.4.1.2  Vascular O2- in patients with CAD with and without type 2 DM 
Twenty  two  (31%)  of  the  CAD  patients  had  type  2  DM.  Demographics  and  clinical 
characteristics for CAD patients with and without type 2 DM are shown in table 5.3. Body mass 
index was significantly higher in the patients with type 2 DM compared to those without. There 
was a higher prevalence of hypertension in the patients with type 2 DM. There was significantly 
higher usage of diuretics in the patients with diabetes. Use of modifiers of renin-angiotensin 
P=0.012  
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system (ARB/ACEi) was also more widespread in patients with type 2 DM although this was 
not statistically significant.  
Biochemistry results are shown in table 5.4. HbA1c was significantly higher in the patients with 
Type 2 DM. There was a trend to lower levels of both LDL and HDL in patients with type 2 DM 
although this was not statistically significant. 
There was no significant difference in vascular O2
- production in patients with CAD and type 2 
DM  compared  to  patients  with  CAD  alone,  0.64±0.43  vs  0.79±0.50  nmol/mg/min,  P=0.164 
(Figure 5.2).The 95% confidence intervals for the difference in mean vascular O2
- production in 
patients with and without type 2 DM was -0.39 to 0.09 nmol/mg/min. 
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Table 5.3 Demographics and clinical characteristics in CAD patients with and without type 
2 DM in vascular O2
- study. 
  CAD alone 
(n=49) 
CAD and type 2 
DM 
(n=22) 
P-value 
Age (years)  64.8±9.6  64.9±11.3  NS 
Male (%)  39(79.6)  19(86.4)  NS 
Systolic BP(mm Hg)  139.7±26.5  138.8±22.2  NS 
Diastolic BP(mm Hg)  79.7±11.0  74.4±13.2  NS 
Heart rate (beats/min)  63.0±12.1  64.9±14.2  NS 
Body Mass Index, kg/m
2  28.7±4.7  32.2±5.1  0.023 
Current smokers (%)  2(4.1)  1(4.5)  NS 
Hypertension (%)  20(40.8)  21(95.5)  <0.0001 
Myocardial Infarction (%)  24(49)  14(63.6)  NS 
TIA/CVA (%)  2(4.1)  2(9.1)  NS 
Chronic renal failure (%)  2(4.1)  1(4.5)  NS 
Heart failure (%)  5(10.2)  7(31.8)  NS 
Aspirin (%)  41(83.7)  20(90.2)  NS 
Other antiplatelet agent (%)  16(32.7)  4(18.2)  NS 
Statin (%)  43(87.8)  20(90.9)  NS 
ACEi/ARB (%)  28(57.1)  17(77.3)  NS 
Beta-blocker (%)  35(71.4)  18(81.8)  NS 
Calcium channel blocker (%)  15(30.6)  7(31.8)  NS 
Nitrate (%)  27(55.1)  9(40.9)  NS 
Diuretic (%)  10(20.4)  11(50)  0.026 
Oral hypoglycaemic agent (%) 
Meformin 
Glitazones 
Sulphonylureas 
n/a  11(50) 
8(36) 
2(9) 
6(27) 
n/a 
Insulin (%)  n/a  4(18.2)  n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
    
150 
Table 5.4. Biochemistry results for vascular O2
- studies in CAD patients with and without 
type 2 DM 
  CAD  alone 
(n=49) 
CAD  and  type  2 
DM (n=22) 
P-value 
Cholesterol (mmol/L)  4.10±1.01  3.99±1.11  NS 
Triglycerides (mmol/L)  2.04±0.98  2.63±1.97  NS 
LDL (mmol/L)  2.01±0.80  1.81±0.85  NS 
HDL (mmol/L)  1.16±0.28  1.10±0.22  NS 
CRP(mg/L)  5.27±10.9  2.59±2.91  NS 
HbA1c (%)  5.6±0.42  7.2±1.26  <0.0001 
Urinary ACR (mg/mmol)  3.19±8.95  2.79±2.69  NS 
All variables mean ± Standard deviation. LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C -reactive protein; HbA 1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 5.2. Vascular O2
- production in saphenous veins in patients with CAD alone and 
CAD with type 2 DM. 
 
5.4.2  EPR spectroscopy studies 
5.4.2.1  EPR spectroscopy studies in patients with CAD 
O2
- release from mononuclear cell and whole blood was assessed in 89 patients with CAD and 
68 healthy controls. Participant demographics and clinical characteristics are shown in table 5.5. 
Controls were younger than patients with CAD and included more women. Diastolic blood 
pressure  was  lower  in  patients  with  CAD  compared  to  controls  there  was  no  significant 
P=0.164  
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difference in systolic blood pressure. There was widespread use of cardiovascular secondary 
prevention strategies in patients with CAD. 
Biochemistry results are shown in table 5.6. As would be expected given the prevalence of statin 
therapy total cholesterol and LDL cholesterol levels were lower in patients with CAD. HDL was 
lower in and triglyceride levels higher in patients with CAD. HbA1c, CRP and urinary ACR 
were all higher in the CAD group. 
Mononuclear cell O2
- release is shown in figure 5.3. Basal O2
- release from mononuclear cells 
was significantly greater in patients with CAD compared to controls 70.0±52.68 vs. 49.7±30.98 
AU, P=0.01. In addition PMA stimulated O2
- levels were also higher in CAD patients compared 
to controls (773.4±371.5 vs. 416.6±189.4 AU, P<0.0001).  
O2
- levels in whole blood were also increased in CAD patients compared to controls 54.7±57 x 
10
3  AU  vs.  31.4±14  x10
3AU,  P=0.043  (figure  5.4).The  95%  confidence  intervals  for  the 
difference in mean whole blood O2
- between patients with CAD compared to controls were 14.3 
to 45.8 x10
3 AU.  
    
153 
Table 5.5. Demographics and clinical characteristics in patients with CAD and controls in 
EPR spectroscopy studies 
  CAD 
(n=89) 
Controls 
(n=68) 
P-value 
Age (years)  67.0±9.1  60.8±10.5  <0.0001 
Male (%)  69(77.5)  41(60.3)  0.023 
Systolic BP, mm Hg  139.2±23.6  137.6±18.8  NS 
Diastolic BP, mm Hg  77.4±11.3  81.3±10.6  0.03 
Heart rate (beats/min)  63.2±11.1  68.2±12.7  0.01 
Body Mass Index, kg/m
2  29.2±4.8  26.0±3.6  NS 
Current Smokers (%)  8(9.0)  4(5.9)  NS 
Type 2 diabetes mellitus (%)  25(28.1)  0  n/a 
Hypertension  49(55.1)  18(27.3)  0.001 
Myocardial Infarction  42(47.2)  0  n/a 
TIA/CVA  6(6.7)  1(1.5)  NS 
Chronic renal failure  5(5.6)  0  NS 
Heart failure  14(15.7)  0  n/a 
Aspirin  76(85.4)  9(13.2)  <0.0001 
Other antiplatelet agent  23(25.8)  1(1.5)  <0.0001 
Statin  80(89.9)  8(11.8)  <0.0001 
ACEi/ARB  52(58.4)  (8.8)  <0.0001 
Beta-blocker  68(76.4)  5(7.4)  <0.0001 
Calcium channel blocker  32(36.0)  4(5.9)  <0.0001 
Nitrate  56(62.9)  0  <0.0001 
Diuretic  21(23.6)  5(7.4)  0.008 
Oral hypoglycaemic agent  16(18.0)  0  n/a 
Insulin  5(5.6)  0  n/a 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Table 5.6.Biochemistry results in patients with CAD and controls in EPR spectroscopy 
studies 
  CAD 
(n=89) 
Controls 
 (n=68) 
P-value 
Cholesterol (mmol/L)  4.04±0.86  5.67±1.16  <0.0001 
Triglycerides (mmol/L)  1.99±0.72  1.51±0.79  0.001 
LDL(mmol/L)  1.96±0.72  3.45±1.04  <0.0001 
HDL(mmol/L)  1.17±0.27  1.53±0.40  <0.0001 
CRP(mg/L)  4.25±8.94  1.96±2.37  0.002 
HbA1c(%)  6.19±1.09  5.52±0.32  <0.0001 
Urinary ACR(mg/mmol)  2.79±6.03  1.34±0.94  0.046 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
Figure 5.3. Basal and stimulated mononuclear cell O2
- production in patients with CAD 
and controls (mean+standard deviation)  
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Figure 5.4. Whole blood O2
- production in patients with CAD compared to controls  
 
5.4.2.2  EPR spectroscopy studies in patients with CAD, with and without type 2 DM 
EPR spectroscopy O2
- studies were performed in 25 patients with CAD and type 2 DM and 64 
patients with CAD alone. Demographics and clinical characteristics are shown in table 5.7.There 
was a higher prevalence of hypertension in the patients with type 2 DM. Blood pressure was not 
difference between the two groups there was however higher usage of ARB/ACEi, calcium 
channel blockers and diuretics in patients with type 2 DM. 
Biochemistry results are shown in table 5.8.Unsurprisingly patients with type 2 DM had higher 
HbA1c levels compared to patients with CAD alone. There were no other significant differences 
between the two groups. 
P=0.043 
n=68  n=89  
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Basal mononuclear cell O2
- was not increased in patients with type 2 DM compared to those 
without diabetes, rate 53.7±32.5 vs. 75.7±57.3 AU, P=0.12. In fact there was a trend towards 
lower O2
- levels in patients with type 2 DM. There was no difference in stimulated mononuclear 
cell O2
- release between patients with and without type 2 DM, 30.2±21.5 vs.34.7±21.4 AU 
p=0.38 (Figure 5.5). There was also no difference in whole blood O2
- release between the 2 
groups. 60.8±68.2 x 10
3 AU in patients with type 2 DM vs 52.4±53 x10
3 AU in patients without 
diabetes  P=0.8  (figure  5.6).The  95% confidence intervals for the  difference in  mean  whole 
blood superoxide between patients with and without type 2 DM were -35.2 to 33.3 x10
3 AU. 
There was a strong correlation between whole blood O2
- release and basal mononuclear cell O2
-
release, r=0.689, P<0.0001 (figure 5.7).  
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Table 5.7. Demographics and clinical characteristics for patients with CAD with and 
without type 2 DM in the EPR spectroscopy study 
  CAD alone 
(n=64) 
CAD and type 2 
DM  
(n=25) 
P-value 
Age (years)  66.1±9.8  69.1±6.8  NS 
Male (%)  48(75)  21(84)  NS 
Systolic BP (mm Hg)  138.5±25.4  141.1±18.2  NS 
Diastolic BP(mm Hg)  78.5±11.6  74.7±9.9  NS 
Heart rate (beats/min)  63.5±12.2  62.4±7.9  NS 
Body Mass Index (kg/m
2)  28.8±4.9  30.5±4.2  NS 
Current Smoker (%)  5(7.8)  3(12)  NS 
Hypertension (%)  28(43.8)  21(84)  0.004 
Myocardial Infarction (%)  28(43.8)  14(56)  NS 
TIA/CVA (%)  2(3.1)  4(16)  NS 
Chronic renal failure (%)  3(4.7)  2(8)  NS 
Heart failure (%)  8(12.5)  6(24)  NS 
Aspirin (%)  53(82.8)  23(92)  NS 
Other antiplatelet agent (%)  16(25)  7(28)  NS 
Statin (%)  57(89.1)  23(92)  NS 
ACEi/ARB (%)  33(51.6)  19(76)  0.042 
Beta-blocker (%)  48(75)  20(80)  NS 
Calcium channel blocker (%)  18(28.1)  14(56)  0.026 
Nitrate (%)  42(65.6)  14(56)  NS 
Diuretic (%)  11(17.2)  10(40)  0.05 
Oral hypoglycaemic agent (%)  0  15(60)  n/a 
Insulin (%)  0  5(20)  n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 5.8 Biochemical analysis for patients with CAD, with and without type 2 DM in the 
EPR spectroscopy study 
  CAD alone 
(n=64) 
CAD and type 2 
DM 
 (n=25) 
P-value 
Cholesterol (mmol/L)  4.07±0.87  3.95±0.87  NS 
Triglycerides (mmol/L)  1.89±0.82  2.22±1.23  NS 
LDL(mmol/L)  2.00±0.74  1.83±0.66  NS 
HDL(mmol/L)  1.20±0.28  1.10±0.24  NS 
CRP(mg/L)  4.16±9.4  4.45±7.78  NS 
HbA1c (%)  5.7±0.35  7.4±1.3  <0.0001 
Urinary ACR (mg/mmol)  2.46±6.61  3.6±4.3  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 5.5 Mononuclear cell O2
- prodction in patients with CAD, with and without type 2 
DM (mean+standard deviation) 
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Figure 5.6. Whole blood O2
- release in patients with CAD with and without type 2 DM.  
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Figure 5.7. Basal mononuclear cell O2
- release and whole blood O2
- release.  
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5.5  Discussion 
In this study vascular, mononuclear and whole blood O2
- was increased in patients with CAD 
compared to healthy controls. However patients with type 2 DM had similar levels of oxidative 
stress compared to those without diabetes. Whole blood O2
- levels are a simple measure of 
oxidative stress and were strongly correlated with mononuclear O2
- production. Whole blood O2
- 
levels may therefore be a measure of oxidative stress that can be applied to larger studies in the 
future. 
The  finding  of  increased  vascular  O2
-  production  in  patients  with  CAD  is  in  keeping  with 
previous  other  studies
87;179.  It  is  understood  this  is the  first  study  to  use  EPR  spectroscopy 
techniques to assess mononuclear cell O2
- production in patients with established CAD. Basal 
mononuclear cell O2
- levels may modify oxidative status of blood as it circulates and in addition 
reduce NO bioavailability contributing to endothelial dysfunction
116. Stimulated mononuclear 
cell O2
- production indicates the responsiveness of the cells to stimuli. Mononuclear cells have 
been shown to have higher stimulated levels of O2
- in patients with cardiovascular risk factors
252. 
Increased responsiveness may contribute to increased ROS production in vascular tissues. Little 
was previously known regarding mononuclear production of O2
- in patients with established 
CAD. However our finding of increased levels compared to controls is in keeping with other 
studies  that  have  shown  increased  phagocyte  O2
-  in  patients  with  cardiovascular  risk 
factors
116;252;253. To the best of knowledge this is the first study to show that whole blood O2
-
levels are increased in patients with CAD and that these levels correlate with phagocyte O2
- 
levels. Whole  blood  O2
-  production  may  provide  information  about  both  systemic  levels  of 
oxidative stress and white cell O2
- release.  
It is of interest that patients with CAD have increased levels of oxidative stress despite the use 
of ACEi/ARBs and statins which have been shown to reduce O2
- production
262;263. Elevated 
levels of oxidative stress are thought to be pivotal in the development of cardiovascular disease  
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and  in  particular  the  development  of  endothelial  dysfunction
84.  The  endothelial  dysfunction 
observed  in  patients  with  CAD  may  be  partly  a  consequence  of  these  elevated  O2
-  levels. 
Increased O2
- levels seen in patients with CAD may be a target for therapy but larger studies are 
needed  to  show  the  prognostic  significance  of  O2
-  and  whether  lowering  these  improves 
cardiovascular outcomes. 
Both hyperglycaemia and diabetes have previously been shown to be associated with increased 
levels of oxidative stress
91;177 However in contrast to other studies the presence of type 2 DM 
was not associated with increased O2
- in the vasculature, mononuclear cells or whole blood. 
There are a number of possible explanations for these findings. Pharmacological management of 
patients with type 2 DM may be one explanation. ACEi/ARBs, statins and metformin have all 
been shown to reduce O2
- production
262;263;265. In this study a high proportion of patients with 
type  2  DM  were  on  ACEi/ARBs,  in  contrast  in  the  study  by  Guzik  et  al.
87  where  use  of 
ACEi/ARBs  was  similar  between  patients  with  and  without  diabetes.  In  this  study  36%  of 
patients were taking metformin. It is possible that the patients with type 2 DM had higher levels 
of vascular superoxide that were controlled by medication. 
As has been previously discussed the categorisation of patients in to diabetes or no diabetes is 
somewhat arbitrary. Hyperglycaemia and insulin resistance are continuous variables. Impaired 
glucose tolerance and insulin resistance were not assessed formally in our study; however given 
the elevated body mass index in the control group it is likely that a proportion of these patients 
had impaired glucose tolerance and insulin resistance. Fortuno et al.
252 showed that in patients 
with metabolic syndrome mononuclear O2
- production was related to insulin resistance Patients 
with  CAD  without  diabetes  but  with  insulin  resistance  may  have  attenuated  the  difference 
between the two groups.   
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In  chapter  4  it  was  shown  that  patients  with  type  2  DM  and  CAD  had  greater  degrees  of 
endothelial  impairment  compared  to  patients  with CAD  alone.  Increased  oxidative  stress in 
patients  with  type  2  DM  was  previously  believed  to  explain  the  impairment  in  endothelial 
function
84. However in this study increased oxidative stress does not explain the greater degrees 
of endothelial dysfunction found in patients with type 2 DM. This data does not refute the 
importance of oxidative stress in the development of cardiovascular disease and endothelial 
dysfunction in patients with type 2 DM. These results do however show that patients with CAD 
and type 2 DM, on secondary prevention therapies with well controlled cardiovascular risk 
factors and reasonable glycaemic control do not have elevated oxidative stress. The finding that 
patients with type 2 DM have greater degree of endothelial dysfunction despite comparable 
levels of oxidative stress suggests that other mechanisms underlying endothelial dysfunction in 
this group of patients are important. Furthermore these mechanisms are not being addressed by 
current cardiovascular management strategies.  
Future studies are required to further understand the role of oxidative stress in cardiovascular 
disease. This includes the prognostic value of O2
- levels and the impact of decreasing superoxide 
levels  on  surrogate  endpoints  such  as  endothelial  dysfunction  but  more  importantly  on 
cardiovascular outcomes. The use of whole blood O2
- levels could be applied to larger studies to 
try  and  answer these  questions.  In  patients  with  type  2  DM  further  studies  are  required  to 
identify mechanisms underlying impaired endothelial function.  
This study clearly has a number of limitations. It is an observational study so although O2
- levels 
are elevated in patients with CAD this gives use no information on the consequences of this 
effect.  Furthermore  results  are  only  available  for  a  small  group  of  patients  making  further 
subgroup analysis limited. Our control groups were not well matched in terms of sex or age. 
This was partly a consequence of using patients with VV as controls. Healthy controls were 
recruited form health clubs and this may have biased us to recruiting more female patients. Age  
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has been associated with increased levels of oxidative stress
266;267. Gender may also have effects 
on levels of oxidative stress
79. This study focused only on one ROS and although O2
- is felt to be 
the key ROS others may also be important.  
5.6  Chapter summary 
This study has found increased levels of oxidative stress in patients with CAD compared to 
controls.  Levels  of  oxidative  stress  are  however  similar  between  patients  with  type  2  DM 
compared to those without. Although oxidative stress may be important in the development of 
endothelial function and CVD, increased levels of oxidative stress do not explain the greater 
degree of endothelial impairment seen in patients with CAD and type 2 DM. Whole blood O2
- 
levels may be a simple direct measure of ROS suitable for large scale clinical studies. 
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6  Dyslipidaemia in type 2 diabetes mellitus 
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6.1  Introduction 
Abnormal  lipids  are  a  major  risk  factor for  cardiovascular  disease  (CVD). Type  2  diabetes 
mellitus  (DM)  and  other  insulin  resistant  states  are  associated  with  a  characteristic 
dyslipidaemia. This dyslipidaemia may partly explain the increased endothelial dysfunction in 
patients with type 2 DM described in chapter 4. 
6.1.1  Diabetic dyslipidaemia 
In insulin resistant states and type 2 DM abnormalities in lipoprotein metabolism result in a 
dyslipidemia  characterised  by  high  triglyceride  levels  and  low,  high  density  lipoprotein 
cholesterol  (HDL)
40.  Low  density  lipoprotein  cholesterol  (LDL)  levels  are  not  significantly 
increased; there is however a preponderance of small dense LDL particles
268. This has been 
called  the  atherogenic  lipoprotein  phenotype
269.  This  phenotype  may  be  partly  genetically 
determined, however insulin resistance appears to play a key role
236. 
6.1.2  Hypertriglyceridaemia 
The role of elevated triglycerides in the development of CVD is complex. Triglyceride levels are 
associated  with  increased  risk  of  CVD
270.  The  risks  associated  with  hypertriglyceridaemia 
decrease after adjustment for HDL levels but remain significant
270. Much of the increased risk 
associated with elevated triglycerides appears to be due to various effects and interactions with 
other  lipoproteins
268.  Hypertriglyceridemia  and  altered  metabolism  of  triglyceride  rich 
lipoproteins is pivotal in the development of the dyslipidemia seen in insulin resistant states
236. 
Triglycerides are transported in the circulation as chylomicrons and very low density lipoprotein 
(VLDL). Type 2 DM and insulin resistance is associated with increased levels of VLDL
40. 
Insulin resistance increases three main sources of triglycerides for VLDL assembly in the liver. 
These are increased mobilisation of fatty acids from the adipose tissue, increased hepatic uptake 
of  VLDL,  intermediate  LDL  (ILDL)  and  chylomicron  remnants,  and  increased  de  novo  
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lipogenesis
271. Overproduction of VLDL results in low levels of HDL and generation of small 
dense  LDL.  This  arises  through  in  part  to  cholesterol  transfer  protein  (CETP)-mediated 
triglyceride enrichment of LDL and HDL particles and the action of hepatic lipase on these 
particles
271. 
6.1.3  Small dense LDL particles 
The structure of LDL is not homogenous. Usually 3 peaks are seen in the LDL density profile 
termed LDL-I, LDL-II and LDL-III
272. LDL-I has lowest density and LDL-III, also called small, 
dense LDL has the highest density. In humans LDL shows a bimodal distribution and can be 
separated in to two phenotypes. Phenotype A consists of larger more buoyant LDL and pattern B 
where  smaller  denser  LDL  predominates
272.  An  increase  in  small  dense  LDL  particles  is  a 
feature of insulin resistance
273. LDL size correlates positively with HDL levels and negatively 
with triglyceride levels
274. Triglyceride is a major determinant of appearance of small, dense 
LDL particles. Small dense LDL is seen infrequently in patients with plasma triglyceride levels 
of less than 1.3mmol/L
275. When triglyceride levels increase above this level small dense LDL 
increases in proportion to rise in triglycerides. The formation of small dense LDL particles in 
patients with hypertriglyceridaemia appears in part to be related to hepatic lipase activity
236. 
Hepatic  lipase  activity  is  increased  in  insulin  resistant  states
271.  Hepatic  lipase  converts 
triglyceride enriched LDL to small dense LDL It is suggested that raised triglyceride levels are a 
key determinant of hepatic lipase activity
236.  
A  number  of  studies  have  shown  an  increased  risk  of  CVD  with  small  dense  LDL
276;277. 
However in many of these studies after multivariate adjustment small dense LDL is no longer an 
independent predictor of cardiovascular risk
277. Small dense LDL may simply be a marker of a 
cluster of a broader pathology occurring as part of insulin resistant states rather than the driving 
factor underlying increased atherosclerosis.  
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Despite  the  above  concerns  small  dense  LDL  exhibits  a  number  of  features  that  are 
proatherogenic. The susceptibility to oxidation increases with decreasing LDL size
278. Small 
dense LDL is taken into arterial tissues more readily than larger LDL and resides in the sub-
endothelial  space  for  longer  due  to  increased  proteoglycan
279.  Small  dense  LDL  is  also 
associated with impaired endothelial function
237.  
6.1.4  HDL 
HDL  levels  are  low  in  type  2  DM  and  other  insulin  resistant  states
40.  Like  LDL,  HDL  is 
heterogeneous with multiple subclasses of different diameter and density existing
280. In type 2 
DM and other insulin resistant states there are reductions in the larger less dense species of HDL 
with relative increases in levels of smaller denser HDL 
268. The causes of low HDL in type 2 
DM are likely to be multiple. One major factor appears to be transfer of cholesterol from HDL 
to triglyceride rich lipoproteins and transfer of triglyceride to HDL. Triglyceride rich HDL is 
hydrolysed by hepatic lipase and cleared from the plasma 
268. As has already been discussed 
hepatic lipase is increased in insulin resistance 
236. 
HDL  levels  are  inversely  correlated  with  cardiovascular  risk 
49;50.  HDL  mediates  reverse 
transport of cholesterol. In addition HDL activates eNOS and may be associated with improved 
endothelial function 
211;281. 
6.1.5  Managing dyslipidaemia in DM 
To  date  much  of  the  focus  on  lipid  management  for  CV  prevention  in  type  2  DM  has 
concentrated on the management of LDL. Levels of LDL are an important risk factor for CVD 
and statin therapy is generally safe and well tolerated 
44. Concentrating on LDL alone will 
neglect to address important lipid disorders in type 2 DM and may hinder the further prevention 
of cardiovascular disease in patients with type 2 DM. 
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6.1.6  Lifestyle interventions 
Weight loss through calorie restriction has a beneficial effect on dyslipidaemia in type 2 DM 
282. 
Low  carbohydrate  diets  may  be  more  effective  than  other  weight  loss  diets.  In  a  small 
randomised control study a low carbohydrate diet was associated with greater reductions in 
triglyceride levels and increase in HDL levels compared to a conventional low calorie, high 
carbohydrate diet. At 12 months there was no significant difference in weight loss achieved or 
LDL levels 
283 . 
Dietary modification with increased intake of omega -3 fatty acids may also be beneficial. Fish 
oil increased HDL and reduced triglycerides but had no effect on levels of small dense LDL in 
patients with type 2 DM 
53. 
Exercise can improve lipoprotein profiles in patients with insulin resistance. In a study of 111 
overweight individuals increasing the amount and intensity of exercise increased LDL particle 
size, HDL levels and reduced triglyceride levels. There were no changes in LDL levels 
284 . 
6.1.7  Statins 
The evidence for the use of statins in the prevention of CVD is extensive 
44. Statin therapy is 
therefore the mainstay of treatment for the management of dyslipidaemia in patients with type 2 
DM.  Statins  predominantly  lower  LDL  levels  through  the  inhibition  of  hepatic  cholesterol 
synthesis and up-regulation of LDL receptors. Statins have a lesser effect on triglyceride levels 
and HDL levels 
44. The effect of statins on levels of small dense LDL is variable with some 
classes increasing LDL size to a greater degree although results have been variable 
277.  
6.1.8  Fibrates 
The mechanism of action of fibrates is not fully understood however one effect of fibrates is to 
decrease VLDL levels by increasing lipoprotein lipase activity 
271. Fibrate therapy is therefore 
associated with increased HDL levels, decreased triglyceride levels and a decrease in small  
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dense LDL 
285. There have been a number of fibrate studies assessing surrogate markers of 
atherosclerosis progression that showed promising results. The Diabetes Atherosclerosis study 
assessed the effect of fenofibrate on atherosclerosis progression as assessed by angiography 
286. 
Fibrate therapy was associated with a reduction in the progression of angiographic markers of 
atherosclerosis. This effect appears to be partly mediated by changes in LDL size associated 
with fenofibrate 
287.  
The results from large prospective clinical outcome trials of fibrates have been mixed however. 
The Veterans Affairs High-Density Lipoprotein Intervention study trial (VA-HIT) showed that 
in men with established coronary artery disease (CAD) and low HDL levels gemfibrozil reduced 
the  risk  of  major  cardiovascular  events 
288.  The  use  of  other  lipid  lowering  medication  in 
particular  statins  were  extremely  low  in  this  study.  The  Fenofibrate  Intervention  and  Event 
Lowering in Diabetes (FIELD) study looked at fenofibrate in over 9000 patients with type 2 DM 
289. Compared to placebo fenofibrate did not reduce the primary endpoint of cardiovascular 
events  there  was  however  a  significant  reduction  in  non-fatal  myocardial  infarction  and 
revascularisation 
289. In the FIELD study a significantly higher proportion of patients in the 
placebo group commenced statin therapy compared to those in the treatment group. This may 
account for the apparent lack of benefit seen with fenofibrate. Most recently the lipid arm of the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial aimed to address whether 
intensive lipid management would be associated with further cardiovascular risk reduction 
290. 
Over 5000 patients were randomised to either simvastatin and fenofibrate or simvastatin alone. 
There were no significant differences in LDL or HDL cholesterol between the two groups. 
Fibrate therapy was associated with a significant reduction in triglyceride levels. Combination 
therapy was not associated with a reduction in cardiovascular risk compared to statin therapy 
alone. Subgroup analysis however showed there appeared to be benefit in patients with a high 
baseline triglyceride and low baseline HDL levels
290. At present there is no evidence supporting  
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the widespread use of fibrates in patients with type 2 DM. Fibrate therapy may however be 
beneficial in selected groups, and further research is required. 
6.1.9  Nicotinic acid 
Nicotinic acid predominantly raises HDL levels but in addition reduces triglyceride, LDL and 
small  dense  LDL  levels 
285.  Nicotinic  acid  is  associated  with  reduction  of  atherosclerosis 
assessed during angiography and significant regression of carotid intima media thickness 
291;292. 
There is however only one cardiovascular outcome study, Coronary Drug Project 
293. This study 
showed a reduction in myocardial infarction with niacin. Results of large clinical trials with 
niacin are awaited. There is concern regarding the use of niacin in patients with type 2 DM as it 
is associated with impaired glycaemic control. This effect however appears to be minimal when 
niacin is used in low doses. 
6.1.10 Summary 
Type 2 DM is commonly associated with a mixed dyslipidaemia of raised triglycerides, low 
HDL and increased small dense LDL levels. This dyslipidaemia appears to be a consequence of 
insulin resistance and may explain the increased cardiovascular risk. These lipid abnormalities 
may also partly account for the impaired endothelial function seen in patients with type 2 DM 
and other insulin resistant states. Strategies that specifically tackle these lipid abnormalities may 
be  beneficial  in  preventing  CVD  in  these  groups,  although  evidence  from  clinical  trials  to 
support this hypothesis is limited at present.  
6.2  Aims 
In  chapter  4  patients  with  type  2  DM  and  CAD  were  shown  to  have  impaired  endothelial 
function compared to patients with CAD alone. In this cohort oxidative stress does not appear to 
account for this difference in endothelial function.  Type 2 DM is associated with a typical 
dyslipidaemia. These lipid abnormalities may persist in patients with type 2 DM and established  
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CAD  and  may  partially  account  for  the  greater  impairment  in  endothelial  function.  The 
hypothesis  was  therefore  that  patients  with  type  2  DM  and  CAD  would  continue  to  have 
elevated  triglyceride  levels,  low  HDL  and  a  preponderance  of  small  dense  LDL  particles 
compared to patients without diabetes. Furthermore that this lipid abnormality may explain the 
greater endothelial dysfunction found in patients with CAD and diabetes compared to patients 
with CAD alone.  
The  aims  of  this  study  were  to  perform  detailed  lipid  analysis  including  LDL  and  HDL 
subfraction analysis in patients with CAD undergoing CABG with and without type 2 DM to try 
and explain the difference in endothelial function that had previously been observed. 
6.3  Methods 
Patients with established CAD with and without diabetes were recruited as part of the VASCAB 
study. Detailed lipid analysis was performed in these patient according to the methods described 
in chapter 2. 
6.4  Results 
In total 90 patients with CAD alone and 36 patients with type 2 DM and CAD were recruited as 
part of the VASCAB study. Demographics and clinical characteristics are shown in table 6.1. 
Patients with type 2 DM had significantly higher body mass index (BMI) compared to those 
without  diabetes.  In  patients  with  type  2  DM  prevalence  of  hypertension  was  significantly 
higher as was the use of modifiers of the renin-angiotensin system and diuretics.  
There was no difference in LDL levels in patients with type 2 DM compared to those without. 
There was however a preponderance of small dense LDL particles in patients with type 2 DM. 
LDL peak particle diameter (25.6±2.24 vs 25.8±0.53 nm; P=0.010) and mean particle diameter 
(25.8±2.24 vs 26.0±0.44 nm, P=0.035) were significantly smaller (table 6.2). The proportion of  
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LDL  present  in  fraction  3  (small  LDL-III)  was  greater  in  subjects  with  diabetes  (53±2  vs. 
47±1%, P=0.041) (Figure 6.1). Levels of HDL were significantly lower in patients with diabetes 
compared  to  those  without  diabetes  (1.07±0.05  vs.  1.27±0.04  mmol/L,  P=0.015,  table  6.2). 
There  was  a  trend  towards  smaller  dense  particles  (measured  as  mean  particle  diameter) 
although this was not significant. There was a trend to greater triglyceride levels in patients with 
type 2 DM although this was not statistically significant (Table 6.2). 
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Table 6.1. Demographics and clinical characteristics of patients with CAD and type 2 DM 
compared to CAD alone 
  CAD alone 
(n=90) 
CAD and Type 
2 DM (n=36) 
P-value 
Age (years)  65.7±9.2  66.9±10.0  NS 
Male (%)  67(77)  31 (83.8)  NS 
Systolic BP (mm Hg)  139.0±24.8  140.3±19.7  NS 
Diastolic BP (mm Hg)  78.8±11.3  74.7±12.7  NS 
Heart rate (beats/min)  64.0±12.6  64.6±11.6  NS 
Body Mass Index, kg/m
2  28.7±4.8  31.3±4.6  0.014 
Current smokers (%)  8(9.2)  3(8.1)  NS 
Hypertension (%)  36(41.4)  33(89.2)  0.0001 
Myocardial Infarction (%)  41(47.1)  22(59.5)  NS 
TIA/CVA (%)  5(5.7)  4(10.8)  NS 
Chronic renal failure (%)  5(5.7)  2(5.4)  NS 
Heart failure (%)  11(12.6)  11(29.7)  NS 
Aspirin (%)  72(82.8)  33(89.2)  NS 
Other antiplatelet agent (%)  26(29.9)  9(24.3)  NS 
Statin (%)  76(87.4)  35(94.6)  NS 
ACEi/ARB (%)  45(51.7)  30(81.1)  0.007 
Beta-blocker (%)  64(73.6)  31(83.8)  NS 
Calcium channel blocker (%)  25(28.7)  17(45.9)  NS 
Nitrate (%)  51(58.6)  19(51.4)  NS 
Diuretic (%)  14(16.1)  18(48.6)  0.001 
Oral hypoglycaemic agent (%)  0  23(62.2)  n/a 
Insulin (%)  0  8(21.6)  n/a 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 6.2 Lipid results for patients with type 2 DM and CAD compared to CAD alone 
   
n 
Type 2 diabetes 
mean±SEM  
 
n 
No diabetes 
mean±SEM 
P-value 
Total Cholesterol (mmol/L)  36  3.83±0.17  90  4.09±0.10  NS 
LDL-cholesterol (mmol/L)  34  1.79±0.12  90  2.00±0.08  NS 
LDL MPD (nm)  28  25.78±0.08  79  25.98±0.05  0.035 
LDL PPD(nm)  28  25.56±0.08  79  25.83±0.06  0.010 
HDL-cholesterol (mmol/L)  36  1.07±0.05  90  1.21±0.04  0.015 
HDL MPD (nm)  27  9.57±0.03  80  9.65±0.02  0.075 
Triglycerides (mmol/L)  36  2.38±0.29  84  1.92±0.10  NS 
SEM standard error of the mean; LDL low density lipoprotein; HDL, high density lipoprotein; 
MPD, mean particle diameter; PPD, peak particle diameter. 
Figure 6.1. LDL particle size in patients with CAD and type 2 DM compared to CAD alone 
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6.5  Discussion 
This study has shown that LDL levels are similar in patients with and without type 2 DM but 
there was a preponderance of small dense LDL particles. In addition HDL levels were lower in 
patients with type 2 DM. Triglyceride levels were increased in patients with type 2 DM but were 
not significantly different from levels in patients without diabetes.  
Low HDL levels and increased small dense LDL particles have been reported by other groups as 
a feature of type 2 DM and other insulin resistant states 
117;273. Hypertriglyceridaemia is thought 
to be an important factor driving this abnormality 
271. Although triglyceride levels were elevated 
in patients with type 2 DM, the difference was only moderate and not statistically significant. 
Other  groups  have  reported  that  triglyceride  levels  above  1.3mmol/L  are  associated  with 
increase  in  small  dense  LDL  particles; triglyceride  levels  that  are  within  the range  seen  in 
patients with type 2 DM in this study 
275. 
Small  dense  LDL  particles  are  associated  with  endothelial  dysfunction 
237.  The  finding  of 
increased  small  dense  LDL  in  this  study  may  explain  the  greater  endothelial  dysfunction 
associated with type 2 DM described in chapter 2. The precise mechanisms underlying small 
dense LDL and endothelial dysfunction are not fully understood. However small dense LDL has 
greater  susceptibility  to  oxidation  and  oxidised  LDL  reduces  endothelium  dependent 
vasodilation 
278;294. Although small dense LDL is associated with increased CV risk the effect of 
LDL size as a predictor is often lost during multivariate adjustment further more at present the 
effect of modifying LDL particle size is unclear 
277. 
The finding of significantly lower HDL levels in patients with type 2 DM may also explain the 
greater impairment of endothelial function described in patients with type 2 DM. HDL levels are 
a determinant of endothelial function and may be more important than LDL particle size 
193;209.  
178 
HDL can activate and increase expression of eNOS which may partly account for the association 
between HDL levels and endothelial function 
211;281.  
The patients in this study all had established CAD and were undergoing elective CABG. These 
patients should therefore be on optimal secondary prevention therapies. Use of statins was high 
in patients with and without diabetes reflected by the low LDL levels found in both groups. 
Indeed patients with type 2 DM had a trend towards lower LDL levels. The fact that patients 
with type 2 DM in this study continued to have low HDL levels and a preponderance of small 
dense LDL highlights the limitations of current secondary prevention strategies. Statin therapy 
will only have some impact on LDL particle size and HDL levels 
44;236. This study was not 
powered to analyse the effect of different statins on lipid profiles although other studies have 
suggested that different statins may have different effects on LDL particle size 
277. Currently 
there  is  no  evidence  from  clinical  trials  to  support  the  use  of  one  statin  above  another 
independent of LDL levels 
44. More information on the effect of modifying LDL size on clinical 
outcomes is needed.  
The dyslipidemia found in patients with type 2 DM compared to those without may partly 
explain the impaired endothelial dysfunction found in these patients. Future studies are needed 
to show whether addressing LDL particle size and HDL levels improves endothelial function 
and cardiovascular outcomes. Current management strategies are limited. There is currently no 
evidence to support the widespread use of fibrates in patients with type 2 DM, although the use 
in selected groups may be beneficial 
290. Other options for improving dyslipidaemia associated 
with insulin resistant states include weight loss, dietary modification and increasing levels of 
physical activity. However with all of these interventions it will be difficult to separate whether 
modifying LDL size or increasing HDL levels are most important as the two variables are so 
inextricably linked.  
179 
This  study  has  a  number  of  limitations.  Patient  with  type  2  DM  were  found  to  have  both 
impaired endothelial function and increased small dense LDL and low HDL but since this is a 
cross-sectional study conclusions regarding causation cannot be made. The small numbers of the 
study limited subgroup analysis. The impact of addressing the specific lipid abnormalities in 
patients with type 2 DM on endothelial function is not known. The relative importance on the 
different aspects of diabetes related dyslipidaemia can also not be determined. 
6.6  Chapter summary 
In patients with type 2 DM and CAD there is a preponderance of small dense LDL particles and 
low HDL levels compared to patients with CAD alone. These lipid abnormalities may account 
for  the  impaired  endothelial  function  associated  with  type  2  DM.  Strategies  to  specifically 
address these abnormalities may improve endothelial function and cardiovascular outcomes in 
patients with type 2 DM. 
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7  Strategies for managing cardiovascular disease in type 2 
diabetes mellitus; the role of low density lipoprotein lowering  
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7.1  Introduction 
7.1.1  Low density lipoprotein and cardiovascular disease 
Low density Lipoprotein (LDL) cholesterol is an important risk factor for cardiovascular disease 
(CVD) 
41. Lowering LDL significantly reduces rates of CVD. Although lowering LDL by any 
means, including surgical methods is effective in reducing CVD the majority of the evidence 
comes from statin trials 
42;43. The Cholesterol trialists collaboration showed a 20% reduction in 
cardiovascular events per mmol/L reduction in LDL 
44. This benefit was seen across the range of 
LDL  concentrations.  Guidelines  for  the  management  of  cardiovascular  disease  in  high  risk 
patients are therefore recommending increasingly low LDL-cholesterol targets in patients at 
high cardiovascular risk 
22-24. Although patients with type 2 diabetes mellitus (DM) do not have 
elevated  LDL  levels  compared  to  those  without  diabetes,  considering  the  increased 
cardiovascular risk in patients with type 2 DM aggressive LDL lowering is one strategy for 
reducing CVD in these patients.  
LDL-cholesterol contributes to the development of CVD through a number of mechanisms. 
LDL-cholesterol  is  a  key  component  of  atherosclerotic  plaques;  however  the  role  in  the 
development of CVD is much more complex than simple accumulation of lipid within the vessel 
wall. LDL-cholesterol contributes to oxidative stress and endothelial dysfunction that underlie 
the atherosclerotic process 
87;179. 
LDL-cholesterol levels are an important determinant of endothelial function
179. Lowering LDL 
improves  endothelial  function.  This  is  seen  in  statin  therapy  and  by  removal  of  LDL  by 
apheresis 
207;295;296.  LDL  can  impair  endothelial  function  through  a  number  of  mechanisms. 
LDL-cholesterol  levels  are  an  important  determinant  of  oxidative  stress 
87;179.  Furthermore 
Oxidised LDL-cholesterol can impair endothelial nitric oxide synthase (eNOS) activity by a  
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depletion  of  caveolae  cholesterol,  a  redistribution  of  eNOS  away  from  caveolae  and  a 
diminished capacity to activate eNOS 
297;298. 
7.1.2  Statin therapy 
Statins are effective at lowering LDL levels, are generally safe and well tolerated and therefore 
provide the mainstay of cholesterol lowering therapy. It can be difficult to differentiate between 
lipid effects and statin effects. Clearly achieving lower LDL targets will usually require more 
intensive statin therapy so LDL levels may be a surrogate marker for the intensity of statin 
therapy.  Previous  studies  have  shown  that  lipid  lowering  with  statins  is  associated  with 
improvements in endothelial function 
207. Endothelial function improves rapidly following the 
initiation of statin therapy and is not related to the degree of LDL lowering 
208. Statins have a 
number of effects that can contribute to improved endothelial function independent of lipid 
effects.  Statins  can  increase  eNOS  expression;  phosphorylation  and  activation 
299.  Arginase 
competes with eNOS for L-arginine and has been implicated in development of endothelial 
dysfunction 
202. Statins inhibit a number of small signalling molecules for example inhibition of 
RhoA  with  consequent  inhibition  of  arginase  activity 
299.  Statins  also  reduce  superoxide 
production through inhibition of vascular NAD(P)H oxidise expression and recoupling of eNOS 
263;300. 
The clinical significance of the apparent lipid independent effects of statins is not certain. Meta-
analysis of the large statin trials shows no evidence that statins either as a class or individually 
provided  additional  cardiovascular  risk  reduction  above  that  expected  from  degree  of  LDL 
lowering  achieved 
301.  Indeed  lowering  LDL  surgically  by  ileocecal  bypass  associated  with 
similar risk reductions to those seen in statin prevention trials 
43.  
Statin  therapy  is  generally  safe  and  well  tolerated.  Statin  therapy  can  be  associated  with 
rhabdomyolysis although this is rare. The cholesterol trialists collaboration showed there was no  
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significant difference in rhabdomyolysis in patients on long term statins compared to controls 
44. 
This analysis did not contain many high dose statin trials; and as rate of rhabdomyolysis is dose 
dependent high  dose  statin  therapy  may  alter this  risk.  More  recently  concerns  were  raised 
regarding risk of DM with statin therapy. A meta-analysis by Sattar et al.
302 found an increased 
risk of newly diagnosed DM with statin therapy. The risk of diabetes was small and the clinical 
significance is unclear. Furthermore the possible mechanisms underlying this association are not 
known. The lower LDL targets that are increasingly recommended are likely to increase the use 
of higher doses of statin therapy. It is therefore important as with all preventative therapy to 
reconsider both the risks and benefits of this strategy. 
There is a limit to the reduction in LDL levels that can be achieved with statin therapy alone. 
Combining  other  lipid lowering  agents  with  statins  are  therefore  of  interest. Recent  studies 
however have questioned the benefit of achieving lower LDL levels with combination therapy. 
In patients with familial hypercholesterolaemia there was no additional benefit on carotid intima 
media thickness with the addition of ezetimibe despite lower LDL levels 
303 . More recently the 
Action  to  Control  Cardiovascular  Risk  in  Diabetes  (ACCORD)  trial  showed  no  additional 
benefit on cardiovascular outcomes in patients with type 2 DM following the addition of fibrates 
to statin therapy, although LDL levels were not different between the two groups 
290. The value 
of intensive lipid lowering and the choice of drugs to achieve this are still under debate. 
7.1.3  Summary 
In summary LDL cholesterol is an important factor in the development of  CVD and a key 
determinant  of  endothelial  function.  Lowering  cholesterol  levels  by  any  means  improves 
cardiovascular outcomes. Statin therapy appears to have a number of lipid independent effects 
that  may  further  contribute  to  the  improvements  in  cardiovascular  outcomes,  however  the 
clinical  significance  of  these  effects  are  uncertain.  More  intensive  lipid  lowering  is 
recommended  for  high  risk  groups.  The  effect  of  these  recommendations  on  the  processes  
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underlying cardiovascular disease, such as endothelial function and oxidative stress is currently 
uncertain.  
7.2  Aims  
The  hypothesis  was  that  aggressive  control  of  LDL  cholesterol  levels  in  patients  with 
established coronary artery disease (CAD) in line with current secondary prevention protocols 
will lead to improvement in endothelial function and reduced oxidative stress. 
The aims of this study were therefore to compare lipid profiles, endothelial function, and levels 
of vascular superoxide (O2
-) in a group of patients who underwent coronary artery bypass graft 
surgery in 2003 with patients who underwent surgery in 2007.  
7.3  Methods 
Patients undergoing CABG for severe CAD were recruited as part of the VASCAB study and 
comprised  the  2007  CAD  cohort.  The  2007  cohort  of  patients  was  compared  to  a  cohort 
undergoing CABG in 2003. Clinical examination, routine biochemistry, vascular O2
- and ex vivo 
endothelial  function  was  performed  in  both  2003  and  2007  cohorts.  VV  control  patients 
recruited in 2003 and 2007 were recruited to confirm consistency of assessments for vascular 
O2
- and ex vivo endothelial function. Detailed methods are provided in chapter 2. 
7.4  Results 
7.4.1  Clinical characteristics and cholesterol levels 
The 2007 group was slightly older and contained more males than the 2003. Diastolic blood 
pressure was lower in the 2007 group (Table.7.1). Control subjects undergoing VV surgery were 
similar between 2003 (n=19; age 48±13 years) and 2007 (n=19; age 48±13 years). In patients 
with CAD, statin use increased from 88% in 2003 to 94% in 2007 (P=0.038). Average statin 
dose  increased  from  26±16  mg/d  in  2003  to  37±17  mg/d  in  2007  (P<0.001).  Lower  total  
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(4.0±0.9  vs.  4.8±1.0  mmol/L;  P<0.001)  and  LDL  cholesterol  levels  (2.0±0.7  vs.  3.0±0.9 
mmol/L;  P<0.001) in  2007  reflect  this  increased  statin  usage  (figure  7.1).  HDL  cholesterol 
levels  were  unchanged  between  2007  and  2003  (1.1  [0.9:  1.3]  vs.  1.2  [1.0;  1.4]  mmol/L; 
P=0.124; Figure 7.1).  
7.4.2  Endothelial function 
In patients with CAD endothelium dependent vasodilation, measured as the maximum relaxation 
of  saphenous  veins  to  calcium  ionophore  A23187,  was  significantly  greater  in  the  2007 
compared  to  the  2003  group  (44±15%  vs.  28±12%,  P<0.001,  n=36  each;  Figure  7.2). 
Endothelium-dependent  vasodilation  remained  unchanged  in  saphenous  vein  from  control 
subjects between 2003 and 2007(maximum response to calcium ionophore A23187 in 2003: 
60±11 %, in 2007: 65±15 %; P=0.252; n=14). 
There was an inverse correlation between LDL cholesterol and endothelial function (r=-0.482, 
P<0.0001  figure  7.3)  Linear  regression  analysis  was  performed  with  endothelial  function 
(vasodilatory response to calcium inophore) as the dependent variable and characteristics that 
were different between 2003 and 2007 groups (age, sex, diabetes status, smoking status, LDL-C 
levels,  diastolic  blood  pressure,  statin  dose  and  ACEI/ARB  usage)  together with  a  variable 
indicating year of study as predictors (table 7.2). Only LDL cholesterol contributed significantly 
to endothelial function explaining 15.6% of its variability. 
7.4.3  Vascular O2- generation 
Levels of total vascular O2
- were not significantly different between the 2003 and 2007 groups 
(0.77 [0.53; 1.08] vs. 0.50 [0.37; 0.85] nmol/mg/min; P=0.053; n=33 each) although there was a 
trend towards lower levels in the 2007 group (Figure 7.4). Vascular O2
- production remained 
unchanged in control subjects between 2003 and 2007 (0.47±0.26 vs. 0.43±0.32 nmol/mg/min, 
P=0.697; n=14).  
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Table 7.1 Demographics and clinical characteristics for patients with CAD in 2003 and 
2007 
  2003 
n=121 
2007 
n=105 
P-value 
Age (years)  62 ± 9  65 ± 10  0.028 
Male (%)  77 (64%)  84 (80%)  0.003 
BMI (kg/m²)  28.7 ± 4.9  29.5 ± 5.0  0.243 
Systolic BP (mmHg)  140 ± 14  140 ± 24  0.999 
Diastolic BP (mmHg)  82 ±11  78 ± 12  0.009 
Type 2 DM (%)  27 (22%)  28 (27%)  0.092 
Active smokers* (%)  28 (23%)  18 (17%)  0.071 
Aspirin (%)  103 (85%)  88 (84%)  0.140 
Beta blocker (%)  75 (62%)  67 (64%)  0.106 
ACEI or ARB (%)  58 (48%)  55 (52%)  0.085 
Statin (%)  107 (88%)  99 (94%)  0.038 
Simvastatin  68  58  0.148 
Atorvastatin  19  30  0.073 
Pravastatin  11  4  0.069 
Rosuvastatin  0  2  n/a 
Fluvastatin  0  1  n/a 
*Current smokers and recent history of smoking. Continuous variables are mean± standard 
deviation. Discrete variables are absolute numbers and percentage (%) BP, blood pressure, 
ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 7.2 Determinants of endothelial function in the combined 2003 and 2007 cohort 
  Full model (R
2=0.275)  Stepwise model (R
2=0.156) 
  β  P-value  β  P-value 
Age  0.062  0.558  _  _ 
Sex (0=female;1=male)  0.005  0.965  _  _ 
Type 2 DM 
(0=no;1=yes) 
-0.061  0.562  _  _ 
Active smoking 
(0=no,1=yes) 
0.128  0.245  _  _ 
Diastolic BP   -0.163  0.140  _  _ 
LDL cholesterol  -0.0286  0.022  -0.395  <0.001 
ACEI/ARB 
(0=no,1=yes) 
-0.025  0.856  _  _ 
Statin dose  -0.058  0.597  _  _ 
Year of study  0.343  0.027  _  _ 
 
In the full model all variables were forced into the model. The stepwise model was developed 
using probabilities of F to enter and remove variables of ≤0.05 and ≥0.10 respectively. β 
indicates the partial correlation coefficients, ACEI, Angiotensin-converting enzyme inhibitor; 
ARB, Angiotensin receptor blocker. 
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Figure 7.1 Total cholesterol, LDL and HDL in patients with CAD in 2003 and 2007 
 
   
2003 n=90 
2007 n=90 
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Figure 7.2 Endothelial function in patients with CAD in 2003 and 2007 
 
   
n=36  n=36  
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Figure 7.3 Scatterplot of maximum response to calcium ionophore and LDL-cholesterol 
levels  
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Figure 7.4.Vascular O2
- levels in patients with CAD in 2003 and 2007 
 
 
7.5  Discussion 
The results of this study show that between 2003 and 2007 statin use increased and LDL levels 
decreased.  This  was  paralleled  by  improved  endothelial  function  in  patients  with  CAD. 
Endothelial function did not change in control subjects between 2003 and 2007. Endothelial 
function is an independent predictor of morbidity and mortality in patients with cardiovascular 
disease 
187-189. The improvement in endothelial function may provide surrogate evidence for 
improved cardiovascular outcomes as a result of increased targeting of LDL-cholesterol levels. 
LDL was a significant determinant of endothelial function. This is in keeping with previous 
studies 
108;204;205.  LDL  levels  can  contribute  to  endothelial dysfunction through  a number  of 
different mechanisms. LDL-cholesterol can impair functioning of eNOS and increase oxidative 
P=NS 
n=33  n=33  
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stress 
297;298.  This  will  reduce  the  bioavailability  of NO  and  result  in impaired  endothelium 
dependent vasodilation.  
LDL levels only accounted for 16% of the variability in endothelial function. Clearly other 
factors  in  addition  to  LDL  are  important  in  determining  endothelial  function.  Increased 
oxidative stress has frequently been implicated as a major mechanism underlying endothelial 
dysfunction.  Both  LDL  and  oxidised  LDL  increase  superoxide  production through  xanthine 
oxidase, NAD(P)H oxidase and uncoupling of eNOS 
304-306. Interestingly, despite improvements 
in endothelial function and reduced levels of LDL-cholesterol there were no changes in levels of 
O2
- between 2007 and 2003. In this study changes in levels of oxidative stress do not account for 
the  improvement  in  endothelial  function  seen  in  the  2007  group.  Other  determinants  of 
endothelial function that differed between 2003 and 2007 included use of ACEi/ARBs, and 
diastolic blood pressure. However these were not significant predictors of endothelial function 
in this cohort of patients. 
Statin dose and the choice of statins differed between the two groups. Statins may have a lipid 
independent effect on endothelial function 
208. This effect may be different between different 
statins. Statin dose was significantly different between the two groups but was not a predictor of 
endothelial function. The study was too small to analyse the effects of different statins.  
A number of other factors that have been associated with endothelial function were not analysed 
in this study. LDL particle size may be of particular relevance. LDL particle size is associated 
with endothelial function, with small dense LDL being associated with greater impairment of 
endothelial function 
237. Statin therapy can modulate LDL size causing a shift to larger less 
dense species 
307. There is however wide variation between the different statins. Fluvastatin and 
atorvastatin are reported most frequently as having the greatest beneficial effect on LDL size, 
pravastatin the least 
277.  
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Although lower LDL levels in this study were associated with improved endothelial function 
there is clearly other factors that are important in determining endothelial function. Targeting 
LDL levels can only therefore partly correct endothelial dysfunction. Future studies to identify 
these  other  determinants  are  required  if  further  improvements  in  endothelial  function  and 
cardiovascular outcomes are to be achieved. It would be of interest to see how LDL-cholesterol 
particle size compared between the 2003 and 2007 groups. With regards to statin and LDL 
lowering  future  studies  are  required  to  try  and  distinguish  between  statin  and  LDL  effects. 
Finally outcome studies are required to assess whether the improvements in endothelial function 
are associated with improvements in cardiovascular outcomes.  
In chapter 4 diabetes status was the major determinant of endothelial function. Lack of HbA1c 
measurement in the 2003 cohort limited the direct comparison of endothelial function in patients 
with diabetes in 2007 cohorts. From case note review HbA1c was available for a proportion of 
the patients recruited in 2003. The HbA1c levels were however not taken at similar time prior to 
surgery.  Although  HbA1c  gives  an  indication  of  blood  glucose  levels  over  the  preceding  3 
months, HbA1c is a weighted average of blood glucose levels over this time. This means that 
blood glucose levels over the preceding 30 days contribute significantly more to HbA1c levels 
compared to blood glucose levels over days 90-120. It was therefore felt that using HbA1c levels 
that had been obtained over a range of weeks and months was not appropriate. Although the 
effects of LDL lowering would not be expected to be any less in patients with type 2 DM the 
specific effect on patients with type 2 DM remains unclear and cannot be addressed by this 
study. 
Clearly the major limitation of this study is that it is observational rather than a randomised 
controlled trial. It is therefore not possible to make any conclusions as to whether LDL levels 
and statin therapy cause the differences in endothelial function observed or are merely a markers 
for other changes that exist between the two groups. Furthermore this study cannot distinguish  
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relative contributions between LDL levels and statin dose and individual statins. The study 
initially aimed to investigate the effect of aggressive management of LDL-cholesterol levels in 
patients with and with type 2 DM. A number of features of the study design prevented this 
analysis. The small numbers in this study limited sub group analysis. Furthermore as already 
discussed measures of hyperglycaemia such as HbA1c were not available for the 2003 cohort. 
7.6  Chapter summary 
In summary this study has found a significant improvement in endothelial function in patients 
with established CAD in 2007 compared to 2003. This is paralleled by lower LDL cholesterol 
levels and increased statin usage. This improvement in endothelial function was not associated 
with a reduction in levels of oxidative stress. Endothelial function is an independent predictor of 
morbidity and mortality and may provide surrogate evidence for improved survival of patients 
with CAD as a consequence of current secondary prevention guidelines. LDL-cholesterol levels 
however  only  explain  a  small  proportion  of  the  variability  in  endothelial  function.  Further 
studies  are  therefore  required  to  elucidate  the  other  mechanisms  underlying  endothelial 
dysfunction in patients with CAD. 
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8  Strategies for managing cardiovascular disease; the role of 
physical activity 
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8.1  Introduction 
8.1.1  Sedentary lifestyles and cardiovascular disease 
For over 50 years it has been recognised that sedentary lifestyles are an important risk factor for 
cardiovascular disease (CVD). In 1953 the now classic epidemiological study by Morris et al.
58 
showed that bus conductors compared to bus drivers had lower rates of coronary artery (CAD). 
Furthermore when conductors were diagnosed with CAD it tended to be later in life with a lower 
mortality. This difference was partly attributed to the conductors being more physically active at 
work compared to bus drivers. Since then numerous studies have confirmed a reduction in levels 
of CVD with increased levels of physical activity 
69;71. Increased levels of physical activity also 
reduce the risk of further cardiovascular events in patients with established CVD 
71. For the 
prevention of  CVD it  is  recommended  that  individuals  take  30  minutes  of regular  physical 
activity most days of the week 
22  
Part of the reduction in cardiovascular events can be explained by the effect on conventional risk 
factors. Increasing levels of physical activity increased high density lipoprotein (HDL) levels by 
approximately  3%  in  both  men  and  women  in  Heritage  study 
51.  Meta-analysis  of  exercise 
studies on total cholesterol and low density lipoprotein (LDL) levels showed more variable 
results with some but not all studies reporting moderate reductions of total and LDL cholesterol 
following interventions aimed at increasing physical activity 
308. Increasing physical activity 
reduces  blood  pressure  on  average  by  3.4/2.4  mmHg  however  greater  reductions  can  be 
achieved in hypertensive individuals 
309 Not all the risk reduction can be explained by reductions 
in conventional risk factors, there appears to be an independent effect of exercise 
69. Other 
mechanisms that may contribute to the beneficial effects of increased physical activity include 
reduced levels of oxidative stress, improved endothelial function, reduced insulin resistance, 
reduced inflammation and improved lipoprotein subclass distribution 
310.   
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8.1.2  Sedentary lifestyles and type 2 diabetes mellitus  
Increasing  physical  activity  is  important  in  both  the  prevention  and  management  of  type  2 
diabetes  mellitus  (DM).  Three  large  studies  the  Diabetes  Prevention  Study  (DPS)  Diabetes 
prevention  project  (DPP)  and  The  Da  Qing  IGT  and  Diabetes  study  looked  at  the  role  of 
physical activity in the prevention of type 2 DM in high risk populations 
311-313. All studies 
showed  a  large  and  significant  reduction  in  the  progression  to  type  2  DM  in  individuals 
randomised to exercise programmes. In patients with established type 2 DM meta-analysis has 
shown that increasing physical activity reduces HbA1c by approximately 0.66% 
314. This is a 
clinically significant result with HbA1c reductions comparable to those achieved in UKPDS and 
of a magnitude that would be expected to result in a reduction of diabetes related complications. 
8.1.3  Physical activity as a strategy for tackling CVD in patients with type 2 DM 
Physical activity may reduce the excess cardiovascular risk associated with insulin resistant 
states such as type 2 DM. The Whitehall study looked at the relationship between levels of 
physical  activity  and  CAD  mortality  in  men  with  impaired  glucose  tolerance/diabetes  and 
normal glycaemia 
315. In men with impaired glucose tolerance/diabetes the relationship between 
levels of physical activity and CAD mortality was steeper compared to the normoglycaemic 
men. The risk reduction associated with increased physical activity was therefore greater in 
patients with impaired glucose tolerance/diabetes compared to normoglycaemic individuals 
315. 
Similar results have been observed in other studies. The aerobic centre longitudinal study found 
unfit men with the metabolic syndrome had cardiovascular mortality rates of 31.0/10000 years 
of  observation  compared  to  11.9/10000  years  of  observation  in  fit  men  with  the  metabolic 
syndrome
316. Rates in unfit and fit men without the metabolic syndrome were 19.0 and 5.0 
deaths/10 000 years respectively
316. 
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8.1.4  Cardiac rehabilitation; a strategy for increasing physical activity  
Across the general population levels of activity are low. In Scotland only 38% of men and 27% 
of women met the recommended weekly levels of physical activity 
72. There is evidence that 
levels of activity in individuals with type 2 DM may be even lower 
317. Cardiac rehabilitation is 
defined as a “programme that aims to enable patients with established cardiovascular disease 
maintain  optimal  physical  and  psychosocial  health” 
318.  One  of  the  key  aspects  of  cardiac 
rehabilitation  is  a  structured  10-12  week  exercise  programme.  The  typical  comprehensive 
cardiac rehabilitation programme consists of 4 phases, phase 1 starting whilst  the person is 
inpatient,  phase  2  immediately  following  discharge.  Phase  3 takes  the  form  of  a  structured 
exercise programme together with advice and support on risk factors. Phase 4 is the long term 
maintenance of physical activity and lifestyle change e.g. membership of a local gym. In some 
instances exercise only cardiac rehabilitation may be offered. 
A Cochrane review of 32 trials found that exercise only cardiac rehabilitation reduced all cause 
mortality by 27%, cardiac death by 31% and the combined end point of mortality, non fatal MI 
and  revascularization  by  19% 
319.  There  was  no  additional  benefit  from  comprehensive 
programmes;  indeed  comprehensive  cardiac  rehabilitation  had  a  smaller  effect  on  all  cause 
mortality. It was unclear why there was the discrepancy between the exercise only programmes 
and comprehensive cardiac rehabilitation and this may simply be a reflection of study design.  
There are few large randomised trials looking at the impact of cardiac rehabilitation programmes 
on cardiac risk factors. In the Cochrane review only a minority of studies analysed lipid levels 
319. In the studies of exercise only cardiac rehabilitation there was no effect on total cholesterol, 
LDL, HDL or triglycerides. In the comprehensive cardiac rehabilitation studies there was a 
significant  reduction  in total cholesterol  and  LDL with  no significant changes  in  HDL  and 
inconsistent effects on triglyceride levels. Of the minority of studies that reported blood pressure 
as  an  outcome  there  were  no  significant  changes following  rehabilitation 
319.  There is  little  
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information  regarding  cardiac  rehabilitation  in  patients  with  type  2  DM  or  the  effects  on 
glycaemic control. 
8.1.5  Cardiac rehabilitation and endothelial function 
Exercise programmes have been shown to improve endothelial function in patients with CAD 
233;235;264. Edwards et al.
233 measured endothelial function using brachial FMD before and after 
12 weeks of exercise only cardiac rehabilitation. A control group were patients who did not have 
access to cardiac rehabilitation due to lack of insurance or distance from the rehabilitation class. 
Patients  attending  cardiac  rehabilitation  had  improved  endothelial  function  compared  to  the 
control group. This was a small study with only 9 patients in each group, no comment was made 
on diabetes status of patients and there was no assessment of conventional risk factors before 
and after cardiac rehabilitation. Hambrecht et al.
235 also reported improvements in endothelial 
function in patients with established CVD following increased physical activity. Endothelial 
function assessed during coronary artery angiography improved following 4 weeks of exercise 
training.  The  mechanisms  underlying  this improvement  were  not  clear. The  patients  in this 
group were highly selected, both diabetes and hypercholesterolaemia were exclusion factors. 
Finally Adams et al.
264 randomized patients either to an exercise group or control group prior to 
surgical revascularisation. Segments of left internal mammary artery obtained at time of bypass 
showed improved endothelial function in the exercise group. This study looked at the effects of 
an  in  hospital  exercise  training  program  rather  than  more  standard  cardiac  rehabilitation 
programme  and excluded patients with type 2 DM and hypercholesterolaemia. Blood pressure 
fell significantly in the training group but there were no significant differences in lipids or other 
cardiovascular risk factors.  
8.1.6  Cardiac rehabilitation and oxidative stress 
Physical  activity  may  modify  levels  of  oxidative  stress.  In  patients  following  surgical 
revascularisation  circulating  markers  of  oxidative  stress;  lipid  peroxidation  products  
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(thiobarbituric acid reactive substances, diene conjugates and lipid hydroperoxide) and markers 
of blood antioxidant levels (total antioxidative capacity and glutathione markers ) were reduced 
following a 12 week exercise programme 
320. In this study the greatest improvements were seen 
in the patients with lowest levels of fitness. 
In both the studies by Edwards et al.
233 and Adams et al.
264 the improvements in endothelial 
function were associated with improvements in markers of oxidative stress. Edwards et al.
233. 
assessed  levels  of  oxidative  stress  using  total  plasma  SOD  activity,  glutathione  peroxidase 
activity and levels of isoprostanes. In the cardiac rehabilitation group there was a reduction in 
the levels of oxidative stress. Adams et al.
264 showed that exercise training was associated with 
reduced  expression  of  NAD(P)H  oxidase  subunits  and  NAD(P)H  oxidase  activity  and  ROS 
(total superoxide production as measured by SOD inhibitable reduction of ferricytochrome C in 
segments of internal mammary artery obtained at the time of surgery.  
8.2  Aims  
The  hypothesis  was  that  phase  3  of  the  cardiac  rehabilitation  programme  would  improve 
endothelial  function,  reduce  oxidative  stress  and  improve  HDL  levels  in  patients  with 
established CAD. In patients with type 2 DM who have more marked endothelial dysfunction it 
was hypothesised that increasing physical activity would be of greater benefit.  
The aims of this study were using cardiac rehabilitation as a strategy for increasing levels of 
physical activity:  
1.  To  investigate  the  effect  of  phase  3  cardiac  rehabilitation  on  conventional 
cardiovascular risk factors. 
2.  To investigate the effect of phase 3 cardiac rehabilitation on endothelial function. 
3.  To measure mononuclear and whole blood superoxide (O2
-) levels as an indicator of 
degree of oxidative stress before and after cardiac rehabilitation.  
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8.3  Methods 
Patients who had undergone CABG and were attending cardiac rehabilitation were recruited to 
assess the effect of increased exercise on endothelial function and levels of O2
-. Patients were 
assessed before and after a 10 week programme of education and exercise classes provided as 
part of phase 3 of cardiac rehabilitation. Detailed clinical examination and routine biochemistry 
was performed at both visits. Endothelial function was assessed using a PWA based technique. 
Whole blood and mononuclear cell O2
- was assessed using EPR. A detailed description of the 
methods used is provided in chapter 2.  
8.4  Results 
Thirty  four  patients  attending  cardiac  rehabilitation  following  coronary  artery  by-pass  were 
recruited. Of these patients 29 completed the study and attended for visits both before and after 
cardiac rehabilitation. Demographics for these patients are shown in table 8.1. Three patients 
were unable to attend for the second visit. Reasons included moving from the area, ill health and 
not being available to attend the unit due to a return to work. Two participants were not willing 
to attend for a second visit. 
Clinical  examination  recordings  pre  and  post  cardiac  rehabilitation  are  shown  in  table  8.2. 
Diastolic blood pressure and heart rate fell significantly following cardiac rehabilitation. There 
was a trend to reduced body mass index and waist circumference but this was not significant. 
Levels of physical activity were assessed by taking total leisure time activity recorded in the 
SPAQ. Levels of physical activity increased significantly following cardiac rehabilitation from 
317.5 [207.5; 567.5] minutes per week to 540[362.5; 1316.3] minutes per week,  P<0.0001. 
Functional  capacity  significantly  increased  following  cardiac  rehabilitation  from  4.87±0.92 
Metabolic Equivalent of Task (METS) to 5.93±0.98 METS, P<0.0001.  
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Biochemistry results are shown in table 8.3. Total cholesterol and HDL cholesterol increased 
following cardiac rehabilitation. There was a small but significant rise in HbA1c. There were no 
other significant changes. 
Endothelium dependent vasodilation was improved following cardiac rehabilitation. Maximum 
change in peripheral AIx following salbutamol was -8.3±8.2% at visit 2 compared to -1.1±7.5% 
at visit 1, P=0.003(figure 8.1). In 4 patients endothelial function was worse at visit 2. No clear 
reason for this finding could be identified. This aberrant response following exercise did not 
appear to be accounted for by number of exercise classes attended, change in weight, HDL, 
HbA1c  or  blood  pressure.  There  was  no  significant  difference  in  endothelium  independent 
vasodilation between the two visits; -18.1±8.8% vs.-19.9±8.7% P=NS (figure 8.2).  
There  were  no  significant  changes  in  basal  mononuclear  cell  superoxide  release  (66.6 
[35.3;102.2]  AU  vs  53.5  [38.3;102.7]  AU  P=0.93,  figure  8.3),  stimulated  mononuclear  cell 
superoxide release (529.3 [422.2;1056.6] AU vs 441.6 [340.3,829.9] AU, P=0.094,figure 8.4) or 
whole blood superoxide release following cardiac rehabilitation (61.4[30.0;80.8] x 10
3AU vs 
37[22.8;58.6] x 10
3 AU, P=0.44,figure 8.5). 
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Table 8.1. Demographics of patients attending for cardiac rehabilitation 
  Recruited  
(n=34) 
Completed study 
(n=29) 
Age (years)  66.4±8.4  67.0±8.6 
Male (%)   30(81.1)  25(86.2) 
Current smokers (%)  2(5.4)  0 
Type 2 DM (%)  5(13.5)  4(13.8) 
Hypertension (%)  19(51.4)  15(51.7) 
Myocardial Infarction (%)  20(54.1)  16(55.2) 
Cerebrovascular disease (%)  3(8.1)  2(6.9) 
Chronic renal failure (%)  1(2.7)  0 
Heart failure (%)  3(8.1)  3(10.3) 
Aspirin (%)  36(97.3)  29(100) 
Other antiplatelet agent (%)  4(10.8)  1(3.4) 
Statin (%)  32(86.5)  25(86.2) 
ACEi/ARB (%)  22(59.5)  17(58.6) 
Beta-blocker (%)  27(73.0)  22(75.9) 
Calcium channel blocker (%)  1(2.7)  0 
Nitrate (%)  3(8.1)  2(6.9) 
Diuretic (%)  9(24.3)  6(20.7) 
Oral hypoglycaemic agent (%)  2(5.4)  1(3.4) 
Insulin (%)  0  0 
Continuous variables are mean± standard deviation. Discrete variables are absolute numbers and 
percentage  (%)  BP,  blood  pressure,  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular 
accident. ACEi, Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 8.2 Clinical examination before and after phase 3 cardiac rehabilitation 
  Pre rehabilitation  
(n=29) 
Post 
rehabilitation 
(n=29) 
P-value 
Systolic BP (mm Hg)  137.8±21.8  135.8±22.2  NS 
Diastolic BP (mm Hg)  81.2±12.5  76.6.3±10.8  0.007 
Heart rate (beats/min)  72.3±10.8  64.9±8.9  0.008 
Body Mass Index (kg/m
2)
   29.3±6.39  28.4±3.80  NS 
Waist circumference (cm)  100.9±9.8  99.5±7.8  NS 
Mean±Standard deviation, BP, blood pressure. 
 
Table 8.3 Basic biochemistry and white cell count results before and after phase 3 cardiac 
rehabilitation 
  Pre rehabilitation  
(n=29) 
Post 
rehabilitation 
(n=29) 
P-value 
Cholesterol (mmol/l)  3.54±0.74  3.84±0.8  0.016 
Triglycerides (mmol/l)  1.38±0.54  1.48±1.0  NS 
LDL (mmol/l)  1.79±0.69  1.93±0.78  NS 
HDL(mmol/l)  1.11±0.3  1.23±0.34  0.004 
CRP(mg/L)  6.21±8.8  4.68±7.0  NS 
HbA1c (%)  5.52±0.38  5.86±0.46  0.04 
Urinary ACR(mmol/l)  4.25±6.21  3.85±6.52  NS 
Fasting Glucose(mmol/l)   5.51±0.17  5.75±0.15  NS 
Total white cell count 
(10
9/L) 
7.03±1.88  6.48±1.38  NS 
Lymphocytes(%)  31.4±8.2  33.7±8.1  NS 
Mononuclear cell (%)  8.2±2.9  5.9±2.3  NS 
Granulocytes(%)  60.3±9.1  60.4±9.1  NS 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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Figure 8.1. Endothelium dependent vasodilation pre and post cardiac rehabilitation 
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Figure 8.2. Endothelium independent vasodilation following cardiac rehabilitation 
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Figure 8.3 Basal mononuclear cell O2
- production before and after cardiac rehabilitation 
 
   
P=NS  
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Figure 8.4 Stimulated mononuclear cell O2
- production before and after cardiac 
rehabilitation 
 
   
P=NS  
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Figure 8.5 Whole blood O2
- production before and after cardiac rehabilitation 
 
 
8.5  Discussion 
Endothelial function improved significantly following completion of the phase 3 stage of cardiac 
rehabilitation. Levels of oxidative stress as assessed by mononuclear and whole blood O2
- levels 
were  not  altered  by  cardiac  rehabilitation  program.  There  was  a  significant  increase  HDL-
cholesterol following cardiac rehabilitation. 
The finding of improved endothelial function following cardiac rehabilitation is in keeping with 
a  number  of  other  studies
233;235;264.  Endothelial  function  is  an  important  predictor  of 
P=NS  
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cardiovascular morbidity and mortality. The improvements in endothelial function seen in this 
study may result in improved cardiovascular outcomes. In the studies by Adams et al.
264 and 
Edwards et al.
233 reductions in levels of oxidative stress occurred alongside the improvements in 
endothelial  function.  Reduced  levels  of  oxidative  stress  were  therefore  thought  to  be  the 
mechanism underlying improved endothelial function. In this study there were no changes in 
mononuclear cell or whole blood  O2
- levels in our patients following cardiac rehabilitation, 
suggesting  that  reduced  levels  of  oxidative  stress  did  not  underlie  the  improvements  in 
endothelial function observed.  
Low HDL levels are a strong risk factor for  CVD 
48-50. Previous studies have shown HDL 
cholesterol levels are correlated with endothelial function 
209. It is well established that HDL can 
be increased by increasing levels of physical activity 
51. Some but not all previous studies have 
shown an improvement in levels of HDL following cardiac rehabilitation 
319. In this study there 
was a significant increase in HDL cholesterol following 10 weeks of exercise training as part of 
cardiac  rehabilitation. The  increase  in  HDL  levels  in  our  study  may  partly  account  for  the 
improvement  in  endothelial  function  observed.  HDL  can  contribute  to  improvements  in 
endothelial function through a number of mechanisms including activation of endothelial nitric 
oxide synthase (eNOS) 
281. 
HDL  levels  may  simply  be  a  marker  for  increased  levels  of  physical  activity  with  other 
mechanisms  driving  the  improvements  in  endothelial  function  observed.  In  addition  to 
increasing HDL cholesterol levels increased physical activity can alter lipoprotein composition. 
Exercise increases the mean size of HDL and LDL particles 
284 . Small dense LDL particles have 
a number of features that are atherogenic and are associated with endothelial dysfunction 
237.  
Increased  insulin  sensitivity  is  likely  to  partly  account  for  the  reduction  in  cardiovascular 
mortality associated with increased levels of physical activity 
321. Insulin resistance is associated  
211 
with  endothelial  dysfunction 
197.  Insulin  resistance  may  contribute  to  impaired  endothelial 
function  through  impairment  of  insulin  stimulated  nitric  oxide  (NO)  production 
197;199. 
Improving insulin sensitivity pharmacologically with thiazolidinediones or metformin has been 
shown  in  small  studies  to  improve  endothelial  function 
230;231.  Insulin  resistance  was  not 
formally assessed in this study. There was a small although non-significant reduction in waist 
circumference measurements. Even small reductions in central obesity may be associated with 
improvements in insulin sensitivity 
60. 
Increasing levels of physical activity may be a strategy for tackling endothelial dysfunction in 
patients with established CVD. This strategy may be particularly beneficial in patients with type 
2  DM  who  have  a  greater  degree  of  endothelial impairment  and  higher  cardiovascular  risk 
compared to patients without diabetes. In these patients insulin resistance is thought to be a key 
mechanism underlying increased cardiovascular risk and endothelial dysfunction 
15;18;199. The 
improvements in endothelial function seen following cardiac rehabilitation in this study may be 
partly mediated by improvements in HDL levels. There are currently no pharmacological agents 
that  specifically  increase  HDL,  lifestyle  changes  such  as  increasing  physical  activity  are 
therefore the main strategy for addressing low HDL levels. Four patients in this study had worse 
endothelial function following exercise. The reasons for this aberrant response were not clear. 
Future  studies  are  required  to  assess  the  frequency  and  intensity  of  exercise  required  for 
improvements in endothelial function. In addition long term follow-up studies are required to 
assess  whether  improved  endothelial  function  is  associated  with  improved  cardiovascular 
outcomes. It will also be important to investigate the role of other mechanisms such as LDL 
particle  size  and  insulin  resistance  that  may  contribute  to  improved  endothelial  function 
following increased physical activity.  
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There are a number of limitations to this study. This study was a cross-sectional observational 
study. The lack of a control group clearly limits the conclusions that can be drawn from this 
study with regard to the causal link between increased physical activity and improvements in 
endothelial function. When designing the study the lack of a control group was of concern. 
Cardiac rehabilitation is a standard part of a patients management post cardiac events that is 
known to reduce morbidity and mortality. It would therefore have been unethical to recruit a 
control group who were not offered cardiac rehabilitation. When designing the study it had been 
hoped to partially compensate for a lack of control group by looking at the number of exercise 
classes attended however the final number of patients recruited made this analysis impossible. 
One  of  the  aims  of  this  study  was  to  assess  the  effect  of  increased  physical  activity  on 
endothelial function in patients with type 2 DM however due to the small numbers of patients 
recruited were not able to look at this group separately. Increased insulin sensitivity is thought to 
be an important mechanism of the improved endothelial function and reduced cardiovascular 
risk associated with increased physical activity. Insulin sensitivity was not formally assessed in 
this study so it is not possible to comment on this mechanism.  
    
213 
9  Final discussion 
    
214 
9.1  Discussion 
Type 2 diabetes mellitus (DM) is associated with 2-4 fold increase in risk of cardiovascular 
disease (CVD) compared to patients without diabetes 
9. Type 2 DM is dramatically increasing in 
prevalence due to a combination of an ageing population, obesity epidemic and increasingly 
sedentary lifestyles
4. Currently management of cardiovascular risk in patients with type 2 DM 
focuses on control of blood pressure, low density lipoprotein (LDL) and hyperglycaemia. Recent 
studies such as ADVANCE and ACCORD have highlighted the limitations of this approach
26;27. 
New strategies are needed particularly in light of the predicted worldwide rise in cases of type 2 
DM. Changes in the mechanical and functional properties of arteries are key in the development 
of atherosclerotic plaques that cause coronary artery disease (CAD) 
74;82;93. Understanding these 
process and the underlying mechanisms should help identify new management strategies.  
I  have  shown  using  ex vivo  and in vivo techniques  that  endothelial  function is impaired in 
patients with CAD compared to healthy controls. This finding is in keeping with a plethora of 
previously  published  work 
87;109;179;182;187;188.  Furthermore  using  ex  vivo  techniques  I  have 
confirmed that endothelial function is significantly worse in patients with CAD and type 2 DM 
compared  to  patients  with  CAD  alone 
110;194;195.  Endothelial  dysfunction  is  an  important 
prognostic factor in patients with established CVD 
187;188. It is hoped that improving endothelial 
function will improve cardiovascular outcomes. The majority of patients in this study were well 
treated  with  established  cardiovascular  secondary  prevention  therapies.  Cardiovascular  risk 
factors including blood pressure, LDL levels and hyperglycaemia were also well controlled. 
That endothelial dysfunction persists in these patients highlights the need for novel therapeutic 
strategies. Type 2 DM was the only significant determinant of endothelial dysfunction. The 
mechanisms  underlying  endothelial  dysfunction  are  not  fully  understood  but  may  include 
hypergylcaemia,  insulin  resistance,  dyslipidaemia  and  oxidative  stress 
84;87;89;108;197;204;205.  
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Understanding the development of endothelial dysfunction in patients with type 2 DM may 
identify novel cardiovascular prevention strategies.  
Previous  evidence  supported  increased  oxidative  stress  as  the  major  mechanism  underlying 
endothelial dysfunction in type 2 DM 
87. In my study superoxide (O2
-) levels were similar in 
patients with and without type 2 DM, suggesting that increased oxidative stress did not account 
for the increased endothelial dysfunction associated with type 2 DM. The reasons underlying the 
different findings in this study compared to earlier reports of elevated oxidative stress in type 2 
DM are not clear. It is hypothesised that the pharmacological management of the patients with 
type  2  DM  may  have  lowered  O2
-  levels  to  those  of  patients  without  diabetes.  Use  of 
Angiotenisn-converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARBs) 
are more widespread in patients with CAD and type 2 DM compared to CAD alone. These 
agents have been shown to lower NAD(P)H oxidase vascular O2
- production
262. Statins have also 
been shown to reduce O2
- production
263. The use of statins was high in patients with and without 
type 2 DM. Finally approximately half of patients with type 2 DM were taking metformin. 
Metformin has been shown to reduce oxidative stress in cultured cells 
265. The results of this 
study do not refute the role of oxidative stress in the development of endothelial dysfunction but 
does suggest that oxidative stress does not explain endothelial dysfunction associated with type 
2 DM in this group of patients.  
Type 2 DM and other insulin resistant states are associated with low high density lipoprotein 
(HDL)  levels  and  a  preponderance  of  small  dense  LDL  particles
40;268.  This  pattern  of 
dyslipidaemia was confirmed in patients with type 2 DM and CAD in this study. Small dense 
LDL  particles  have  been  associated  with  increased  cardiovascular  risk  and  endothelial 
dysfunction
237;276.  Low  HDL  levels  are  also  an  important  cardiovascular  risk  factor  and 
associated with endothelial dysfunction
49;50;209. It is proposed that the persisting dyslipidaemia 
seen  in  patients  with  type  2  DM  may  partly  explain  the  endothelial  dysfunction  that  was  
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observed.  The  optimal  treatment  for  the  specific  lipid  abnormalities  associated  with  insulin 
resistance  is  complex.  Fibrates  reduced  triglyceride  levels  increase  HDL  and  increase  LDL 
particle size. In theory fibrates are an optimal therapy however results from the ACCORD study 
question this approach 
290 . In ACCORD fenofibrate added to statin therapy was not associated 
with improved cardiovascular outcomes. Whether fibrate therapy may be of benefit in selected 
patients is currently unclear. Insulin resistance is understood to be the major process driving 
lipid abnormalities associated with type 2 DM 
268;271. Strategies that improve insulin sensitivity 
such  as  increased  physical  activity  are  therefore  of  interest  in  the  management  of  the 
dyslipidaemia associated with type 2 DM.  
Structural changes in the vasculature such as increased arterial stiffness are understood to play 
an important role in the development of cardiovascular disease
80;93;119. Age and hypertension are 
the key determinants of arterial stiffness
122. The relative contribution of other factors such as 
type  2  DM  and  hypercholesterolaemia  is  currently  uncertain
122.  Furthermore  the  optimal 
methods  for  assessing  arterial  stiffness  in  routine  clinical  care  unclear.  Aortic  pulse  wave 
velocity (PWV) is currently the gold standard method for assessing arterial stiffness although 
this method is associated with a number of limitations
121. This study has shown increased aortic 
PWV in patients with CAD compared to control in keeping with other studies. The problems 
associated with measurement of aortic PWV are well recognised and were highlighted in this 
study. The difficulties associated with recording aortic PWV make simpler methods attractive. 
Other surrogate markers of arterial stiffness including augmentation index (AIx), and brachial 
PWV  were  not  increased  in  this  cohort  of  patients  with  CAD.  The  use  of  these  surrogate 
markers of arterial stiffness has been previously called in to question by the results of other 
studies 
127;137;155. This study adds further weight to the evidence against these other measures of 
arterial stiffness in preference to aortic PWV. Time to reflected wave (TR) assessed by PWA is 
a simple measure that correlates with PWV
176. TR was significantly reduced in patients with  
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CAD compared to controls. The use of TR as a simple surrogate measure of arterial stiffness 
warrants further investigation.  Although  there  is a wealth  of evidence  for  increased arterial 
stiffness in patients with type 2 DM this study was unable to confirm this observation. This 
finding  is  in  keeping  with  the  meta-analysis  by  Cecelja  et  al.
122.  showing  diabetes  status 
accounts for only a small proportion of variability in arterial stiffness. The role of assessing 
arterial stiffness and the optimal techniques for doing this in routine clinical care remain unclear.  
Intensive cholesterol lowering has increasingly been a strategy for preventing CVD in high risk 
patients such as those with diabetes or established CVD. Intensive statin therapy may improve 
endothelial function through both reductions in LDL levels and lipid independent effects
206-208. 
This study found that in 2007 compared to 2003 LDL levels were significantly lower, statin 
usage  increased  and  endothelial  function  improved.  Endothelial  function  is  an  important 
prognostic factor in patients with established CVD 
187;188. The increased endothelial function 
seen  in  this  study  may  therefore  provide  indirect  evidence  for  improved  cardiovascular 
outcomes as the result of intensive lipid lowering strategies. Oxidative stress has been proposed 
as one mechanism by which LDL levels contribute to endothelial dysfunction 
87;179. The reduced 
LDL levels and improved endothelial function observed in the 2007 cohort of patients was not 
associated  with  reduced  levels  of  oxidative  stress.  This  finding  adds  further  weight  to  the 
findings of chapter 3 that suggest oxidative stress may not be a key contributor to the endothelial 
dysfunction in this group of patients. LDL levels only accounted for less than a fifth of the 
variability in endothelial function. Other mechanisms are clearly important and remain to be 
elucidated. The specific effect of intensive LDL lowering in patients with type 2 DM could not 
be determined by this study. 
Insulin resistance is also thought to be an important factor underlying both development of CVD 
and endothelial dysfunction
15;197. Type 2 DM is by definition an insulin resistant state. Insulin 
resistance is also common in patients with established CAD without overt diabetes
227. Increased  
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physical activity is associated with reduced cardiovascular risk and this is likely to be in part due 
to improved insulin sensitivity 
69. This study showed increased physical activity following the 
cardiac rehabilitation programme improved endothelial function in patients with type 2 DM, 
possibly  mediated  through  increased  HDL  levels.  A  “prescription”  of  regular  supervised 
exercise classes, similar to the cardiac rehabilitation programme may be a strategy for reducing 
the  cardiovascular  risk  associated  with  type  2  DM.  Exercise  classes  as  a  cardiovascular 
management strategy are attractive as the risks/side effects are low and there are likely to be 
multiple  additional  benefits.  Increased  physical  activity  may  help  to  address  a  number  of 
cardiovascular risk factors such as HDL levels, LDL particle size, insulin resistance that are not 
well controlled with currently available drugs
51;310. 
9.2  Study limitations  
Clearly there are a number of limitations with this study. The major limitations are discussed 
below. 
Firstly the number of patients and controls recruited in to this study was relatively small. This 
may have been of particular importance when comparing the differences between patients with 
and without type 2 DM in whom the numbers were further still. The effect of type 2 DM on 
arterial stiffness in a group of patients with established CAD are likely to be small. This study is 
likely to have been under powered to detect such small differences within groups of patients. 
However despite the small numbers of patients within this study a number of clearly significant 
differences such as endothelial function were identified between patients with and without type 
2 DM.  
One of the major themes of this study was to assess the effect of type 2 DM on cardiovascular 
phenotypes.  In  a  number  of  the  sub-studies  in  particular  the  arterial  stiffness  and  cardiac 
rehabilitation studies that number of patients with diabetes was smaller than expected. This  
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limited the conclusions that can be drawn specifically regarding the impact of diabetes and will 
further studies are required to address this shortcoming.  
All the sub-studies that form this thesis are observational. Although a number of important 
associations have been identified as part of this study causation cannot clearly be attributed. For 
example prospective interventional studies would be required to ascertain whether there is a 
direct causative role between low HDL levels and endothelial dysfunction.   
The main technique employed to assess endothelial dysfunction was an ex vivo technique. Ex 
vivo techniques are clearly limited by the availability of tissue but the results also need to be 
interpreted  carefully  as  the  samples  may  behave  differently  compared  to  when  in  vivo. 
Alternative in vivo measures of endothelial function were used when possible and confirmed the 
ex vivo results. 
Due  to  the  nature  of  the  ex  vivo  tests  used  (endothelial  function  testing  and  vascular  O2
- 
assessment) the characteristics of the control group was significantly different to the patient 
group in terms of age and gender. This limits some of the conclusions that can be drawn with 
regards to mechanisms underlying differences between the two groups. A further control group 
for in vivo studies was recruited that was better matched in terms of age and sex and partially 
compensated for the limitations of the ex vivo control group.  
9.3  Future directions 
One of the key findings of this study is that endothelial dysfunction remains a major problem in 
patients with type 2 DM which is not adequately addressed by current cardiovascular prevention 
strategies.  This  endothelial  dysfunction  may  partly  account  for  the  worse  cardiovascular 
outcomes  associated  with  type  2  DM.  Results  from  this  study  have  shown  some  potential 
therapeutic targets that may result in improved endothelial function. Correcting the specific lipid 
abnormalities associated with insulin resistant states, namely low HDL and small dense LDL,  
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may be of particular benefit. Furthermore use of structured exercise programmes to increase 
levels of physical activity may be beneficial by targeting cardiovascular risk factors such as low 
HDL  levels  that  are  not  presently  well  addressed  by  currently  available  cardiovascular 
prevention therapies. Future studies to assess the impact on cardiovascular outcomes in addition 
to surrogate markers such as endothelial function are required. 
A large proportion of the variability in endothelial function found was not explained by factors 
measured as part of this study. Understanding these mechanisms may identify more targeted 
approaches  than  those  discussed  above.  The  role  of  mitochondrial  dysfunction  in  the 
development of insulin resistant states such as type 2 DM and complications of diabetes is of 
particular interest. Mitochondrial function has been shown to be impaired in insulin resistant 
states
322. This impairment in mitochondrial function is thought to be due to smaller and fewer 
mitochondria
322. Mitochondrial dysfunction is thought to be an important mechanism underlying 
insulin resistance in skeletal muscle
322. Mitochondrial dysfunction is also thought to play an 
important role in the development of atherosclerotic lesions and endothelial dysfunction
323;324. 
Endothelial  mitochondrial  dysfunction  may  contribute  to  endothelial  dysfunction  through  a 
number  of  mechanisms  including  increased  oxidative  stress,  altered  intracellular  calcium 
signalling and endothelial cell apoptosis amongst others
323;325. Factors thought to contribute to 
mitochondrial dysfunction include aging, genetic factors, oxidative stress
322-324. Strategies that 
improve  mitochondrial  function  may  therefore  reduce  insulin  resistance  and  improve 
cardiovascular outcomes. Both thiazolidinediones and metformin have been shown to increase 
mitochondrial biogenesis 
265. Aerobic exercise has also been shown to increase mitochondrial 
biogenesis
322. Novel agents that target mitochondrial oxidative stress are of particular interest. 
Ongoing  work  in  the  VASCAB  cohort  of  patients  by  Dr  Ruth  Mackenzie  has  suggested 
increased  levels  of  mitochondrial  oxidative  stress  in  patients  with  CAD  and  type  2  DM 
compared to patients with CAD alone (data submitted for PhD thesis to University of Glasgow,  
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2010).  MitoQ10  is  a  mitochondrial  targeted  antioxidant  that  is  currently  the  focus  of  the 
cardiovascular research group lead by Professor Dominiczak. Work from this group has shown 
MitoQ10 is associated with improved endothelial function in animal studies 
326.  
In  summary  based  on  the  work  in  this  thesis  future  directions  should  include  studies  to 
investigate  the  effect  of  improving  endothelial  function  (through  the  management  of 
dyslipidaemia and insulin resistance) on cardiovascular outcomes in patients with type 2 DM. 
Further studies are also required to elucidate the additional mechanisms that are contributing to 
endothelial dysfunction in patients with type 2 DM as only a proportion of the variability to be 
explained by conventional cardiovascular risk factors. 
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10 Supplementary data 
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10.1 Participant questionnaire 
All participants recruited to the VASCAB study completed a questionnaire to provide detailed 
information regarding lifestyle and medical history.  
Figure 10.1. Participant questionnaire 
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10.2 Scottish physical activity questionnaire 
Participants recruited to the exercise study were asked to complete the Scottish physical activity 
questionnaire at visits 1 and 2. 
Figure 10.2 Scottish physical activity questionnaire. 
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Figure 10.3 Letter of ethical approval for VASCAB study 
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Figure 10.4 Letter of ethical approval for exercise study.  
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10.3 VASCAB study participants 
10.3.1 All participants  
In total 126 patients with coronary artery disease (CAD) undergoing elective coronary artery 
bypass grafting (CABG) were recruited for the VASCAB study. Eighty control subjects were 
recruited in total. Table 10.1 shows demographics and clinical characteristics for patients with 
CAD compared to all controls. Control patients were younger than CAD patients. A higher 
proportion of the patients with CAD were male. There was no difference in systolic blood 
pressure between the two groups however patients with CAD had significantly lower diastolic 
blood pressure. Body mass index was significantly higher in patients with CAD compared to 
controls. As would be expected the use of secondary cardiovascular prevention therapies such as 
aspirin,  statins  and  modifiers  of  rennin-angiotensin system  was  widespread  in  patients  with 
CAD.  
The  control  group  consisted  of  64  healthy  controls  and  16  patients  attending  for  elective 
varicose vein surgery. The patients undergoing varicose vein (VV) surgery were significantly 
younger  than  the  healthy  controls  otherwise  the  group  were  similar.  Table  10.2  shows  the 
participant characteristics for the healthy controls compared to VV controls. 
Table 10.3 shows the biochemistry results for patients with CAD compared to all controls. Total 
cholesterol and low density lipoprotein (LDL) levels were significantly lower in the patients 
with  CAD  reflecting  the  widespread  use  of  statins  in  this  group.  Triglyceride  levels  were 
significantly higher and high density lipoprotein (HDL) levels significantly lower in the CAD 
group.  C-reactive  protein  (CRP),  glycated  haemoglobin  (HbA1c)  and  urinary  albumin  to 
creatinine ratio (ACR) were all significantly higher in the patients with CAD.   
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Table  10.4  shows  the  biochemistry  results  for  healthy  controls  compared  to  VV  controls. 
Healthy controls had higher LDL levels compared to the patients undergoing VV surgery there 
were no other significant differences. 
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Table 10.1. Participant characteristics for patients with CAD and all controls in the 
VASCAB study 
  CAD 
(n=126) 
All controls (n=80)  P-value 
Age (years)  66.1 ±9.34  59.6±11.6  <0.0001 
Male (%)  100(79.4)  43(53.8)  <0.0001 
Systolic Blood pressure (mm Hg)  138.7±23.6  137.2±18.6  NS 
Diastolic Blood pressure (mm Hg)  77.8±11.8  81.4±10.4  0.028 
Heart rate (beats/min)  64.4±12.3  68.6±12.6  0.022 
Body Mass Index (kg/m
2 )  29.4±4.84  25.9±3.5  <0.0001 
Current smokers (%)  11 (8.7)   5(6.3)  NS 
Type 2 diabetes mellitus (%)  36(28.6)  0  n/a 
Hypertension (%)  69(54.8)  21(26.3)  <0.0001 
Myocardial Infarction (%)  63(50)  0  n/a 
TIA/CVA (%)  9(7.1)  1(1.3)  NS 
Chronic renal failure (%)  7(5.6)  0  NS 
Heart failure (%)  22(17.5)  0  n/a 
Aspirin (%)  105(83.3)  10(13)  <0.0001 
Other antiplatelet agent (%)  34(27.0)  1(1.3)  <0.0001 
Statin (%)  109(86.5)  9(11.3)  <0.0001 
ACEi/ARB (%)  74(58.7)  6(7.5)  <0.0001 
Beta-blocker (%)  94(74.6)  5(6.3)  <0.0001 
Calcium channel blocker (%)  41(32.5)  5(6.3)  <0.0001 
Nitrate (%)  68(54)  0  <0.0001 
Diuretic (%)  31(24.6)  6(7.5)  0.001 
Oral hypoglycaemic agent (%)  24(19)  0  n/a 
Insulin (%)  8(6.3)  0  n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and  percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident.  ACEi, 
Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker.  
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Table 10.2 Participant characteristics for healthy controls and patients with VV recruited 
for the VASCAB study 
  Healthy 
controls 
(n=64) 
Varicose vein 
controls (n=16) 
Age (years)  61.6±8.23  52.8±18.6 
Male (%)  37(57.8)  7(43.8)* 
Systolic Blood pressure (mm Hg)  137.2±18.4  137.3±22.2 
Diastolic Blood pressure (mm Hg)  81.0±10.20  84.1±11 
Heart rate (beats/min)  67.8±11.76  75.2±15.6 
Body Mass Index (kg/m
2 )  25.9±3.68  26.5±1.8 
Current smokers (%)  3(4.7)  2(12.5) 
Type 2 diabetes mellitus (%)  0  0 
Hypertension (%)  18(28.1)   2(12.5) 
Myocardial Infarction (%)  0  0 
TIA/CVA (%)  0  1(6.3)** 
Chronic renal failure (%)  0  0 
Heart failure (%)  0  0 
Aspirin (%)  8(12.5)  2(12.5) 
Other antiplatelet agent (%)  0  1(6.3) 
Statin (%)  7(10.9)  2(12.5) 
ACEi/ARB (%)  5(7.8)  2(12.5) 
Beta-blocker (%)  4(6.3)  2(12.5) 
Calcium channel blocker (%)  4(6.3)  0 
Nitrate (%)  0  0 
Diuretic (%)  4(6.3)  1(6.3) 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and  percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident.  ACEi, 
Angiotensin-converting  enzyme  inhibitor,  ARB,  Angiotensin  receptor  blocker.*P=0.038, 
**P=0.01. 
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Table 10.3 Biochemistry results for all CAD participants compared to all controls.  
  CAD  
 (n=126) 
All controls 
(n=80) 
P-value 
Cholesterol (mmol/L)  4.00±0.94  5.70±1.14  <0.0001 
Triglycerides (mmol/L)  2.04±1.21  1.51±0.78  0.001 
LDL(mmol/L)  1.92±0.74  3.46±1.01  <0.0001 
HDL(mmol/L)  1.17±0.31  1.55±0.41  <0.0001 
CRP(mg/L)  4.09±8.08  2.00±2.33  0.003 
HbA1c (%)  6.16±1.12  5.52±0.31  <0.0001 
Urinary ACR (mg/mmol)  4.58±17.6  1.30±0.92  0.019 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
Table 10.4 Biochemistry results for healthy controls compared to VV controls. 
  Healthy 
controls(n=64) 
VV control (n=16) 
Cholesterol (mmol/L)  5.81±1.14  4.99±0.92 
Triglycerides (mmol/L)  1.54±0.81  1.29±0.55 
LDL(mmol/L)  3.57±0.98  2.75±1.04* 
HDL(mmol/L)  1.53±0.42  1.64±0.36 
CRP(mg/L)  1.78±1.96  3.42±3.87 
HbA1c (%)  5.53±0.33  5.41±0.15 
Urinary ACR (mg/mmol)  1.31±0.97  1.22±0.44 
All  variables  mean  ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio.*P=0.034. 
10.3.2 Patients with type 2 diabetes mellitus 
Thirty  seven  (28.6%)  of  the  participants  with  CAD  had  type  2  diabetes  mellitus  (DM). 
Participant characteristics for participants with CAD and type 2 DM compared to those with 
CAD alone are shown in 10.5.The patients with type 2 DM had significantly higher body mass 
index (BMI) compared to those with CAD alone. There was higher prevalence of hypertension 
in the patients with type 2 DM. Use of both diuretics and ACEi/ARB was higher in patients with 
type 2 DM.  
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Patients with type 2 DM and CAD had significantly lower HDL levels compared to patients 
with CAD alone (table 10.6). As would be expected HbA1c levels were higher in patients with 
type 2 DM.  
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Table 10.5 Participant characteristics for patients with CAD and type 2 DM and patients 
with CAD alone 
  CAD alone 
(n=90) 
CAD and type 2 
DM (n=36) 
P-value 
Age (years)  65.7±9.2  66.9±10.0  NS 
Male (%)  67(77)  31 (83.8)  NS 
Systolic BP (mm Hg)  139.0±24.8  140.3±19.7  NS 
Diastolic BP (mm Hg)  78.8±11.3  74.7±12.7  NS 
Heart rate (beats/min)  64.0±12.6  64.6±11.6  NS 
Body Mass Index, kg/m
2  28.7±4.8  31.3±4.6  0.014 
Current smokers (%)  8(9.2)  3(8.1)  NS 
Hypertension (%)  36(41.4)  33(89.2)  0.0001 
Myocardial Infarction (%)  41(47.1)  22(59.5)  NS 
TIA/CVA (%)  5(5.7)  4(10.8)  NS 
Chronic renal failure (%)  5(5.7)  2(5.4)  NS 
Heart failure (%)  11(12.6)  11(29.7)  NS 
Aspirin (%)  72(82.8)  33(89.2)  NS 
Other antiplatelet agent (%)  26(29.9)  9(24.3)  NS 
Statin (%)  76(87.4)  35(94.6)  NS 
ACEi/ARB (%)  45(51.7)  30(81.1)  0.007 
Beta-blocker (%)  64(73.6)  31(83.8)  NS 
Calcium channel blocker (%)  25(28.7)  17(45.9)  NS 
Nitrate (%)  51(58.6)  19(51.4)  NS 
Diuretic (%)  14(16.1)  18(48.6)  0.001 
Oral hypoglycaemic agent (%) 
Metformin 
Sulphonylurea  
Thiazolidinediones 
0  23(62.2) 
17 (47.2) 
13 (36) 
4 (11) 
n/a 
Insulin (%)  0  8(21.6)  n/a 
Continuous variables are mean ± standard deviation. Discrete variables are absolute numbers 
and  percentage  (%)  TIA;  transient  ischaemic  attack,  CVA,  cerebrovascular  accident.  ACEi, 
Angiotensin-converting enzyme inhibitor, ARB, Angiotensin receptor blocker. 
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Table 10.6 Biochemistry results in patients with CAD alone compared to patients with 
CAD and type 2 DM 
  CAD alone 
(n=90) 
CAD and type 2 
DM 
(n=36) 
P-value 
Cholesterol (mmol/L)  4.09±0.91  3.82±0.99  NS 
Triglycerides (mmol/L)  1.92±0.89  2.38±1.71  NS 
LDL (mmol/L)  2.00±0.73  1.74±0.74  NS 
HDL (mmol/L)  1.21±0.33  1.07±0.24  P=0.030 
CRP(mg/L)  4.29±8.75  3.78±6.60  NS 
HbA1c (%)  5.62±0.37  7.39±1.29  <0.0001 
Urinary ACR(mg/mmol)  2.31±6.24  3.59±4.17  0.021 
All  variables  mean ±  Standard  deviation.  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein;  CRP,  C-reactive  protein;  HbA1c,  glycated  haemoglobin;  urinary  ACR,  urinary 
albumin:creatinine ratio. 
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